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Dedication




The prevalence of pancreatic cancer in the general population is too low—even in high 
prevalence areas such as Northern Europe and North America (8-12 per 105 population)— 
relative to the diagnostic accuracy of present detection methods to permit primary screening 
in the asymptomatic adult population. The lifetime risk of developing pancreatic cancer for 
patients with hereditary pancreatitis is 20% by the age of 60 years and 40% by the age of 70 
years, an aim of this thesis is to establish if this risk can be further stratified according to 
genotype or founder group, despite further clarifying the role of founder effect no significant 
stratification by genotype was possible. A 40% lifetime risk is still low given current 
screening modalities. Conventional radiological imaging methods such as endoluminal 
ultrasound and endoscopic retrograde pancreatography have proved valuable in the detection 
of early neoplastic lesions in patients with familial pancreatic cancer, but these are less 
effective in individuals with gross morphological features of chronic pancreatitis as seen in 
most cases of HP. Detection of molecular changes in early or pre-malignant lesions could 
help in distinguishing pancreatitis and cancer. In this thesis I will show that although mutant 
K-ras is common in the pancreatic juice of patients with pancreatic cancer, it is also present 
in patients with chronic pancreatitis, as well as increasingly in the older population without 
pancreatic disease. Nevertheless, the presence of mutant K-ras may identify a genuinely 
higher-risk group, enabling additional diagnostic imaging and molecular resources to be 
focussed on such a group. I have also shown that epigenetic changes (promoter methylation) 
detected in pancreatic juice can be used to further stratify risk and to clarify the relationship 
o f molecular changes with age.
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Chapter 1- Pancreatic Cancer
Incidence and Mortality
Pancreatic ductal adenocarcinoma, PDAC, is one of the top ten causes of cancer-related 
death in the Western world (Fernandez et al. 1994; Bramhall et al. 1995). Although the 
prevalence of pancreatic cancer in Northern Europe and North America is not especially 
high (8-12 per 105 population) the disease is virtually universally fatal (Gudjonsson 
1995; Sener et al. 1999).
The incidence of pancreatic cancer has reached a plateau in recent years in England and 
Wales. The incidence in males started falling in the early 1980s. However, in females, 
there was a gradual increase in the 1970s and 1980s before starting to decline in the 
1990s as shown in Figure 1 (Quinn et al. 2006). The incidence of pancreatic cancer is 
approximately 7-10 per 100,000 populations with a slight preponderance towards males.
By comparison, in the United States, the incidence of pancreatic cancer has increased 
three-fold from 1920- 1978, possibly due to improved diagnostic techniques, but has 
remained relatively constant since. The incidence is approximately 10-12 per 100,000 
populations, again with a higher incidence in males.
The sharp increase in incidence of this malignancy was also noted in Japan- this country 
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Figure 1: Age standardised (European) incidence rates, pancreatic cancer, by sex, 
UK, 1993-2004 (Quinn et al. 2006)
(Taken from http://info.cancerresearchuk.org/cancerstats/tvpes/pancreas/ without 
permission)
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The diagnosis of pancreatic cancer bears grim consequences to a patient- imminent 
death usually within 12 months in 90% of cases. Pancreatic cancer is a malignancy with 
an aggressive nature and ranks amongst the top ten most common cause o f cancer death 
in the western world.In the 1999 report from the Cancer Research Campaign, there were 
6770 new cases of pancreatic cancer diagnosed in England and Wales in 1996. In 1998, 
6560 deaths were attributed to this cancer (Coleman et al. 1999), accounting for an 
annual mortality of ~3% of cancer deaths in the United Kingdom. In the United States 
and Europe, PDAC accounts for 28000 and 40000 deaths per year respectively.
Pancreatic cancer poses a great diagnostic problem to clinicians worldwide. Patients 
remain well for a long time before symptoms arise. In the majority of cases, when the 
disease is clinically evident, more than 80% of patients have positive regional lymph 
node or distant metastasis. The median survival of these patients is 4-6 months with few, 
if any, survivors after five years. Only a small proportion of these patients (5-10%) will 
be suitable for surgical resection and even with surgery the five-year survival rate is 10- 
24% (Allema et al. 1995; Nitecki et al. 1995; Yeo et al. 1995; Pedrazzoli et al. 1998) 
but there may be a small to modest improvement with adjuvant treatment (Ghaneh et al. 
1999). Even though respectable five-year survival figures may be achieved with 
resection and adjuvant treatment, virtually all of these patients are also dead within the 
next 2-3 years. Very early cancers (<lcm in diameter and no lymph node metastases) 
may result in five-year survival rates of ~50% and the prospect of genuine cure -  
unfortunately such tumours are rarely found in routine clinical practice (Tsuchiya et al. 
1986).
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Despite advances in techniques for resectional surgery, safer anaesthesia for more 
radical operative procedures, trials for adjuvant treatment regimes and modem 
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Figure 2: Number of deaths and age-specific mortality rates, pancreatic cancer, by 
sex, UK, 2005 (Quinn et al. 2006)
















Each year, approximately 7000 deaths are attributed to pancreatic cancer in the United 
Kingdom, 40,000 in Europe and 28,000 in the United States. The median survival of 
these patients is 4-6 months with few, if any, survivors after five years. Only a small 
proportion of these patients (5-10%) will be suitable for surgical resection and even with 
surgery the five-year survival rate is 10-24% (Allema et al. 1995; Nitecki et al. 1995; 
Yeo et al. 1995; Pedrazzoli et al. 1998) but there may be a small to modest improvement 
with adjuvant treatment (Ghaneh et al. 1999). Although respectable five-year survival 
figures may be achieved with resection and adjuvant treatment, virtually all of these 














Figure 3: One- and five-year relative survival by age and sex, patients diagnosed 
with pancreatic cancer, England, 1998-2001 and followed up to the end of 2003
(Quinn et al. 2006)





Pancreatic cancer is extremely rare under the age of 40 and from then, the risk increases 
approximately linearly Figure 4.
Age at diagnosis
Figure 4: Numbers of new cases and age specific incidence rates, by sex, pancreatic 
cancer, UK 2004 (Quinn et al. 2006)




The age-adjusted incidence and death rates from pancreatic cancer vary from country to 
country- the incidence in India and Singapore is markedly lower than England and 
Wales, the United States and Japan (Quinn et al. 2006). There is also ethnic group 
variability- in the United States, the incidence rates were highest in African American 
when compared with Caucasians or Asian Americans.
Smoking
This appears to be the most consistent risk factor associated with pancreatic cancer. The 
mortality ratio from pancreatic cancer in smokers compared to non-smokers has been 
shown to be around 2:1 in the United States, UK and Japan (Hirayama 1989). A 
population-based, case-control study of 526 cigarette smokers and 2153 control subjects 
by Silverman et al (Silverman et al. 1994) showed a 70% increased risk o f pancreas 
cancer in the former group compared with the later group. The overall proportion of 
pancreas cancer attributable to cigarette smoking was 29% in blacks and 26% in whites. 
The link between smoking and pancreas cancer were supported by further studies by 
Siemiatycki et al (Siemiatycki et al. 1995), Femandz et al (Fernandez et al. 1996), and 
Partanen et al (Partanen et al. 1997) - all these authors reported attributable risk 
percentages ranging between 14-33.
The influence of smoking cessation was looked at by Fuchs and they found a 48% 
reduction in pancreatic cancer risk within two years of smoking cessation and the risk 
was reduced to that of a non-smoker after ten years (Fuchs et al. 1996).
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The risks of pancreatic cancer from cigar smoking was analysed by Shapiro et al 
(Shapiro et al. 2000) -  although cigar smoking did not appear to increase the risk of 
pancreatic cancer related mortality (relative risk 1.3, 95% Cl 0.9-1.9), if a smoker 
inhaled the smoke, there was an increased risk of developing pancreatic cancer (relative 
risk 2.7, 95% Cl 1.5-4.8) (Shapiro et al. 2000).
Pancreatic Cancer in High Risk Groups
The prevalence of pancreatic cancer in the general population is too low - even in high 
prevalence areas such as Northern Europe and Northern America (8-12 per 105 
population) (Gudjonsson 1995; Sener et al. 1999) - relative to the diagnostic accuracy of 
present detection methods to permit primary screening in the asymptomatic adult 
population.
The recognition that the lifetime risk of developing pancreatic cancer in high risk groups 
such as patients with Hereditary Pancreatitis (HP) is extremely high (20% by the age of 
60 years and 40% by the age of 70 years) (Howes et al. 2002) poses considerable 
challenges and opportunities for secondary screening in those patients without any 
clinical features of pancreatic cancer. Even for secondary screening, the requirements for 
cancer detection at a biological stage that would be amenable to cure by surgery (total 
pancreatectomy) still require diagnostic modalities with a very high sensitivity and 
specificity. Conventional radiological imaging methods such as endoscopic ultrasound 
(EUS) and endoscopic retrograde cholangiopancreatogtram (ERCP), which have proved 
to be valuable in the early detection of early neoplastic lesions in patients with Familial
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Pancreatic Cancer (FPC), may well be applicable to patients with HP but only in those 
without gross morphological features of chronic pancreatitis (other than parenchymal 
atrophy). Unfortunately, most cases of HP also have associated gross features o f chronic 
pancreatitis that are likely to seriously undermine the diagnostic value o f these 
conventional imaging modalities (Muller et al. 1994; Midwinter et al. 1999).
High Risk Conditions for Developing Pancreatic Cancer
Pancreatic cancer may develop in conditions with pre-existing pancreatic disease 
(chronic pancreatitis, HP and cystic fibrosis), as part of a ‘pure’ Familial Pancreatic 
Cancer (FPC) syndrome, in families in which there is an excess of pancreatic cancers 
(FEPC) and as part of a recognized familial cancer syndrome.
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Table 1: Conditions with increased susceptibility for PDAC
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Chronic Pancreatitis
Around 70% of cases of chronic pancreatitis are related to chronic alcohol abuse and 
only a tiny proportion has an obvious environmental, metabolic or anatomical cause. 
Tropical pancreatitis has been postulated to be one end of the spectrum of presentation 
for chronic pancreatitis. The patients with tropical pancreatitis are usually from India, 
Africa and Asia. The patients are mostly young (average age of onset 12-15 years), there 
is a high incidence in females, the malnourished and the disease shows rapid progression 
and causes severe pancreatic damage with multiple large ductal calculi. There is usually 
no history of alcoholism or biliary tract disease (Balakrishnan et al. 2006). The SPINK.1 
N34S gene mutation has been show to play a role in the increased risk o f tropical 
pancreatitis development (Rossi et al. 2001; Schneider et al. 2002).
Many of the remainder may be related to the inheritance of particular gene variants that 
may modify the disease such as mutation of the CF gene (CFTR) (Cohn et al. 1998) and 
SP1NK1 in Hereditary Pancreatitis (Pfutzer et al. 2000; Witt et al. 2000).
The diagnosis of chronic pancreatits is based on the fulfilment of one or more of the 
following criteria: (i) pancreatic calcifications on x ray, computed tomography (CT) 
scan, ultrasonography (USS), or EUS (hyperechoic foci, hyperechoic strands, lobularity, 
cysts, calcifications, duct dilation, duct irregularity, hyperechoic duct margins, visible 
side branches, and intraductal calcifications) (ii) moderate to marked pancreatic ductal 
lesions on endoscopic retrograde or intraoperative pancreatography (“Cambridge” 
criteria); (iii) typical histology on an adequate surgical pancreatic specimen.
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There is wide variation in the estimation of the increased risk of pancreatic cancer from 
chronic pancreatitis, ranging from to 2.3 to 18.5-fold (Bansa et al. 1995; Talamini et al. 
1999). Lowenfels et al with the International Pancreatitis Study Group showed that the 
10 and 20 year cumulative incidence of developing pancreatic cancer after a diagnosis of 
chronic pancreatitis was 1.8% and 4% respectively (Lowenfels et al. 1993). This was 
equivalent to a 15- to 16-fold increased risk compared to the general population. One 
Italian case-control study estimated that the risk of developing pancreatic cancer after 
follow-up for at least five years of cases with chronic pancreatitis was 5-fold (Fernandez 
et al. 1995) whilst the risk in another study from the same country was found to be 13- 
fold (Talamini et al. 1999; Talamini et al. 2000). Studies from Sweden, however, 
reported only a marginal two-fold risk after 10 years follow up, bringing into question 
whether chronic pancreatitis was a genuine risk factor in addition to other confounding 
factors, in particular tobacco consumption (Ekbom et al. 1994; Karlson et al. 1997).
Howes et al highlighted that in a study by Malka et al involving mainly chronic 
pancreatitis patients (85% of the 373 patients), the overall increased risk of pancreatic 
cancer was significant with a standardised incidence ratio 26.7 (Howes et al. 2002; 
Malka et al. 2002).
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HP is a rare autosomal dominant condition (with -80%  penetrance) characterized by the 
early onset of acute pancreatitis that progress to chronic pancreatitis. In around 70% of 
cases, the cause is one of several mutations in the cationic trypsinogen gene (PRSS1) 
and in the remainder of cases the gene(s) responsible is (are) not known (Whitcomb et 
al. 1996; Gorry et al. 1997). In the table below (Table 2), is a list of the database of 




Table 2: Mutations in pancreatitis adapted from the University of Leipzig database
gene amino acid variant location nucleotide change patients
PRSS1 5'UTR3 -28delTCC 1
PRSS1 intron 1 IVS1+40delC 1
PRSS1 p.A16V exon 2 0 .47O T >10
PRSS1 p.D19A exon 2 c.56A>C 1
PRSS1 p.D22G exon 2 c.65A>G 1
PRSS1 p.K23R exon 2 c.68A>G 1
PRSS1 P.N29I+N54S exon 2
large conversion from PRSS2: C.41- 
34_c.200+236conNM_002770.2:c.41-34_c.200+236 1
PRSS1 P.N29I exon 2 c.86A>T >50
PRSS1 P.N29T exon 2 c.86A>C 1
PRSS1 P.P36R exon 2 C.107OG 1
PRSS1 P.Y37X exon 2 0.111O A 1
PRSS1 P.V39A exon 2 c.116T>C 1
PRSS1 exon 2 IVS2+1G>A 1
PRSS1 p.E79K exon 3 c.235G>A 4
PRSS1 p.G83E exon 3 c.248G>A 1
PRSS1 pl88N exon 3 c.263T>A 1
PRSS1 p.K92N exon 3 c.276G>T 1
PRSS1 p.DIOOH exon 3 c.298G>C 1
PRSS1 p.L104P exon 3 c.311T>C 1
PRSS1 P.R116C exon 3 C .3460T 3
PRSS1 P.R122C exon 3 c.364C>T 2
PRSS1 p.R122H exon 3 c.365G>A >100
PRSS1 P.R122H exon 3 c.365G>A, c.366C>T 2
PRSS1 P.V123M exon 3 c.367G>A 1
PRSS1 p.T137M exon 3 C .1370T 1
PRSS1 P.C139S exon 3 c.415T>A 1
PRSS1 p.C139F exon 3 C.416G>T 1
PRSS1 intron 4 IVS4-8C>T; IV S 4-110T 1
PRSS1 intron 4 IVS4-24C>T 3
PRSS1 p.D162D exon 4 C.486G>T
polymorp
hism
PRSS1 P.G208A exon 5 1
PRSS1 P.N246N exon 5 C .7380T
polymorp
hism
PRSS2 P.G191R exon 4 C .7380T c.571g>a
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gene
am ino acid  
variant
location nucleotide change fam ilies
SPINK 1 large deletion promotor - intron 2 c. 1-320_c. 55+961 del 1336 bp 1
SPINK 1 promotor c.1-253T>C polymorphism
SPINK 1 promotor c.1-215G>A 1
SPINK 1 promotor c.1-215G>T 1
SPINK 1 promotor c.1-164G>C polymorphism
SPINK 1 promotor c.1-147A>G 2
SPINK 1 promotor c.1-142T>C 1
SPINK 1 5' UTR 0.1-53O T 1
SPINK 1 promotor c.1-41G>A 5
SPINK 1 promotor c.1-7T>G polymorphism
SPINK 1 p.M1T exon 1 c.2T>C 1
SPINK 1 p.L12F exon 1 4
SPINK 1 exon 1 c.27delC 2
SPINK 1 L14P exon 1 41T>C 1
SPINK 1 intron 1 IVS1-62T>C polymorphism
SPINK 1 intron 1 IVS1-37T>C linkage with N34S
SPINK 1 S25S exon2 75C>T polymorphism
SPINK 1 intron 2 IVS2+268A>G linkage with N34S
SPINK 1 intron 2 IVS2-352A>G polymorphism
SPINK 1 intron 2 c.87+1G>A 1
SPINK 1 Y33stop exon 3 98¡nsA polymorphism
SPINK 1 p.N34S exon 3 c.101A>G >200
SPINK 1 p.D50E exon3 c.150T>G 1
SPINK 1 P.Y54H exon 3 c.160T>C 1
SPINK 1 p.P55S exon 3 0.163O T <10
SPINK 1 p.R65Q exon 3 c.194G>A 1
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gene
am ino acid  
varian t
location nucleotide change fam ilies
SPINK 1 p.K66N exon 3 1
SPINK 1 intron 2 IVS2-23A>T polymorphism
SPINK 1 intron 3 IVS3+2T>C <10
SPINK 1 intron 3 IVS3-1643G>C polymorphism
SPINK 1 intron 3 IVS3-604G>A linkage with N34S
SPINK 1 intron 3 IVS3-476T>G polymorphism
SPINK 1 intron 3 IV S 3-3210T polymorphism
SPINK 1 intron 3 IVS3-66-65insTTTT linkage with N34S
SPINK 1 intron 3 IVS3+1250A 1
SPINK 1 intron 3 IVS3+184T>A <10
SPINK 1 p.R67C exon 4 c.199C>T 1
SPINK 1 p.G77G exon 4 c.231G>A polymorphism
SPINK 1 3'UTR 272C>T polymorphism
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In seminal study by Lowenfels et al and the International Pancreatitis Study Group, they 
estimated that the cumulative lifetime risk (to the age of 70 years) for pancreatic cancer 
was -40%  in patients with HP (Lowenfels et al. 1993; Lowenfels et al. 1997). This has 
been confirmed in a larger study by Howes et al and collaborators in the European 
Registry o f Hereditary Pancreatitis and Familial Pancreatic Cancer (EUROPAC) who 
found that lifetime risk of developing pancreatic cancer was also 60% (95% confidence 
intervals [Cl], 45-75%) (Howes et al. 2000).
Lowenfels et al also reported that patients with a paternal transmission of HP was 
associated with a much greater increased lifetime risk of developing pancreatic cancer 
(~70%) (Lowenfels et al. 1997; Lowenfels et al. 1999), but the EUROPAC data clearly 
showed that the risk is identical (-40%) irrespective of the parental gender-mode of 
transmission (Lerch et al. 1999; Howes et al. 2004).
The EUROPAC data demonstrated that the risk of pancreatic cancer was extremely low 
in patients with HP aged <40 years but rose from this age such that the risk was 20% by 
the age o f 60 years and 40% by the age of 70 years (Howes et al. 2002). The level of risk 
was further confirmed in a study by the EUROPAC group in 2004, with the cumulative 
risk of pancreatic cancer estimated at 44% at 70 years from symptom onset with a 
standardized incidence ratio of 67% Figure 5 (Howes et al. 2004).
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Time to Pancreatic Cancer by Mutation Status
No. at Risk
R122H 207 192 158 131 »2 59 3* 19 6
N291 76 70 63 43 28 19 8 4 0
Nag 66 58 53 45 34 19 11 8 1
Figure 5: The time to pancreatic cancer in patients with Hereditary Pancreatits
(Howes et al. 2004).
This shows that there are no significant differences by mutation status and that lifetime 
risk is approximately 40% (to age 75).
Despite all the advances in our understanding of the pathobiology of pancreatic cancer 
and the diagnostic technology available, the mortality rate of this disease is still closely 
mirrored by the incidence. Pancreatic cancer develops as a result of interplay between 
genetic and environmental factors. With intensive studies of the epidemiology and 
genetic nature of this disease, hopefully, one day soon we will be able to fully 




CF is the commonest known genetic disease that is inherited in an autosomal recessive 
manner. The CF gene encodes the Cystic Fibrosis Transmembrane Conductance 
Regulator (CFTR) protein, a membrane-bound chloride channel. In CF the function of 
CFTR is impaired or altogether lost due to one of around 1,000 point mutations in each 
of the two inherited alleles. The damage to the pancreas in cystic fibrosis begins in utero. 
Due to the previous limited life expectancy of patients with CF, the risk of pancreatic 
cancer was not certain and indeed hardly relevant. But now patients with CF are living 
longer and longer due to great improvements in medical care.
In 1993, a British study of 412 patients with CF showed a significantly increased 
observed to expected ratio of pancreatic cancers- but this estimate was based on only 
two observed pancreatic cancers (Sheldon et al. 1993). A study in 1995 based on 28,511 
patients with CF from Canada and the USA confirmed the increased risk for pancreatic 
cancer and all digestive tumours but the overall cancer risk was not elevated (Neglia et 
al. 1995). In 1994, a case of pancreatic cancer was reported (the fifth case up to then) in 
a 39-year-old man with CF carrying the common AF508 mutation in the CFTR gene 
(Tsongalis et al. 1994).
Maisonneuve et al, in a study published in 2003, concluded that in adult CF patients, 
there is an increased risk of digestive tract tumours, especially small bowel, colon and 
biliary tract tumours (Maisonneuve et al. 2003). The increased risk was more 
pronounced in patients who had had organ transplantation. In a follow up report 
published in 2007, the group reaffirmed that although the estimated risk of pancreatic
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cancer in CF is five to six times greater than in the general population, the absolute risk 
of pancreatic cancer in patients with CF is negligible (Maisonneuve et al. 2007).
Family History
The appreciation that aggregation of pancreatic cancer occurs in certain families has 
emerged over the past 15 years or so. A case control study from Louisiana, reported a 
5.35% (95% Cl, 2.1-13.2%) relative risk of pancreatic cancer among relatives with the 
same cancer. The relationship between family history and the risk of pancreatic cancer 
was specifically investigated in first-degree relatives in a case-control study conducted 
in Northern Italy. The relative risk was found to be 3.0 (95% Cl, 1.4-6.6) in first-degree 
relatives compared to control. This level of relative risk was confirmed in a study on the 
Francophone community from Canada, in which 7.8% of patients with pancreatic cancer 
were reported to have a first-degree relative with the same disease, a 13-fold difference 
compared with matched control cases.
An analysis from The John’s Hopkins registry (USA) found that 3.7% of second-degree 
relatives developed pancreatic cancer compared with 0.6% in cases without a family 
history. In the latest investigation, a population-based case-control study o f pancreatic 
cancer was conducted in three areas of the USA (Silverman et al. 1999). This study 
found a significantly increased risk for pancreatic cancer in subjects reporting first- 
degree relatives not only for pancreatic cancer (odds ratio [OR] =3.2) but also for colon 
cancer (OR=1.7) or ovarian cancer (OR=5.3). There was a non-significant elevated risk 
for cancers of the endometrium (OR=l .5) or breast (OR=l .3).
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Familial Pancreatic Cancer
FPC is a rare family cancer syndrome that is poorly understood and with an apparent 
autosomal dominant mode of inheritance with restricted but unknown level of 
penetrance (Lynch et al. 1996). Much more common than FPC is the aggregation of 
pancreatic cancer within certain families, either as the only cancer type or in association 
with other cancers (Lai et al. 2000).
Although there is a probable inheritance pattern in patients with FPC, the causative gene 
has yet to be identified. However, although patients with Puetz-Jeghers syndrome is 
associated with a -100 fold increased risk of pancreatic cancer development, there is 
strong evidence from Griitzmann et al that the LK.B1/STK.11 gene inactivation does not 
play a part in the genetics of FPC (Grutzmann et al. 2004).
Familial Atypical Mole-Multiple Melanoma
FAMMM is an autosomal dominant disease associated with multiple atypical naevi, 
malignant melanoma and extra-cutaneous malignancies. Germ-line mutations of the 
CDKN2A gene (that encodes p l6 1NK4a) have been found to co-segregate with melanoma 
in a sub-set of FAMMM kindreds with linkage to the CDKN2A locus on chromosome 
9p21 which occur in about 25% of all FAMMM families (Hussussian et al. 1994; Kamb 
et al. 1994).
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CDKN2A is an important tumour suppressor gene and is functionally altered in ~85% 
cases o f sporadic pancreatic cancers by a variety of genetic mechanisms (Caldas et al. 
1994). The p l6 INK4a protein is critically involved in cell cycle control by binding to 
cyclin-dependent kinases -4 (cdk4) and -6 (cdk6) inhibiting the formation of catalytic 
complexes with cyclin D and hence the phosphorylation of pRb, which is essential for 
cell cycle progression through Gi (Serrano et al. 1993; Fang et al. 1998). Indeed other 
families with individuals with multiple melanomas may also have germline mutations 
of the cdk4 (CDK.4) gene on chromosome 12q 13 (Zuo et al. 1996).
A Dutch study of 200 individuals from nine FAMMM families reported that nine of 43 
cancers identified were pancreatic producing an observed to expected frequency ratio of 
13.4 (Bergman et al. 1990). A USA study by Goldstein et al found a 22-fold increased 
risk o f pancreatic cancer (7 cases observed vs 0.32 expected; standardized incidence 
ratio, 21.8; 95% Cl, 8.7- 44.8) in FAMMM patients with functionally impaired 
CDKN2A mutations when compared to patients with functionally intact CDKN2A 
(Goldstein et al. 1995). Interestingly, there are families with and without pancreatic 
cancer that have the same CDKN2A mutations, indicating additional mechanisms to the 
development of pancreatic cancer in these families (Goldstein et al. 2000).
A study by Vasen et al specifically investigated 27 Dutch FAMMM families for the p 16- 
Leiden mutation (a 19 bp deletion in exon 2 of the CDKN2A gene). They found the p 16- 
Leiden mutation in 19 families that included 86 patients with melanoma. The second 
most frequent cancer was pancreatic cancer, which was observed in 15 patients from
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seven families at a mean age at diagnosis of 58 years (range 38-77 years). The estimated 
cumulative risk of developing pancreatic cancer in putative mutation carriers by the age 
o f 75 years was 17% (compared to 0.5-0.9% for the general population).
In Germany, Bartsch et al analysed five families with a pancreatic cancer-melanoma 
syndrome (families with at least one patient with histologically confirmed pancreatic 
cancer and at least one first-degree relative with histologically confirmed malignant 
melanoma) for the p l6 INK4a mutations and found two of the five families to carry a 
germline mutation (Bartsch et al. 2002). This group observed that the age o f occurance 
o f the pancreatic cancer/ malignant melanoma were about 15 years younger than in the 
general German population. Bartsch et al speculated that the phenotypic prevalence of 
pancreatic cancer and melanoma among p i6 INK4a mutation carriers might be explained 
by an early inactivation of p l61N1C4a together with modifying genes, partly or completely 
suppressing the pancreatic cancer or melanoma phenotype.
Peutz-Jeghers Syndrome
Peutz-Jeghers syndrome is an autosomal dominant disease characterized by the presence 
o f hamartomatous polyps in the gastrointestinal tract, muco-cutaneous melanin 
pigmentation and various gastrointestinal and non-digestive tract cancers. The gene 
responsible is LKB1/STK11 (located on chromosome 19pl3), a tumour suppressor gene 
that encodes for a serine-threonine kinase and is postulated to inhibit cell proliferation at 
the level of G1 (Hemminki et al. 1998; Jenne et al. 1998). Studies have indicated a 
significantly increased risk of pancreatic cancer, other digestive tract cancers including
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gastric and small bowel and also breast, ovarian and endometrial cancers with an overall 
10 to 20-fold risk (Giardiello et al. 1987; Hizawa et al. 1993; Boardman et al. 1998). 
Giardiello et al recently performed an individual patient meta-analysis to determine the 
risk o f cancer risk in 210 patients with Peutz-Jeghers syndrome (Giardiello et al. 2000). 
The relative risk (RR) for all cancers was 15.2 (95% Cl, 2-19%) with a cumulative risk 
for all cancers of 93% between the ages of 15 and 64 years. There was a statistically 
significant increase of the RR for pancreatic cancer (132; 95% Cl, 44-261%).
Familial Breast Cancer And Breast /Ovarian Cancer Syndromes (BRCA1 and 
BRCA2)
Mutations of the BRCA1 and BRCA2 genes account for around 5-10% of all breast 
cancers (lau et al. 2001) and in one Canadian study accounted for 11.7% (95% Cl, 
9.2%-14.8%) of all ovarian cancers. Pancreatic cancer as well as ovarian, colorectal, 
stomach and prostate cancers occurred among first-degree relatives o f carriers of 
BRCA2 mutations only when mutations were in the ovarian cancer-cluster region 
(OCCR) of exon 11, whereas an excess of breast cancer was seen when mutations were 
outside the OCCR, The penetrance of BRCA2 mutations for cancers o f all sites 
combined was greater for men (53%) than for women (38%) (Risch et al. 2001).
The prevalence of BRCA1 and BRCA2 mutations in the general population is high and 
estimates vary from 0.12% to 0.66% (lau et al. 2001) but is even higher in Ashkenazi 
Jews: the 185delAG BRCA1 mutation occurs in 1.1%, the 5382insC BRCA1 mutation is 
found in 0.13% and the 6174delT BRCA2 mutation occurs in 1.4% (Roa et al. 1996).
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Indeed it has been estimated that the prevalence of BRCA1 and BRCA2 mutations in 
Ashkenazi Jews may be even higher (2.0-2.5%) (Warner et al. 1999).
Tonin et al found a frequency o f 4.1% BRCA2 mutations amongst 220 Jewish families 
affected by breast cancer. Pancreatic cancer was present in 19 of these families and was 
predictive of the presence of a germline mutation. There was a BRCA1 or BRCA2 
mutation in 14/19 families (74%; 11 in BRCA1 and 3 in BRCA2) whilst in the absence 
of pancreatic cancer there was no mutation in either gene in 53% of families (Tonin et 
al. 1996). Thorlacius et al identified the 999del5 BRCA2 mutation in 16 out of 21 
Icelandic families with male and female breast cancer, prostate cancer and ovarian 
cancer. There were 11 pancreas cancers in the mutation-positive families but none in 
mutation-negative families (Thorlacius et al. 1996).
Phelan et al reported similar findings in a study of 49 families with site-specific breast 
cancer eight of which had a BRCA2 mutation. Pancreatic cancer occurred in 4/8 
mutation-positive families compared to only 5/41 mutation-negative families and 
occurred at a younger age in those with a mutation (Phelan et al. 1996). A similar pattern 
o f disease association between pancreatic cancer and the germline mutation occurs in the 
case of BRCA1 breast cancer families. A study by Johannsson et al of 47 kindreds from 
southern Sweden identified a BRCA1 germline mutation in 15 kindreds and another 
with linkage to the BRCA1 region. There were two cases of pancreatic cancer 
(diagnosed at 42 and 54 years of age) both of whom had inherited the at-risk haplotype 
(Johannsson et al. 1996).
56
The Breast Cancer Linkage Consortium investigated 173 breast-ovarian cancer families 
with BRCA2 mutations from 20 centres in Europe and North America and observed a 
significantly increased RR for pancreatic cancer (3.51; 95% Cl, 1. 87-6.58%). (The 
Breast Cancer Linkage Consortium 1999).
An alternative way of investigation is to study the prevalence of germline mutations in 
patients with sporadic pancreatic cancer. Goggins et al, found BRCA2 mutations in 3/41 
(7%) of patients with pancreatic cancer (of which two had the 6174delT mutation) 
(Goggins et al. 1996), and Ozcelik et al identified 2/42 (4.9%) cases, apparently none 
with a family history. Ozcelik et al also found the BRCA2 6174delT mutation in 4/39 
(10%) patients of Jewish descent with pancreatic cancer and no family history. This 
prevalence level was significantly higher than the prevalence of the 6174delT mutation 
in the general Ashkenazi population (1.4-2.5%). The cumulative risk for pancreatic 
cancer by the age of 75 years in BRCA2 mutation carriers was estimated to be 7% 
compared to 0.85% for the general population (Ozcelik et al. 1997).
In a study Lai et al investigated germline mutations (CDKN2A, BRCA1, BRCA2, 
hMSH2, and hMLHl) in 102 consecutive cases of pancreatic cancer and ascertained 
levels of risk based on the family history. Thirty-eight (37%) patients were characterized 
as high or intermediate risk, five (13%) of whom had a germ-line mutation -one in 
CDKN2A (I49S); one in BRCA1 (5382 insC); and three in BRCA2 (6174delT). All four 
BRCA1 and BRCA2 mutations were identified in Ashkenazi Jewish patients, o f whom
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there were 14 (14%) in the study. Four of the five mutation carriers had a strong family 
history associated with family cancer syndromes linked to the relevant mutated genes. 
Mutations were not identified in patients in whom a family history of pancreatic cancer 
was the solitary risk factor and a mutation was found in only one patient with early-age 
disease onset. The absence of germ-line mutations in most high- and intermediate-risk 
cases indicates that there are other unidentified genes predisposing to pancreatic cancer 
(Lai et al. 2000).
In a collaborative study by Hahn et al, 26 European familial pancreatic cancer families 
(64 patients) were analysed for BRACA2 mutations. Three families were found to carry 
a frameshift mutation in the BRACA2 gene. The group also identified two families with 
sequence variants of the gene. In conclusion of the study, Hahn et al recommended 
BRACA2 genetic testing and counselling strategies in families with familial pancreatic 
cancer as their data supported an important role for BRACA2 mutations in this subgroup 
of patients (Hahn et al. 2003).
Ataxia Telangiectasia
AT is an autosomal recessive syndrome with an estimated frequency of one per 40,000 
to one per 300,000 births. AT is characterized by a progressive cerebellar ataxia, oculo­
cutaneous telangiectasias, oculo-motor apraxia, respiratory tract infections and an 
increased risk of lymphoproliferative malignancies in particular. There is increased 
radiosensitivity and an overall risk of cancer of around 50- to 150-fold in homozygotes 
and perhaps a 3-fold risk in heterozygotes (Swift et al. 1987; Swift et al. 1991).
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The gene responsible is the ATM gene located on chromosome llq22-23 and between 
0.2% and 1% of the general population are heterozygous carriers of an altered ATM 
allele (Savitsky et al. 1995). Irradiation-induced double strand DNA damage results in 
ATM binding to and serine 15 phosphorylation of p53, thereby contributing to the 
activation and stabilization of p53 (Khanna et al. 1998) and ATM is also directly 
responsible for the phosphorylation of BRCA1 in response to ionizing radiation (Cortez 
et al. 1999).
Seven cases of pancreatic cancer were reported in blood relatives of 110 white families 
with AT compared to 3.3 expected cases and there was one case amongst the spouse 
controls (1.3 expected) but these differences were not statistically significant (Swift et 
al. 1987). Two recent studies from the Nordic countries and Britain have failed to reveal 
an increased incidence of pancreatic cancer in AT families (Inskip et al. 1999; Olsen et 
al. 2001).
Hereditary Non-Polyposis Colon Cancer
HNPCC is the most common genetic predisposition to colorectal cancer. It is an 
autosomal dominant syndrome characterized by early-age onset of right-sided colon 
cancers and in 25% of cases is associated with an increased incidence of multiple 
cancers (Lynch et al. 1985). Lynch syndrome II is characterized by site-specific 
colorectal cancer with early onset but also includes an excess of extra-colonic cancers 
including gynaecological (endometrial, ovarian and breast) cancers and transitional 
urothelial tumours as well as gastric, small bowel and pancreatic cancers (Lynch et al.
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1997). The disease is caused by mutations in one of several DNA mismatch-repair genes 
(notably hMLHl, hMSH2 and hMSH6 but also hPMSl and hPMS2) (Akiyama et al. 
1997; Peltomaki et al. 1997). An ATM polymorphism (1853D) may modulate the 
penetrance of hMSH2 and hMLHl (Maillet et al. 2000). The exact risk o f pancreatic 
cancer in the Lynch 11 syndrome is poorly documented.
Six cases with pancreatic cancer were identified amongst 293 putative gene carriers 
from 40 Finnish HNPCC kindreds. The cumulative risk (to the age of 80 years) for 
pancreatic and biliary tract cancers was estimated to be 17.5% (Aamio et al. 1995). 
Lynch et al reported one HNPCC family with carcinoma of the bile duct, urothelial 
tumours and an extremely early-onset carcinoma of the pancreas, in patients considered 
to have inherited the deleterious genotype (Lynch et al. 1991).
Familial Adenomatous Polyposis
FAP is an autosomal dominant disease with near complete penetrance. It is characterized 
by the appearance of >100 (usually 1000s of) colorectal polyps from an early age that 
invariably undergo malignant transformation and lead to death from metastases if not 
removed by surgical resection. Extra-colonic manifestations of FAP include epidermoid 
cysts, congenital hypertrophy of the retinal pigment epithelium, multiple gastric and 
duodenal polyps and desmoid tumours. The cause of FAP (in at least 80% of families) is 
a germline functional mutation of the tumour-suppressor APC gene located on 5q21. 
Mutations are mostly due to point mutations, usually leading to truncation and also
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frameshift mutations (Groden et al. 1991; Kinzler et al. 1991) or genomic 
rearrangements (Su et al. 2000).
The APC protein regulates of P-catenin regulated transcription. P-catenin can associate 
with Tcf/Lef DNA-binding proteins and can form DNA sequence specific transcription 
complexes. The APC protein associates with P-catenin together with glycogen synthase 
kinase-3 (GSK.3) and axin or conductin thereby leading to its degradation. An attenuated 
form of FAP, in which patients develop fewer tumors and at an older age, is associated 
with an allele of APC carrying a mutation on exon 9 (APCAs9) (Su et al. 2000).
There appears to be a relatively small increased risk of pancreatic cancer in FAP, 
although the exact risk is not known due to rather few studies. Data from the Johns 
Flopkins registry revealed an increased R.R of 4.46 (95% Cl, 1.2-11.4%) for pancreatic 
adenocarcinoma (Giardiello et al. 1993).
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Li-Fraumeni
The Li-Fraumeni syndrome is an autosomal dominant condition with a predisposition to 
the early onset of sarcomas, breast cancer, brain tumors, lung cancer, adreno-cortical 
tumours and leukaemias (Strong et al. 1987). The causative gene in many cases is the 
TP53 tumour-suppressor gene that encodes for the p53 protein and lies on chromosome 
17pl 3. p53 has an absolutely critical role in the control of the cell cycle and is centrally 
involved in DNA repair processes and apoptosis (Malkin et al. 1990; Srivastava et al. 
1990).
Many Li-Fraumeni patients have mutations in exons 5 to 8 of TP53 but around 50% 
patients have no germline mutation in this gene (Frebourg et al. 1995). The presence of a 
germline missense mutation in the core DNA binding domain produces a much more 
highly penetrant phenotype with a higher incidence of cancers and diagnosis at an earlier 
age (Birch et al. 1998).
The extent of pancreatic cancer involvement in the Li-Fraumeni syndrome is unclear due 
to limited data. In a study of 24 kindreds from the USA in 1988, one case of pancreatic 
cancer was seen in each of three families and two cases were seen in a fourth family (Li 
et al. 1988). A follow-up study was reported in 1998 of these 24 kindreds diagnosed 
between 1968 and 1986. Two- hundred family members developed a primary tumour, 
seven of which were pancreatic cancers. Thirty (15%) of these patients subsequently 
developed another cancer including a single case of pancreatic cancer (Hisada et al. 
1998).
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Diabetes Mellitus and Obesity
There is much controversy surrounding the association between diabetes and pancreatic 
cancer. Many studies have been carried out to try to unravel the relationship between 
pancreatic cancer and diabetes.
There is an incompletely understood relationship between pancreatic cancer and diabetes 
mellitus. In 1995 Evans et al reported a large pedigree with nine cases of PDAC and an 
autosomal dominant pattern of inheritance and in whom diabetes mellitus and pancreatic 
exocrine insufficiency developed prior to the onset of pancreatic cancer (Evans et al. 
1995). Members of the family developed pancreatic cancer at an earlier and earlier age 
in subsequent generations (anticipation). Five of the nine cases with cancer had diabetes 
mellitus >10 years prior to the development of pancreatic cancer and both conditions 
were diagnosed concomitantly in the remainder. A meta-analysis in 1995 by Everhart et 
al o f 20 case-control and cohort studies of diabetics revealed a relative risk of 2.1 (95% 
Cl, 1.68-2.8) for pancreatic cancer. Diabetes mellitus of >5 years standing carried the 
same relative risk as those diagnosed sooner. The increased risk was restricted to 
patients with non-insulin dependent diabetes mellitus. A study by Kath et al of 2,720 
insulin- dependent diabetic patients found four cases of pancreatic cancer, which was not 
significantly different from the incidence in non-diabetics (Kath et al. 2000).
This significant association between diabetes mellitus and pancreatic cancer is supported 
by more studies. In 1997, Wideroff et al investigated 109,581 individuals hospitalized
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with diabetes mellitus in Denmark. The standardized incidence ratio (SIR) for pancreatic 
cancer was 2.1 (95% Cl, 1.9-2.4) with a follow-up time of 1-4 years; the SIR declined to 
1.3 (95% Cl, 1.1-1.6) after 5-9 years of follow-up. Similar findings were reported from 
Sweden (Chow et al. 1995). Calle et al in 1998 examined the association o f pancreatic 
cancer mortality (2,953 deaths) and diabetes mellitus (mostly non-insulin-dependent) of 
at least one year's duration in a cohort of 1,089,586 subjects (Calle 1998). Diabetes was 
significantly related to pancreatic cancer mortality in both men (relative risk = 1.49; 
95% Cl, 1.25-1.77) and women (1.51; 95% Cl, 1.24-1.85). In 1999, Silverman et al 
found that patients who had diabetes mellitus for >10 years had a 50% increased risk, 
while patients with diabetes of one-year duration had a 30% increased risk o f pancreatic 
cancer (Silverman et al. 1999). Interestingly, Gapstur et al reported a 2.2-fold increased 
risk of pancreatic cancer in diabetic patients with high post-load plasma glucose level 
compared to those with lower levels (Gapstur et al. 2000).
There are also studies disputing the increased risks of pancreatic cancer by diabetes 
mellitus. Some authors have indicated that diabetes mellitus seem not to be a risk factor 
(Gullo 1999).
Rulyak et al conducted a nested case-control study including 251 members of 28 
families with familial pancreatic cancer (families with at least 2 first- or second -degree 
members with pancreatic cancer) looking at amongst other risk factor, diabetes and 
whether this increases the risk of pancreatic cancer. This group concluded that diabetes
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was not associated with increased pancreatic cancer risk in familial pancreatic cancer 
families (Rulyak et al. 2003).
Conversely, Bonelli et al reported the risk of pancreatic cancer associated with diabetes 
mellitus to be 2.89. When the data was analysed further based on the diabetic treatment 
administered, they found the overall risk was higher for subjects treated with insulin 
(relative risk= 6.49) than those treated with oral hypoglycaemic drugs (relative risk= 
2.12). Furthermore, after 5 years from the diagnosis of diabetes, the increased risk for 
pancreatic cancer associated to diabetes persisted only for patients treated with insulin- a 
7-fold increased risk for developing pancreatic cancer as compared with those treated 
with oral antidiabetics (Bonelli et al. 2003).
A large study looking at fasting serum glucose levels in a Korean cohort o f over a 
million individuals with a 10 year follow up period showed a clear association between 
hyperglycaemia and pancreatic carcinoma (Jee et al. 2005). It still remains unclear 
whether diabetes is a risk factor for pancreatic cancer or an early symptom, a recent 
paper by Chari et al (Chari et al. 2008) suggested that only recent onset diabetes 
increases risk. However, this remains controvertial as the incidence of diabetes at earlier 
time points (before diagnosis with cancer) was still very high in the cohort studies.
The link between pancreatic cancer and obesity has also been studied. Pan et al in 
Canada conducted a large (21022 incident cases of 19 types of cancers and 5039 
controls) population-based, case-control study and reported a positive association
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between obesity and pancreatic cancer. The overall population attributed risk for 
pancreatic cancer related to weight for overweight versus obese patients was -0.33% and 
7.11% respectively (Pan et al. 2004).
Obesity (defined as body mass index of at least 30 kg/m2) has been positively linked 
with pancreatic cancer. A Swedish study observed, compared to normal weight men, 
there was an elevated risk of pancreatic cancer in non-smoking obese men compared to 
no overall increased risk when the group was not stratified by smoking status (Samanic 
et al. 2006).
The findings are in consensus with the earlier reports from Michaud et al (suggesting 
ana 50-70% increased risk of pancreatic cancer in obese patients) (Michaud et al. 2001) 
and Isaksson et al that adult weight gain was associated with a 50% increased risk of 
PDAC (Isaksson et al. 2002).
However, a meta-analysis carried out by Berrington et al in 2003 involving 6391 cases 
of pancreatic cancer reported a weak link between obesity and pancreatic cancer- a 
relative risk per unit increase in body mass index (5 kg/m2) of 1.16 (Berrington de 
Gonzalez et al. 2003). This weak link was further supported by a study examining the 
relationship between anthropometry, physical activity and risk of pancreatic cancer in 
published in 2006. The relative risk per unit increase in body mass index (5 kg/m2) was 
1.09 (Berrington de Gonzalez et al. 2006).
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Origin of Pancreatic Ductal Adenocarcinoma
The pancreas has both endocrine and exocrine functions. The exocrine pancreas makes 
up to over 95% (acinar cells 85%, ductal cells 10%) of the total volume of the gland and 
the endocrine cells occupy only 1-2% of the pancreas. PDAC is the most common type 
o f cancer o f the pancreas accounting for greater than 85% of pancreatic neoplasms.
PDAC cells morphologically resemble ductal epithelial cells but there is much debate as 
to the origin and nature of these tumours. The morphological appearance o f PDAC 
suggests that the cells of origin are of ductal epithelial cell lineage. However, there has 
also been some evidence of islet cells transformation into PDAC (Pour et al. 1999).
Pancreatic Intraepithelial Neoplasia
Pancreatic Intraepithelial Neoplasia (PanfN) is the terminology adopted by the Pancreas 
Think Tank in 1999 to reflect the potential progression to neoplasia of various precursor 
pancreatic lesions. These lesions have been observed in pancreas specimens with ductal 
carcinomas, chronic pancreatitis and even in normal pancreases. PanIN is subclassified 
into PanIN-1 A, Pan IN B-IB, PanIN-2 and PanIN-3 based on the degree o f cytological 
and architectural atypia present. In summary, PanIN-la and Pan-1 B are those lesions 
with slight or no atypia; PanIN-2 designates lesions with moderate atypia; and Panln-3 
designates those lesions with severe atypia. Table 3 explains the cytological and 
architectural criteria in more detail.
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N o r m a l T h e  n o rm a l d u c ta l  a n d  d u c tu la r  e p i th e l iu m  is  a  
c u b o id a l  to  lo w -c o lu m n a r  e p i th e l iu m  w ith  
a m p h o p h i l ic  c y to p la s m . M u c in o u s  c y to p la s m , 
n u c le a r  c ro w d in g  a n d  a ty p ia  a r e  n o t  s e e n .
S q u a m o u s  ( t r a n s i t io n a l )  m e ta p la s ia A  p ro c e s s  in  w h ic h  th e  n o rm a l  c u b o id a l  d u c ta l  
e p ith e liu m  is r e p la c e d  b y  m a tu r e  s q u a m o u s  o r  
t r a n s it io n a l  e p ith e liu m  w i th o u t  a ty p ia .
P a n I N - lA (P a n c r e a t ic  I n tr a e p ith e l ia l  N e o p la s ia  1 -A ):  T h e s e  
a re  f la t  e p ith e lia l  le s io n s  c o m p o s e d  o f  ta l l  c o lu m n a r  
c e l l s  w ith  b a sa lly  lo c a te d  n u c le i  a n d  a b u n d a n t  
s u p r a n u c le a r  m u c in .  T h e  n u c le i  a r e  s m a l l  a n d  ro u n d  
to  o v a l  in  sh a p e .  W h e n  o v a l  th e  n u c le i  a r e  o r ie n te d  
p e r p e n d ic u la r  to  th e  b a s e m e n t  m e m b r a n e .  I t  is  
r e c o g n iz e d  th a t  th e r e  is  c o n s id e r a b le  h is to lo g ic  
o v e r la p  b e tw e e n  n o n -n e o p la s t ic  f la t  h y p e rp la s t ic  
le s io n s  a n d  f la t  n e o p la s t ic  le s io n s  w i th o u t  a ty p ia .
P a n I N - lB (P a n c r e a t ic  I n tr a e p ith e l ia l  N e o p la s ia  1 -B ):  T h e s e  
e p i th e lia l  le s io n s  h a v e  a  p a p il la ry ,  m ic r o p a p i l la r y  o r  
b a s a lly  p s e u d o s t r a t i f ie d  a r c h i te c tu r e ,  b u t  a re  
o th e rw is e  id e n tic a l  to  P a n IN -1  A .
P a n I N -2 (P a n c r e a t ic  I n tr a e p ith e l ia l  N e o p la s ia  2 ):
A r c h i te c tu r a lly  th e s e  m u c in o u s  e p i th e l i a l  le s io n s  
m a y  b e  f la t  o r  p a p il la ry .  C y to lo g ic a l ly ,  b y  
d e f in i t io n ,  th e s e  le s io n s  m u s t  h a v e  s o m e  n u c le a r  
a b n o rm a li t ie s .  T h e s e  a b n o r m a li t ie s  m a y  in c lu d e  
s o m e  lo s s  o f  p o la r i ty ,  n u c le a r  c r o w d in g ,  e n la rg e d  
n u c le i ,  p s e u d o - s t r a t i f ic a t io n  a n d  h y p e r c h r o m a t is m .  
T h e s e  n u c le a r  a b n o rm a li t ie s  fa ll  s h o r t  o f  t h o s e  s e e n  
in  P a n IN -3 .  M ito s e s  a re  r a re ,  b u t  w h e n  p r e s e n t  a re  
n o n - lu m in a l  ( n o t  a p ic a l )  a n d  n o t  a ty p ic a l .  T ru e  
c r ib r i fo rm in g  lu m in a l  n e c ro s is  a n d  m a rk e d  
c y to lo g ic  a b n o rm a li t ie s  a re  g e n e r a l ly  n o t  s e e n ,  a n d  
w h e n  p re s e n t  sh o u ld  s u g g e s t  t h e  d ia g n o s is  o f  
P a n IN -3 .
P a n I N -3 (P a n c r e a t ic  I n tr a e p ith e l ia l  N e o p la s ia  3 ) :  T h e s e  
le s io n s  a re  u su a lly  p a p il la ry  o r  m ic r o p a p i l la r y  - th e y  
m a y  ra re ly  b e  f la t .  T ru e  c r ib r i f o r m in g ,  b u d d in g  o f f  
o f  sm a ll  c lu s te r s  o f  e p ith e lia l  c e l l s  in to  t h e  lu m e n  
a n d  lu m in a l  n e c ro s e s  a ll  s u g g e s t  t h e  d ia g n o s is  o f  
P a n IN -3 .  C y to lo g ic a l ly ,  th e s e  l e s io n s  a re  
c h a ra c te r iz e d  b y  a  lo s s  o f  n u c le a r  p o la r i ty , 
d y s t ro p h ic  g o b le t  c e l l s  (g o b le t  c e l l s  w i th  n u c le i 
o r ie n te d  to w a rd s  th e  lu m e n  a n d  m u c in o u s  
c y to p la s m  o r ie n te d  to w a r d  t h e  b a s e m e n t  
m e m b ra n e ) ,  m ito s e s  w h ic h  m a y  o c c a s io n a l ly  b e  
a b n o rm a l,  n u c le a r  i r r e g u la r i t ie s  a n d  p ro m in e n t  
( m a c ro )  n u c le o l i
Table 3: Existing Pancreatic Intraepithelial Neoplasia nomenclature (Hruban et al. 
2007)
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Linking PanIN and Cancer
A number of pieces of evidence have been put forward in support of the hypothesis 
PanIN is the precursor lesion for pancreatic cancer. A number of studies has proven that 
histological examination of pancreases with PDAC and normal pancreases reveal ductal 
papillary hyperplasia are more common in the former group of pancreases (Cubilla et al. 
1976; Kozuka et al. 1979; Kloppel et al. 1980; Chen et al. 1985; Luttges et al. 1999). 
The incidence of ductal changes in the pancreas increases with age. Lastly, hyperplastic 
ductal lesions may harbour mutations of the K-ras gene which is are characteristic of 
ductal adenocarcinomas (Yanagisawa et al. 1993; Tada et al. 1996; Moskaluk et al. 
1997; Matsubayashi et al. 1998; Terhune et al. 1998; Heinmoller et al. 2000).
Normal
ductal I PanlN-1A || PanlN-1B II PanlN-2 II PanlN-3 II P D AC  || Metastatic |
cells cells
M-----Kras — ► ◄-------- P16'nm----- ► ◄—  P53 - >
SMAD4
Figure 6: Demographic progression model for pancreatic cancer
(Illustrations by A Shekouh, taken with permission)
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Figure 7: Progression model for pancreatic cancer.
(Illustrations by A Shekouh, taken with permission)
Normal duct epithelium progresses to infiltrating cancer (left to right) through a series of 
histologically defined precursors (PanINs). The point mutations in the K-ras gene occur 
early, inactivation of the p i6 gene at an intermediate stage, and the inactivation o f p53, 
SMAD4 occur relatively late.
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Grading and Staging of Pancreatic Ductal Adenocarcinoma
Grading Pancreatic Ductal Adenocarcinoma
The grading of PDAC, as with any other cancers, is a microscopic issue. The pathologist 
with a surgically resected or biopsy specimen, will be able to grade the tumour 
according to the microscopic appearances of the cells, taking into account glandular 
differentiation, mucin production, nuclear atypia and mitotic activity (Kloppel et al. 
1985).
The grading category falls into three divisions- well, moderately and poorly 
differentiated and the aggressiveness of the tumour usually follows accordingly. 
Unfortunately, the process of grading a specimen for PDAC is subjective, not 
reproducible, and very dependent on the experience of the observer. The grading system 
used in most Western countries is the WHO organization Table 4 (Kloppel et al. 1996).
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Grading of pancreatic cancer has been linked to survival benefits following surgical 
resection. Meyer et al confirms the survival benefit in a larger number of patients (91 
patients who had undergone pancreatic resections), with reports of a 5-year survival rate 
of 32% (13/91 patients) for well-differentiated tumours compared with 0% (14/91 
patients) for poorly differentiated tumours (Meyer et al. 2000).
Luttges et al reported that tumour grade is a highly significant prognostic factor- 
especially when based on the observation field with the lowest degree of differentiation. 
The mean survivals were 27.6 months, 18.2 months and 8.1 months for the tumour 
grades well, moderately and poorly differentiated respectively (Luttges et al. 2000).
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From Italy, Benassai reported much improved survival of patients with resected well 
differentiated pancreatic ductal adenocarcinoma (4 patients) compared with patients with 
moderately (21 patients) and poorly differentiated (50 patients) tumours- (median 
survival 54, 33, 16 months respectively; 5-year survival 75%, 42.9%, 4% respectively) 
(Benassai et al. 2000). The actuarial 5-year survival rate for this group o f patients 
following resection of their tumour was 18.7%. The survival rates were also influenced 
by the lymph node status, DNA content of the pancreatic cancer cells, the pathological 
margins and the tumour diameter.
Other authors have reported actuarial survival rates in patients with resected pancreatic 
ductal adenocarcinoma varying from 6.8-24% (Cameron et al. 1993; Baumel et al. 1994; 
Bramhall et al. 1995; Nitecki et al. 1995; Wade et al. 1995; Benassai et al. 2000). 
Again, the patients with smaller tumours, negative lymph nodes, diploid tumours, 
negative resection margins and well-differentiated tumours achieved better survival rates 
than their counterparts.
Grade, stage and nodal status are interrelated making survival analysis a complex issue 
to discuss. This is an important and interesting area, but for the purpose o f this thesis the 
most important observation is that the earlier tumours are detected the better the chances 
of survival.
73
Staging of Pancreatic Ductal Adenocarcinoma
The diagnosis of PDAC is dependent upon physical examination, imaging, and/or 
surgical exploration. Ideally, there should be histological or cytological confirmation of 
the disease, although this may not be attainable in all the cases.
The most widely used staging classification for PDAC is published by the Union 
Internationale Contre le Cancer (UICC). The current classification takes into account the 
following factors- primary tumour (T), lymph node metastasis (N) and distant metastasis 
(M) Table 5 and Table 6. There is a different staging classificatification in Japan which 
will not be discussed in any further detail. Appropriate staging in the diagnosis of 
pancreatic ductal adenocarcinoma is very important to avoid unnecessary exploratory 
surgery, which is time consuming, expensive and inflicts physical and psychological 
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Stage T category N category M category
0 Tis NO MO
IA T1 NO MO
IB T2 NO MO
IIA T3 NO MO
IIB Tl, 2, 3 N1 MO
III T4 Any N MO
IV Any T Any N Ml
T = T u m o u r ,  N =  L y m p h  n o d e s ,  M =  M e ta s ta s is
Table 6: UICC Stage Classification for Pancreatic Ductal Adenocarcinoma (Sobin 
et al. 2006)
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Current clinical practice in the staging of pancreatic ductal adenocarcinoma includes the 
use of biochemical analysis of blood samples for tumours markers carcinoembryonic 
antigen (CEA) and CA19-9. These tumour markers may confirm the suspicion of a 
pancreatic malignancy but they may also be falsely elevated in the presence o f benign 
conditions of the pancreas and liver.
Most pancreatic lesions are initially noticed on USS and/or ERCP. These initial 
investigations may be followed by more detailed imaging with computed tomography 
and/or magnetic resonance scans.
Prior to undertaking potentially curative surgery, there are pancreatic units performing 
laparoscopy to rule out the possibility of metastatic spread of the cancer. In potentially 
resectable pancreatic cancer determined by conventional imaging studies, surgeons have 
found the spread of the cancer outside the pancreas in 10-34% of patients (Conlon et al. 
1996; Friess et al. 1998; Jimenez et al. 2000).
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Conventional Diagnostic Modalities of Pancreatic Ductal Adenocarcinoma
Rapid advances in radiological imaging have enabled clinicians to greatly reduce the 
number of patients undergoing unnecessary surgery in an attempt to cure them o f their 
pancreatic malignancy. With the aid of current diagnostic aids, the number o f patients 
undergoing pancreatic surgery with the intention of cure has been reduced to less than 
10% (Allema et al. 1995; Nitecki et al. 1995).
Despite major advances in laboratory diagnosis and radiological technology, the 
sensitivity and specificity of these tests are still not high enough for them to be used as 
reliable screening tools. The variation in sensitivity and specificity of the imaging and 
laboratory modalities used are shown in the tables to follow.
Tumour Markers
CA 19-9 is one of the most commonly used tumour markers for PDAC but there is a 
variation in the sensitivity. Steinberg et al compared the sensitivity and specificity of 
CA19-9 and CEA results for 37 patients with biopsy proven pancreatic adenocarcinoma- 
14 patients with resectable disease and 23 patients with unresectable disease. 157 
controls were also analysed- 48 patients with benign pancreatic disease, 34 patients with 
non-pancreatic sources of abdominal pain, 58 patients with benign jaundice, 7 patients 
with nonpancreatic malabsorption, and 10 patients with renal failure on dialysis. The 
group reported the sensitivity for CA19-9 (>75U/ml) was 86.5% compared to CEA
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(>5ng/ml) which was 48.4%. The specificity of CA19-9 was 92.5% versus 87.3% for 
CEA (Steinberg et al. 1986).
A collective study from 7 institutions in Japan by Furukawa et al analysing small 
pancreatic adenocarcinoma (2cm or less in greatest dimension) reported the sensitivity 
for CA19-9 to be 58.1% (18 of 31 patients). This compared unfavourable to USS, EUS, 
CT and ERCP which had sensitivity in this study reported as 64.5%, 73.7%, 64.5% and 
93.1% respectively (Furukawa et al. 1996).
Serum CA 19-9 level may also be raised in other malignancies such as adenocarcinoma 
o f the stomach, colon and the hepatobiliary system as well as in obstructive jaundice, 
acute cholangitis and worst of all in chronic pancreatitis (Tanaka et al. 2000). Other 
possible tumour markers such as CEA, SPAN-1, CA 50 and TAG-72, have even lower 
diagnostic efficiencies compared to CA 19-9 (Kuno et al. 1994; Pasquali et al. 1994; 
Safi et al. 1996) (Table 9). For small resectable tumours both the sensitivities and 















































Rosch et al recently compared in a prospective manner the accuracy of USS, computed 
CT, ERCP and EUS in 184 in-patients who were referred for evaluation o f suspected 
pancreatic disease. The final diagnoses were normal pancreas in 36, chronic pancreatitis 
without a focal inflammatory mass in 53 or with a focal inflammatory mass in 18 and 
pancreatic malignancy in 77 cases. The sensitivity for pancreatic disease for TUS was 
94% but the specificity was only 35%. The sensitivity and specificity was 91% and 78% 
for CT, 89% and 92% for ERCP and 93% and 94% for EUS, respectively. There was no 
difference in the sensitivity between the imaging tests in cancer and chronic pancreatitis 
(Rosch et al. 2000). Adamek et al prospectively compared magnetic resonance 
cholangiopancreatography (MRCP) with ERCP in 124 patients with a strong clinical 
suspicion of pancreatic cancer: 37 (30%) had pancreatic carcinoma, 17 (14%) had other 
neoplastic pancreatic diseases, 57 (46%) had chronic pancreatitis and in 13 (10%) the 
main pancreatic duct was normal. The sensitivity of MRCP for diagnosing pancreatic 
cancer was 84% and its specificity was 97%, compared to 70% and 94%, respectively 
for ERCP. The diagnosis of malignancy was confirmed by comparing the MRCP/ERCP 
diagnosis with histopathological evidence using laparotomy or ultrasound guided 
biopsy. In patients lacking histological evidence, a follow up of at least 12 months was 
used as reference (Adamek et al. 2000). In an important prospective study of ERCP in 
14 asymptomatic patients with a history of FPC, Brentnall et al found suspicious lesions 
in seven cases, all of whom were shown to have pancreatic ductal dysplasia (pancreatic 
intraepithelial neoplasia -  PanIN - grades 2 and 3) by histology of the surgically resected 
specimens (Brentnall et al. 1999).
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The diagnosis of pancreatic cancer using endoscopic brush cytology of the pancreatic 
duct has a sensitivity of 67-76% and a specificity of 83-100% (Vandervoort et al. 1999) 
and in the case of biliary duct brushings the sensitivity is 36-50% and the specificity is 
82-97% (Glasbrenner et al. 1999; Vandervoort et al. 1999) (Table 8).
Muller et al reported a much higher sensitivity (93%) using EUS for tumour detection 
than either dynamic CT (53%) or magnetic resonance imaging (MR1; 67%) (Muller et 
al. 1994). The difference was apparently more striking for tumours <20mm with 
sensitivities of 90%, 40% and 33% for EUS, dynamic CT and MR1 respectively. The 
overall accuracy for the diagnosis of malignant lesions was 86% (EUS), 67% (CT), and 
84% (MRI). The final diagnosis for this group of patients were 16 PDAC, 6 
oeriampullary tumour, 2 benign neoplasms, 9 inflammatory tumours, and no tumour. 
The no tumour group of patients were followed up for a period of 9-24 months (Muller 
et al. 1994). Midwinter et al reported that EUS demonstrated 23/24 (96%) pancreatic 
cancers compared with only 19/24 (78%) using spiral CT (Midwinter et al. 1999) Table 
9.
Voss et al evaluated EUS-fine needle aspiration biopsy (EUS-FNAB) in 73 cases (51 
PDAC, 8 neuroendocrine tumours, 6 various neoplasms and 8 pancreatitis). The 
sensitivity, specificity, positive and negative predictive values for differentiating 
pancreatic adenocarcinoma from chronic pancreatitis was 81%, 88 %, 98% and 39% 
respectively (Voss et al. 2000).
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Positron emission tomography (PET) with radiolabelled flurodeoxyglucose has a 
sensitivity o f 71-87% and a specificity of 50-64% for detecting malignant pancreatic 
lesions (Mertz et al. 2000; Sendler et al. 2000). Hosten et al have produced a preliminary 
report to suggest that sensitivity for smaller pancreatic lesions may be increased by using 
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Molecular Diagnosis of Early Pancreatic Pancreatic Ductal Adenocarcinoma in
High Risk Patients
Screening Of Pancreatic Cancer Requirements
The key determinants for screening are (i) the importance of the disease; (ii) the 
prevalence of the disease; (in) the accuracy of the screening methodology; and (iv) the 
cost-benefit ratio of the screening. Whilst there is no doubting the importance of 
pancreatic cancer its prevalence is not high enough per se to justify the use of screening 
(Neoptolemos et al. 1996).
The fundamental requirement for screening is that the benefits for the true positive 
population must outweigh the harm done to the false positive population. In the case of 
pancreatic cancer true positives may (or possibly may not) be saved from a horrible 
death (by removing the tumour surgically), but false positives will undergo an 
unnecessary and possibly life threatening surgical procedure. In very general terms we 
can therefore say that for screening to be ethical, the true positive: false positive (TP: 
FP) ratio must be >1.0, since the proportion of false positives must not exceed that of 
true positives by any large amount. If the TP: FP ratio is « 1 .0  then any benefit derived 
from screening is lost due to the excess morbidity (and mortality), as well as the cost 
associated with treating a large number of false positives. Assuming, the prevalence of 
the at-risk cohort to be 10 per 105 of the population and the sensitivity and specificity for 
the conventional screening modalities for pancreatic cancer to be 85%, then the TP: FP 
ratio is only 6x1 O'4. Thus with these assumptions any screening programme would be
undermined by the overwhelming number of false positives (1,764 false positives for 
each true positive).
Screening might be feasible however by focussing on high-risk sub-groups and thereby, 
in effect, raising the prevalence within the screened group. For pancreatic cancer the key 
risk factors are increasing age, tobacco smoking, chronic pancreatitis, an inherited 
predisposition and diabetes mellitus (Finch et al. 1997; Bramhall et al. 1998). Taking 
into account age, the prevalence of the disease in older patients is still, of itself, not high 
enough to justify the application of screening, nor even if we take into account the 
increased risk group associated with smoking (Neoptolemos et al. 1996).
Again assuming a sensitivity and specificity for the conventional screening modalities 
for pancreatic cancer of 85%, by limiting screening to those aged >40 years, the 
prevalence o f the at-risk cohort increases from 10 per 105 of the population to 20 per 105 
of the population. Unfortunately the TP: FP ratio reduces from 6xl0 '4 to only 1x103. 
We can calculate that the prevalence of the at-risk group would need to be >15,000 per 
105 of the population screened in order to achieve a manageable ratio for a TP: FP ratio 
of >1.0. Even the use of smoking as an additional risk factor does little to tilt the balance 
in favour of screening since the relative risk of pancreatic cancer for smoking is only ~2- 
fold (Silverman et al. 1994). However, by selecting genetically high risk patient groups, 
screening may be a feasible undertaking to identify early pancreatic cancer lesions.
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Groups of individuals at much higher risk have been identified, including patients with 
(sporadic) chronic pancreatitis and a variety of inherited autosomal dominant or 
autosomal recessive disorders (Hruban et al. 1999; Efthimiou et al. 2001) (Table 1). 
Therefore, it may be worth screening in genetically high risk groups, where the risks of 
developing pancreatic cancer might be doubled or more.
The purpose of screening is to identify patients who have developed pre-malignant 
pancreatic neoplasia so that they can be cured. The most common situation is likely to 
involve patients who have background pancreatic pathology (CF, HP and sporadic 
chronic pancreatitis). The only way in which cure can be achieved by total 
pancreatectomy. Certainty as to the high malignant risk is essential as even in modem 
units there is still a substantial morbidity and not insignificant mortality from major 
pancreatic surgery in patients with chronic pancreatitis (Evans et al. 1997; Beger et al. 
1999; Buchler et al. 2000).
Even given high-risk populations the screening methodology has to have a sensitivity 
and specificity in the order of 95-100%. Given our particular requirements the relative 
importance of specificity far exceeds that of sensitivity. For example if we assume a 10- 
fold risk for pancreatic cancer (such as that for chronic pancreatitis) and a sensitivity of 
95% then to achieve a TP: TF ratio >1.0 requires a specificity of 99.9% (actual TP: TF = 
2.1). Reducing the specificity from 99.9% to just 99.5% produces an unacceptable TP: 
TF ratio of 4x10 '1. On the other hand increasing the sensitivity to 99% produces only a 
marginal increase in the TP: TF to 2.2. The situation improves somewhat if the at-risk
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population has a 100-fold risk (such as that for Hereditary Pancreatitis and Peutz-Jeghers 
Syndrome). In this case, given a sensitivity of 95% then a TP: TF =1.0 is achieved with 
a specificity of 98%.
Thus it appears on theoretical grounds that at least some at-risk groups for pancreatic 
cancer might be suitable for screening. The extent to which the risk in these groups is 
defined and the relevance of existing diagnostic tools required for screening needs to be 
examined in further detail.
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Molecular Modalities for Diagnosis of Pancreatic Cancer
It is apparent that the diagnosis of pancreatic cancer at an early curable stage, especially 
in the presence of chronic pancreatitis is served poorly by conventional modalities. The 
requirements for successful screening in pancreatic cancer are for a sensitivity o f 95% 
and a specificity of 98% to 99.9% depending on the prevalence of the pre-selected at- 
risk cohort- this requirement is not fulfilled by the diagnosis of pancreatic cancer by 
tumour markers analysis or by conventional radiological tests. How well do molecular 
tests perform to these requirements?
With advances in the understanding of the molecular biology of pancreatic cancer and 
chronic pancreatitis, new diagnostic modalities are being developed with a potentially 
infinitely better sensitivity and specificity. There are four genes in particular that are 
involved in the molecular pathogenesis of pancreatic cancer and which may provide the 
basis for a molecular screening programme.
K-Ras Oncogene
The RAS protein act as an on-off switch that regulate signal transduction pathways 
controlling cell growth, differentiation and survival. K-ras is a proto-oncogene located 
on chromosome 12pl2 that codes for the 21kDa GTP-binding protein (p21) synthesized 
in cytoplasm and localized on the inner surface of the plasma membrane. The wild-type 
K-ras gene code for proteins that bind guanine diphosphate and guanine diphosphate and 
possesses GTPase activity but the activated form of the gene has no GTPase activity or 
reduced affinity for guanosine diphosphate (GDP) and guanosine triphosphate (GTP)
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(Bos 1988). They are involved in the signal transduction of activated tyrosine kinase cell 
surface receptors to downstream signal cascades. Activation of the gene results from 
point mutations at codon 12, 13 and 61 leading to the substitution of glycine with other 
amino acids, causing the oncogenic Ras protein to be in a permanently active GTP- 
bound state. Mutations of K-ras (nearly all on codon 12) occur in 75-100% of pancreatic 
cancers (Tada et al. 1991; Urban et al. 1993; Berrozpe et al. 1994; Banerjee et al. 1997; 
Wilentz et al. 1998; Kawesha et al. 2000) Table 10.
K-ras mutations have also been found in phenotypically normal and hyperplastic ductal 
lesions (Yanagisawa et al. 1993) and in neoplastic lesions <20mm in size, suggesting a 
very early role in the molecular pathogenesis of PDAC. Luttges et al studied 35 
resection specimens of PDAC and three normal pancreata by single cell microdissection 
and PCR analysis for mutant (mt) K-ras. All of the primary PDACs had mt-K-ras as well 
as 106/364 ductal lesions including adenomatoid hyperplasia, (53%), papillary 
hyperplasia (36%), mucinous hypertrophy (26%) and squamous metaplasia (14%) and 
with only two exceptions the mutation pattern of the ductal lesions and that of the 
corresponding primary tumor were identical. Twenty-one (17%) samples from normal 
ducts also harboured the mt-K-ras, as did three lesions from non-cancerous specimens 
(Luttges et al. 1999). Tada et al reported that 30/30 (100%) micro-dissected 
adenocarcinoma samples had mt-K-ras compared to 17/79 (24%) hyperplastic cell 
samples and none of 12 normal duct specimens (Tada et al. 1996). The overall rate of 
mt-K-ras in 700 chronic pancreatitis patients collated from the published literature in 
2000, was approximately 13% (Lohr et al. 2000). Dergham et al examined 81 cases with
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PDAC, seven of whom had a family history of pancreatic cancer. K-ras mutations were 
not statistically different in patients with (83%) and without a family history of PDAC 
(70%) but the incidence of p53 over-expression was significantly lower in patients with 
a family history of cancer (40% vs 72%) (Dergham et al. 1997).
Mutant K-ras can be detected in the blood, stool, bile and pancreatic juice from shed 
cells and free deoxyribonucleic acid (DNA) (Table 11). The proportion of cases with mt- 
K-ras is dependent on many factors including the mode of sample collection and storage, 
the method o f assay and the test population. Van Laethem et al were able to detect mt-K- 
ras in 20/24 (83%) pancreatic juice samples from patients with PDAC, similar to 
Berthelemy et al who reported mt-K-ras in 17/22 (77%) of patients with pancreatic 
tumours (Berthelemy et al. 1995). Iguchi et al found mt-K-ras in 12/19 (63%) (Iguchi et 
al. 1996) and Kondo et al in 6/9 of patients with pancreatic cancer (Kondo et al. 1994; 
Iguchi et al. 1996). Kondo et al also found that 1/41 (2%) patients with benign 
pancreatic disorders also had mt-K-ras. Watanabe et al found K-ras mutations in the 
duodenal aspirate of 25/38 (66%) patients with pancreatic carcinoma and in 12/38 (32%) 
patients with chronic pancreatitis but not in 42 patients with benign biliary diseases or in 
20 control patients (Watanabe et al. 1999). Wilentz et al, however, found mt-K-ras in 
3/10 (30%) of duodenal juice samples from patients with benign conditions compared to 
29/42 (69%) patients with periampullary cancers (Wilentz et al. 1998). Uehara et al 
found mt-K-ras in the pancreatic juice of 8/10 (80%) cases with pancreatic cancer, 2/3 
(67%) cases with chronic pancreatitis and 1/3 (33%) cases with normal pancreas 
(Uehara et al. 1999).
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Table 10: K-ras Mutations in PDAC Tissues
Series No. in series Methodology Percent with K- 
RAS mutations
Urban et al (Urban et al. 
1993)
12 RFLP 11/12(92)
Hruban et al (Hruban et 
al. 1993)
82 RFLP 68/82(83)
Pellegata et al (Pellegata 
étal. 1994)
35 Sequencing 25/35 (71)
Iguchi et al (Iguchi et al. 
1996)
10 SSCP 9/10(90)
Tada et al (Tada et al. 
1996)
30 Sequencing 30/30 (100)
Dergham et al (Dergham 
étal. 1997)
76 SSCP 64/76 (84)
Banerjee et al (Banerjee 
étal. 1997)
15 RFLP 15/15(100)
Wilentz et al (Wilentz et 
al. 1998)
34 RFLP 22/34 (65)
Ward et al (Ward et al. 
1998)
6 RFLP 4/6 (67)





Lüttges et al (Luttges et 
al. 1999)
35 Denaturing gradient 35/35 (100)
Aoki et al (Aoki et al. 
2000)
10 Sequencing 8/10(80)
Slebos et al (Slebos et al. 
2000)
61 MASA 46/61 (75)
Kawesha et al (Kawesha 
et al. 2000)
97 SSCP 73/97 (75)
P C  =  p a n c r e a t ic  c a n c e r ;  C P  =  c h r o n ic  p a n c r e a t i t i s ;  S e n  =  s e n s i t iv i ty ;  S p e c  =  s p e c if ic i ty ;  S S C P  =  s in g le ­
s t r a n d  c o n f ir m a to r y  p o ly m o r p h is m ;  R F L P  =  r e s t r ic t io n  f r a g m e n t  le n g th  p o ly m o rp h is m ; L C M  =  la s e r  
c a p tu r e  m ic ro s c o p y . N u m b e r s  in  p a r e n th e s e s  a r e  p e r c e n ts
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Table 11: Accuracy of mutant K-ras detection in diagnostic clinical specimens
S é r i é s N o . in  s e r i e s S a m p le M e t h o d o ­
lo g y
K - R A S
K o n d o  e t  a l ( K o n d o  e t  a l. 
1 9 9 4 )
3 3  ( 9  P C , 14 C o n tro l ,  
10 C P )
PJ S S C P S e n  6 /9  ( 6 7 )  
S p e c  0 /2 4  ( 1 0 0 )
T a d a  e t  a l ( T a d a  e t  a l. 1 9 9 3 ) 7  (6  P C , 1 C o n tro l ,  2
C P )
PJ R F L P S e n  6 / 6 ( 1 0 0 )  
S p e c  3 /3  ( 1 0 0 )
B e r th é le m y  e t  a l 
( B e r th e le m y  e t  a l. 1 9 9 5 )
7 4  (2 2 P C , 2 4  C o n tro ls ,  
2 9  C P )
PJ R F L P S e n  1 7 /2 2  ( 7 7 )  
S p e c  5 3 /5 3  
( 1 0 0 )
Ig u c h i  e t  a l ( Ig u c h i  e t  a l. 
1 9 9 6 )
6 0  ( 1 9  P C , 41 C o n tro l) D A S S C P S e n  1 2 / 1 9 ( 6 3 )  
S p e c  4 0 /4 1  ( 9 8 )
W a ta n a b e  e t  a l (W a ta n a b e  e t 
a l .  1 9 9 9 )
1 3 8  (3 8  P C , 100 
C o n tro l)
D A M A S A S e n  2 5 /3 8  ( 6 6 )  
S p e c  8 8 /1 0 0  
(8 8 )
Y a m a s h i ta  e t  a l ( Y a m a s h i ta  
é t a l .  1 9 9 9 )
2 2  (1 3 P C , 9  C P ) PJ S S C P S e n  1 3 / 1 3 ( 1 0 0 )  
S p e c  6 /9  (6 7 )
Y a m a g u c h i  e t  al 
( Y a m a g u c h i  e t  a l. 1 9 9 9 )
4 2  (2 6  P C , 16 C P ) PJ R F L P
S e le c t iv e -
h y b r id iz a t i
o n
S e n  2 1 /2 5  ( 8 4 )  
S e n  1 7 /2 6  ( 6 5 )
U e h a r a  e t  a l ( U e h a r a  e t  a l. 
1 9 9 9 )
16 (1 0  P C , 6  C o n tro l) PJ S S C P S e n  8 /1 0  (8 0 )  
S p e c  3 /6  (5 0 )
C a ld a s  e t  a l (C a ld a s  e t  a l. 
1 9 9 4 )
1 5 ( 1 1  P C , 4  C P ) S to o l S e le c t iv e -
h y b r id iz a t i
o n
S e n  6 /1 1  ( 5 5 )  
S p e c  3 /4  ( 7 5 )
W e n g e r  e t  a l ( W e n g e r  e t  a l. 
1 9 9 9 )
41 (3 6  P C , 5 C P ) S to o l S e le c t iv e -
h y b r id iz a t i
o n
S e n  7 / 3 6 ( 1 9 )  
S p e c  3 /5  ( 6 0 )
Y a m a d a  e t  a l ( Y a m a d a  e t  a l. 
1 9 9 8 )
1 9 (1 5 P C , 4 C P ) S e ru m M A S A S e n  9 /1 5  ( 6 0 )  
S p e c  4 / 4 ( 1 0 0 )
M u lc a h y  e t  a l ( M u lc a h y  e t 
a l .  1 9 9 8 )
2 3  (21  P C , 2  C P ) S e ru m R F L P S e n  1 7 /2 1  ( 8 1 )  
S p e c  2 /2  ( 1 0 0 )
C a s te l l s  e t  a l ( C a s te l l s  e t  a l. 
1 9 9 9 )
81 (4 4  P C , 3 7  C P ) S e ru m R F L P S e n  1 2 /4 4  ( 2 7 )  
S p e c  3 5 /3 7  ( 9 5 )
T h e o d o r  e t  a l ( T h e o d o r  e t  a l. 
1 9 9 9 )
31 (2 0  P C , 11 C o n tro l) S e ru m R F L P S e n  1 4 /2 0  7 0 )  
S p e c  0 /1 1  ( 1 0 0 )
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P C  =  p a n c r e a t i c  c a n c e r ;  C P  =  c h r o n ic  p a n c re a t i t i s ;  S e n  =  s e n s i t iv i ty ;  S p e c  =  s p e c if ic i ty ;  S S C P  =  s in g le ­
s t r a n d  c o n f ir m a to r y  p o ly m o rp h is m ;  R F L P  =  re s t r ic t io n  f r a g m e n t  le n g th  p o ly m o rp h is m ;  M A S A =  m u ta n t 
s p e c i f i c  a l l e le  a m p l i f ic a t io n ;  P J =  p a n c re a t ic  j u ic e ,  D A  =  d u o d e n a l  a s p ira te ;  P D  =  p a n c r e a t ic  d u c t .
N u m b e r s  in  p a r e n th e s e s  a r e  p e r c e n ts .
Puig et al found mt-K-ras in pancreatic fine-needle aspirates in 36/45 (80%) of samples 
analyzed by continuous-enrichment for the mutant allele by enzymatic digestion PCR, 
apparently without a single false positive (Puig et al. 2000). Strum et al found that 24/38 
(63%) patients were correctly diagnosed with PDAC by analysis of endo-biliary 
brushings for mt-K-ras, compared to 8/38 (21%) cases using conventional cytology 
(Sturm et al. 1999). Interestingly, mt-K-ras was found in 8/74 (11%) patients with 
benign disease with no progression to malignant disease after a mean follow up of 30 
months (Sturm et al. 1999). Tada et al found that >1% of the total DNA from pancreatic 
juice was mt-K-ras in 8/15 (53%) of patients with PDAC, 3/3 patients with an 
intraductal papillary neoplasm and 2/19 (11%) patients with benign disease (Tada et al. 
1998).
Free soluble DNA in the circulation is greatly increased in the presence of malignancy 
(<25ng/ ml in healthy subjects) (Shapiro et al. 1983). Yamada et al detected mt-K-ras in 
the blood of 9/15 (60%) patients with PDAC (Yamada et al. 1998). Theodor et al found 
mt-K-ras in the serum of 14/20 (70%) patients with PDAC but none in six patients with 
chronic pancreatitis or in five normal subjects (Theodor et al. 1999).
Using cloning technology, Caldas et al found mt-K-ras in the stool of 6/11 (55%) 
patients with PDAC, which correlated with the mutations found in the primary tumour 
(Caldas et al. 1994). Using selective hybridisation, Wenger et al found mt-K-ras in the
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stool of only 7/36 (19%) patients with PDAC compared to 28/36 (78%) of the tumours 
(Wenger et al. 1999). In the same study, 1/5 patients with chronic pancreatitis had mt-K- 
ras compared to two cases with mutations in the pancreatic tissue (Wenger et al. 1999).
From these studies we can conclude that mt-K-ras is an early and probably essential 
early event in the pathogenesis of the great majority, if not all, PDACs. It suffers from a 
poor specificity however and so the question arises that if it were to be used in a 
screening programme, exactly how this would be done.
The main focus of this thesis will be on the analysis of K-ras in high risk patients as will 
be discussed in more detail in Chapter 4.
TP53 Tumour Suppressor Gene
The TP53 gene is mutated in 50-77% of pancreatic cancers and is altered in -50% of 
malignancies of all types (Rozenblum et al. 1997). In pancreatic cancer there is a 
mutational hotspot located on codon 273 but mutations are found throughout the coding 
sequence, particularly in exons 5-8. Mutant p53 protein has a longer half-life than wild- 
type (wt) p53 protein and the accumulation in cells can be detected by 
immunohistochemistry (Table 12).
Heinmoller et al found alterations in at least one of three main tumour suppressor genes 
(TP53, CDKN2A and SMAD4) in 165 (60%) of 277 pancreatic intraductal lesions 
including some cases with nuclear atypia (Heinmoller et al. 2000). Loss of
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heterozygosity (LOH) of TP53 tended to occur later than for either CDKN2A or 
SMAD4, perhaps reflecting the dominant nature of many p53 mutations. 
Immunohistochemistry was positive for p53 in 81% of tumours with LOH compared to 
only in 38% of pancreatic intraductal lesions with TP53 LOH (Heinmoller et al. 2000).
Ruggeri et al found 71/13 (56%) PDAC tissue specimens staining positive with p53 
antibodies compared to 0/16 of normal pancreata (Ruggeri et al. 1997). Coppola et al 
found positive p53 staining in 20/42 (48%) patients with pancreatic carcinoma and 
positive correlation with tumour grade but not with stage or survival (Dergham et al. 
1997; Coppola et al. 1998). Kawesha et al found positive IHC staining in 64/157 PDACs 
but this was of no prognostic value and did not correlate with any biological or 
histological variable. As already mentioned above Dergham et al found that the 
incidence of p53 over-expression was significantly lower in patients with a family 
history of cancer (40%) compared to those without (72%) (Dergham et al. 1997).
Gansauge et al analyzed 80 tissue samples from patients with chronic pancreatitis for 
alterations of TP53 and K-ras (Gansauge et al. 1998). There were no cases of mt-K-ras 
(codon 12) detected by RFLP but there were eight alterations in TP53 (two in exon 5, 
four in exon 6, two in exon 7) identified by SSCP. DNA sequencing revealed one 
deletion of 21 amino acids (exon 5), four polymorphisms in exon 6 with no change in 
the amino acid sequence, one point mutation in exon 5 and two point mutations located 
in the intron between exons 6 and 7. The relevance of the findings is unclear and it 
should be noted in particular that molecular analysis was undertaken on whole (not
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micro-dissected) specimens. In contrast Luttges et al never found mt-K-ras in 19/429 
(4.4%) microdissected lesions from 8/30 patients with chronic pancreatitis but not a 
single instance of p53 immunopositivity (Luttges et al. 2000).
Yamaguchi et al identified p53 mutations in pancreatic juice using SSCP in 11/26 (421 
cases with pancreatic cancer but not in cases with a mucin-producing adenoma and r 
in patients with chronic pancreatitis (Yamaguchi et al. 1999). Immunocytology with p53 
antibodies using cells from pancreatic duct brushings was shown by Iwao et al to detect 
36/44 (82)% pancreatic carcinomas (Iwao et al. 1997; Iwao et al. 1998). Unfortunately, a 
similar analysis by Maacke et al that confirmed this finding, in that 10/15 (67%) patients 
with pancreatic carcinoma had p53 over-expression in pancreatic cells obtained 
endoscopically, also found p53 over-expression in 16/27 (59%) patients with chronic 
pancreatitis (Maacke et al. 1997). It is likely that p53 over-expression in the ductular 
cells of chronic pancreatitis represents increased p53 activity rather than a manifestation 
o f TP53 mutations.
Laurent-Puig et al found the sensitivity and specificity of enzyme linked 
immunosorbent assay (ELISA) for the detection of p53 antibodies in the sera patients 
with pancreatic cancer was 8/29 (28%) and 32/33 (97%) respectively (Laurent-Puig et 
al. 1995). Suwa et al found that only 16/47 (34%) patients with metastasis from 
pancreatic carcinoma had detectable serum p53 protein but only in 7/57 (12%) patients 
with carcinoma but no metastasis (Suwa et al. 1997).
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Thus, we can conclude that mt-TP53 is a feature of most invasive pancreatic cancers and 
can be detected in some cases in pre-neoplastic lesions. The number of mutations makes 
the detection of mt-TP53 from DNA in pancreatic juice difficult but the specificity for 
pancreatic cancer appears to be very high even in cases with concomitant chronic 
pancreatitis. The early diagnostic data using analysis of DNA from pancreatic juice look 
promising.
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Table 12: Detection of p53 protein in diagnostic clinical samples and pancreatic 
tissue in cases of pancreatic ductal adenocarcinoma
Series No. in series Sample Metho­
dology
p53 mutation
Y a m a g u c h i  e t  a l (Y a m a g u c h i  e t 
a l .  1 9 9 9 )
4 2  (2 6  P C , 16 
C P )
PJ S S C P S e n  1 1 /2 6  (4 2 )  
S p e c  0 / 1 6 ( 1 0 0 )
M a a c k e  e t  a l ( M a a c k e  e t  a l. 1 9 9 7 ) 4 2  (1 5  P C , 2 7  
C P )
P J IH C S e n  1 0 /1 5  (6 7 )  
S p e c  1 6 /2 7  (5 9 )
I w a o  e t  a l  ( Iw a o  e t  a l.  1 9 9 8 ) 7 4  (4 4  P C , 3 0  
C P )
P D
b ru s h in g
IH C S e n  3 6 /4 4  (8 2 ) 
S p e c  3 0 /3 0  (1 0 0 )
L a u r e n t - P u ig  e t  a l (L a u r e n t- P u ig  
e t  a l .  1 9 9 5 )
6 2  (2 9  P C , 3 3  
C o n tr o l)
S e ru m E L IS A S e n  8 /2 9  (2 8 )  
S p e c  3 2 /3 3  (9 7 )
S u w a  e t  a l ( S u w a  e t  a l. 1 9 9 7 ) 1 5 4 ( 1 0 4  P C , 35  
C o n tr o ls ,  15 C P )
S e ru m E L IS A S e n  2 3 /1 0 4  (2 2 ) 
S p e c  4 8 /5 0  (9 6 )
S c a r p a  e t  a l ( S c a rp a  e t  a l. 1 9 9 3 ) 3 4 T is s u e IH C 1 4 /3 4  ( 4 1 )
P e l le g a ta  e t  a l ( P e l le g a ta  e t  a l. 
1 9 9 4 )
35 T is s u e S e q u e n c in g 1 8 / 3 5 ( 5 1 )
D e r g h a m  e t  a l ( D e r g h a m  e t  a l. 
1 9 9 7 )
7 6 T is s u e IH C 3 3 /7 6  ( 4 3 )
K a s u y a  e t  a l (K a s u y a  e t  a l. 1 9 9 7 ) 7 0 T is s u e IH C 4 3 /7 0  ( 6 1 )
S u w a  e t  a l ( S u w a  e t  a l.  1 9 9 7 ) 61 T is s u e IH C 2 8 /6 1  ( 4 6 )
R o z e n b lu m  e t  a l ( R o z e n b lu m  e t  
a l .  1 9 9 7 )
41 T is s u e M /D 3 1 /4 1  ( 7 6 )
R u g g e r i  e t  a l (R u g g e r i  e t  a l. 1 9 9 7 ) 1 3 6 T is s u e IH C 7 1 /1 3 6  ( 5 6 )
C o p o l la  e t  a l ( C o p p o la  e t  a l. 
1 9 9 8 )
4 2 T issue IH C 2 0 /4 2  ( 4 8 )
T o m a s z e w s k a  e t  al 
(T o m a s z e w s k a  e t  a l. 1 9 9 9 )
18 T is s u e IH C 1 8 / 1 8 ( 1 0 0 )
K a w e s h a  e t  a l (K a w e s h a  e t  a l. 
2000)
157 T is s u e IH C 6 4 /1 5 7  (4 1 )
P C  =  p a n c r e a t i c  c a n c e r ;  C P  =  c h r o n ic  p a n c re a t i t i s ;  S e n  =  s e n s i t iv i ty ;  S p e c  =  s p e c if ic i ty ;  E L IS A  =  e n z y m e  
l in k e d  im m u n o s o rb e n t  a s s a y ;  IH C  =  im m u n o h is to c h e m is try ;  S S C P  =  s in g le - s t r a n d  c o n f irm a to ry  
p o ly m o r p h is m ;  M /D  =  m ic r o d i s s e c t io n  a n d  s e q u e n c in g ;  PJ =  p a n c re a t ic  j u ic e ;  P D  =  p a n c r e a t i c  d u c t. 
N u m b e r s  in  p a r e n th e s e s  a r e  p e r c e n ts
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CDKN2A (P16, MST1) Tumour Suppressor Gene
Loss of function of the CDKN2A (MST1) tumour suppressor gene occurs in -85-98%  of 
cases pancreatic cancer by homozygous deletion, intragenic mutation and transcriptional 
silencing via hyperméthylation of CpG islands in the promoter regions o f the gene 
(Caldas et al. 1994; Schutte et al. 1997; Kawesha et al. 2000). Caldas et al found 
CDKN2A homozygous deletions in 15/37 (41%) pancreatic carcinomas (27 xenografts 
and 10 cell lines) and sequence changes in 14 (38%) (Caldas et al. 1994; Muller et al. 
1994). Schutte et al using methylation-specific PCR found inactivation of CDKN2A in 
49/50 (98%) pancreatic carcinomas (propagated as xenografts or cell lines) (Schutte et 
al. 1997). Kawesha et al showed loss of expression the p l6 INIC4a protein by 
immunohistochemistry in 136/157 (87%) PDAC paraffin-embedded tissue samples 
(Kawesha et al. 2000).
Moskaluk et al found that CDKN2A alterations were present in 3/9 pancreatic intra­
ductal lesions from four pancreatic cancers shown to have CDKN2A alterations 
(Moskaluk et al. 1997). In the study by Heinmoller et al already referred to above, there 
was a tendency for LOH of CDKN2A to have occurred earlier in pancreatic intraductal 
lesions than for TP53or SMAD4 (Heinmoller et al. 2000).
Gerdes et al identified PanIN grade la lesions in 10/20 chronic pancreatitis lesions, of 
which four (but none of the 20 non-PanIN tissues) were negative for p l6 INK4a expression 
by immunohistochemistry; one case was shown to have a known CDKN2A 
polymorphism (c.442G >A; A148T) and two had inactivating hyperméthylation o f the
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CDKN2A promoter (Gerdes et al. 2001). These studies suggest that inactivation of 
CDKN2A is an early event in the pathogenesis of pancreatic carcinoma but the 
significance of the alterations observed in chronic pancreatitis is not clear.
SMAD4 (DPC4) Tumour Suppressor Gene
The protein product (Smad4) of the tumour suppressor gene SMAD4 (located on 
18q21.1) is involved in transmitting growth-suppressive signals by the transforming 
growth factor-13 (TGF-13) pathway, which in turn regulates cell growth and 
differentiation through their ability to induce or repress transcription of various genes, 
including cell-cycle control genes (Grau et al. 1997). Receptor-regulated Smads (R- 
Smads 2 and 3) bind to a specific TGF-13-related receptor at the cell surface, are 
phosphorylated on ligand stimulation, associate with a co-Smad (Smad4) and then 
translocate into the nucleus to regulate gene expression. TGF-I3 requires Smad4 to 
inhibit pancreatic cell growth through upregulation of the cell cycle inhibitor p21wafl 
(Grau et al. 1997). Schwarte-Waldhoff et al postulated that part of the SMAD4 tumour 
suppression function is mediated via controlling the expression of vascular endothelial 
growth factor and thrombospondin-1 and imposing growth constraints to tumour cells by 
limited vascularization (Schwarte-Waldhoff et al. 2000).
SMAD4 is inactivated in -50%  of pancreatic cancers by homozygous deletion, LOH and 
intragenic mutation, (Flahn et al. 1996) compared to <10% in other tumour types 
(Schutte et al. 1996). Moskaluk et al found no mutations from analysis o f the entire 
SMAD4 coding sequence of blood DNA from 25 individuals (11 kindreds) with a 
familial aggregation of pancreatic malignancy (Moskaluk et al. 1997).
102
Wilentz et al used DPC4 (SMAD4) IHC of formalin-fixed, paraffin-embedded tissue to 
study 188 PanfNs in 40 pancreata, 38 (95%) of which also contained an infiltrating 
adenocarcinoma. All 82 flat (PanIN-la), all 54 papillary (PanIN-lb) and all 23 atypical 
papillary (PanIN-2) intraductal lesions expressed DPC4 compared to only 20/29 (69%) 
of severely atypical lesions (PanlN-3 lesions, carcinomas in situ). The authors concluded 
that loss of DPC4 expression occurs biologically late in the progression of pancreatic 
cancer, at the stage of histologically recognizable carcinoma (Wilentz et al. 2000). In the 
study by Heinmoller et al, LOH of SMAD4 in pancreatic intraductal lesions, like TP53 
tended, to occur later than LOH of CDKN2A (Heinmoller et al. 2000).
Fukushige et al studied the loss of 18q in cells obtained from pancreatic juice by ERCP 
using fluorescence in situ hybridisation (FISH) (Fukushige et al. 1998). Loss of 18q was 
found in 3/5 patients with pancreatic ductal adenocarcinoma compared to 0/11 (0%) of 
patients with chronic pancreatitis. Three tissue specimens of the patients with pancreatic 
ductal adenocarcinoma were also found to have 18q loss by FISH.
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One of the major problems with screening for pancreatic cancer is that the best screening 
modalities are actually also the diagnostic modalities. This is because of the requirement 
for screening tests, as we have shown, to have a sensitivity of > 95% and a specificity of 
98% or 99.9% depending on whether the risk is 10-fold or 100-fold respectively.
Screening modalities should be relatively cheap and carry a minimum risk. On the other 
hand, the use of a test that has low cost and has little risk attached to it (such as EUS 
every year, say) but that has a sensitivity of <95% and/or a specificity o f <98-99.9% will 
in reality be very costly and have an unacceptable risk because of the generation of a 
large amount of false positives.
Moreover the diagnosis of pancreatic cancer at an early stage is still very problematical, 
often requiring the use of multiple modalities in order to reach a reasonable level of 
diagnostic certainty. Even then the only way in which a certain diagnosis can be reached 
in -5-10% of cases is by a partial pancreatectomy.
With these factors in mind a central objective of the EUROPAC protocol has been to 
modulate screening by reducing the interval for screening during the lesser risk periods 
and on the other hand, by focussing the intensity of diagnostic tests in higher risk 
situations (Howes et al. 2000). Above we have given the evidence demonstrating that the
The European Registry of Hereditary Pancreatitis and Familial Pancreatic Cancer
(EUROPAO Secondary Screening Protocol in High Risk Patients
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diagnostic modalities of high quality dynamic-spiral CT, ERCP, EUS and probably MRI 
have a similar diagnostic accuracy in expert hands. The choice of which to use depends 
on local expertise. Because the diagnostic accuracy of any one modality is slightly less 
or at best just equivalent to that required (sensitivity > 95%; specificity = 98-99.9%) it 
would be sensible to use a combination of modalities in the (as yet unproven) hope that 
the necessary marginal increase in accuracy would be achieved. A combination o f EUS 
with CT performed annually would be one of several reasonable options.
The problem in HP, as opposed to FPC, is the reduced diagnostic accuracy o f all of the 
modalities due to the background morphology of chronic pancreatitis in most o f these 
patients. Thus reliance on the aforementioned approach (EUS with CT performed 
annually) is flawed.
An important tenet of the EUROPAC protocol is that diagnostic molecular methodology 
can be used to (i) identify higher and lesser periods of risk and (ii) ultimately be used for 
diagnosis. It is now clearly established that mt-K-ras arises in premalignant and even in 
normal cells. In pancreatic ductal cells with mt-K-ras the subsequent sequence o f events 
is mutation/altered function of CDKN2A (p l6INK4a) in earlier pancreatic intraductal 
lesions followed by mutations in TP53, then SMAD4 in later pancreatic intraductal 
lesions and in early invasive carcinoma (Figure 7).
Mt-K-ras has been detected in pancreatic juice samples in with pancreatic cancer, 
chronic pancreatitis and in patients with normal pancreas glands. Whilst we have shown
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that mt-K-ras does not have the specificity to diagnose pancreatic cancer, especially in 
the presence of chronic pancreatitis (Wong et al. 2000), we can also reasonably assume 
that PDAC is unlikely to arise in its absence. Thus, we hypothesize that we can use the 
detection of mt-K-ras to identify patients from families with HP who, for a period of 
time, are at higher (mt-K-ras present) or lower (mt-K-ras absent) risk. Furthermore, we 
hypothesize that a reasonable period before re-evaluation is required is three years in 
lower risk cases and one year in higher risk cases. Those at higher risk require 
immediate diagnostic evaluation (made easier if baseline diagnostic tests have been 
performed at previous visits). If the diagnosis of pancreatic cancer is not supported then 
re-testing in one year is reasonable. Since most patients are likely to be mt-K-ras 
negative and remain so, the total cost of the screening programme remains reasonable, 
despite the multiplicity of tests.
The use of molecular technology for diagnostic purposes is more problematical because 
o f the large number of mutations involved and/or the complexity of the mechanisms of 
inactivation of the three main tumour suppressor genes. Nevertheless a clinical 
applicable test for TP53 mutation detection in DNA obtained from pancreatic juice has 
been developed by EUROPAC (Threadgold et al. 2000). This is a yeast functional assay 
for TP53 mutations previously developed to identify mutant TP53 at the transcriptional 
level (mRNA) (Inga et al. 1997; Flaman et al. 1998). The technique has been adapted to 
overcome the instability of RNA in pancreatic juice, by linking PCR products produced 
from exons 5-8 of the DNA in pancreatic juice. Following DNA extraction from the 
pancreatic juice and amplification, p53 exons 5-8 are introduced into a p53-expressing
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plasmid and used to transfect reporter yeast. The technique involves an initial screen of 
clones that lack functional p53. PCR is used to screen out colonies that contain 
rearrangements or large deletions of p53, neither of which are typically found in 
pancreatic cancer. Finally clones are sequenced to eliminate mixed populations that 
would be ascribed to PCR errors and to identify the specific mutation. The sensitivity of 
this technique for the detection of mutant p53 in a background of wild type is as high as 
1 in 3000 (Threadgold et al. 2000).
At the present time the identification of CDK.N2A (p l6INK4a) and SMAD4 abnormalities 
in pancreatic juice is not a simple task. In approximately 60% of pancreatic cancers, 
there was CpG island methylation of at least 1 of 12 cancer-related markers including 
CDKN2A (Ueki et al. 2000). The aberrant CDK.N2A methylation was found to occur at 
a rate of -5-20% and it may be possible to apply a PCR-based method to detect for 
hypermethylation of CDKN2A and/or multiple loci in DNA from pancreatic juice 
samples.
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Hypothesis. Aim and Evidence for EUROPAC Secondary Screening Protocol
The EUROPAC consortium believes that there is a progression of molecular markers in 
pancreatic juice that will allow risk stratification for the development of PDAC (Figure 
8). These proceed from a K-ras mutation via a defined sequence of other mutations and 
markers through to a carcinoma identifiable with imaging. At some point along this 
preogression the development of carcinoma is inevitable and this point would be optimal 
for intervention.
Therefore, the aim of the EUROPAC protocol is to use imaging with CT and/or EUS, in 
combination with molecular analysis of pancreatic juice in high risk individuals, to 
detect PDAC.
The Department of Surgery in Liverpool have analysed pancreatic juice and produced 
data with regards to the determination of the risk of pancreatic cancer 
predicted/observed when compared alongside the results of molecular techniques (Yan 
et al. 2005).
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p53  R A S  p l 6 1 2 %
S p e c ific ity  v 9 6 (8 6 ,9 9 )  66 (54 ,76) 9 0 (70 ,97 )
P a n c re a ti t is
S p e c ific ity  v  100(93-100) 79 (67 ,87) 95 (78 ,99)
C o n tro l
S e n s itiv ity  42 (28 ,56 ) 54(42 ,68) 6 2 (47 ,75 )
Figure 8: Graphs showing sensitivity and specificity of molecular techniques for 
detection of p53, Kras and p!6 mutations (Yan et al. 2005)
Alongside the table are graphs showing the percentage of patients tested with all three 
modalities who had cancer given a positive or negative test (continuous lines). Graph A 
is comparing cancer and pancreatitis and graph B patients with biliary stones (controls) 
and cancer. In A 20 out of 36 patients with a negative p53 test (wild type p53) had 
cancer while 14 of 16 patients with a positive p53 test had cancer. The plot is continued 
including p i6 and then K-Ras tests. A comparison is made (discontinuous line) with a 
prediction based on individual tests (97 p53 tests, 62 p 16 tests, 124 K-Ras tests). The 
greater the independence of the tests the closer the match will be between predicted and 
observed curves. (Yan et al. 2005).
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Figure 9: Graphs showing & probability cancer and series of molecular tests (Yan 
et al. 2005)
Using the same methodology, the percentage of individuals with cancer following 
positive or negative test results can be predicted assuming a level of pre-test prevalence 
equivalent to the probability of high-risk individuals developing cancer within a three 
year screening interval. The graphs shown below indicate the percentages given the 
series of molecular tests on a group of patients with pancreatitis (A) or no pancreatic 
disease (B). The proposed study will determine how accurate these predictions are for 
determining risk in HP (Graph A) or FPC (Graph B).
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Inclusion criteria for Secondary Screening Recruitment
Hereditary Pancreatitis
Any patient with HP over the age of 40 years. Decision on the inclusion of a family as 
having HP is taken on the basis of a multidisciplinary group, including clinicians (I 
performed this role occasionally) and scientists (my supervisor WG often performed this 
role), a clinical geneticist was included when possible. Initial criteria for consideration 
of a pancreatitis family were as follows:
• Two relatives with chronic pancreatitis in two generations, in the absence of 
gallstones, a correlation with alcohol excess or other established non-genetic cause of 
pancreatitis.
• Individuals of any family who carry a predisposing mutation for HP (as described 
earlier).
The multidisciplinary committee considered the family tree and medical notes before 
classifying the family as having HP on the basis of autosomal dominance.
Familial Pancreatic Cancer
Individuals over 40 years of age from an established pancreatic cancer family, or 
occasional younger individuals where affected parents were younger than 50 or where 
affected siblings were younger than 40. As for HP a multidisciplinary committee 
decided on final inclusion of a family as having FPC. The criteria for consideration of a 
family were:
• Two first degree relatives with pancreatic ductal adenocarcinoma; and/or three or 
more relatives with pancreatic adenocarcinoma and/or
ill
• Families with a causative gene linked to pancreatic cancer (e.g. BRCA2 or as yet 
undiscovered genes).
The multidisciplinary committee considered the family tree, medical notes and cancer 
registry reports before classifying the family as having FPC on the basis of autosomal 
dominance.
Individuals from these families will only be considered if they have a first degree 
relative with pancreatic cancer, or second degree if there is additional evidence that the 
individual is a carrier (e.g. identified BRCA2 mutation or a first degree relative with a 
descendent with cancer).
Exclusion criteria for Secondary Screening Recruitment
The following patients will not be recruited into the secondary screening programme for 
pancreatic cancer:
• Individuals under the age of 40 years with the exception of a small proportion of 
individuals from pancreatic cancer families where the family pedigree indicates a 
high risk of developing pancreatic cancer earlier than 40 years and a very small 
proportion of patients younger than the age of 40 years with Hereditary Pancreatitis 
who will undergo an ERCP as part of their routine clinical management.
• Any patient unable to give informed consent.




The EUROPAC consortium has produced flowcharts for the secondary screening of 
patients with Hereditary Pancreatits and individuals from Familial Pancreatric Cancer 
Families.
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Figure 10: Baseline screening in Hereditary Pancreatits and Familial Pancreatric 
Cancer
Baseline Screening in Hereditary Pancreatitis and 
Fam ilial Pancreatic Cancer
Risk evaluation
(Based on age, family history, clinical correlation -  typically beginning at 40)
Imaging C T  and EUS








If high risk yearly evaluation 
If low risk three yearly evaluation
Imaging C T
YES
Figure 11: Secondary Screening protocol for patients with Hereditary Pancreatitis
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Equivocal Evidence of CT
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Figure 12: Secondary Screening protocol for Familial Pancreatic Cancer High Risk 
Group
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Despite the rapid advances in the various imaging modalities and molecular biology 
techniques, our ability to detect early pancreatic ductal adenocarcinoma is still in its 
infancy. The identification of K-ras mutations, which is the most simple and sensitive of 
the available molecular approaches, is unsuitable for diagnosis in isolation, as it lacks 
specificity for cancer. The molecular diagnosis of pancreatic ductal adenocarcinoma 
must therefore involve the analysis of more than one molecular marker, such as TP3. As 
yet insufficient data have been obtained as to the accuracy of molecular analysis in the 
diagnosis of early pancreatic cancer. EUROPAC has made a decision to adopt and 
concentrate on a specific set of molecular examinations. The implications o f these assays 
needs to be established by longitudinal clinical correlation and requires the integrated 
collaboration of all groups caring for patients with Hereditary Pancreatitis and other high 
risk groups which will require risk estimation of patients in high risk groups (this will 
not be discussed further in this thesis).
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Aims and objectives
Based on the discussion in the previous sections and the difficulties we face in detecting 
PDAC at an early, potentially curable stage, the aim of this research is to stratify cancer 
risk in patients with HP based on germline genotype and development of novel 
molecular tests for somatic mutations in pancreatic juice.
Therefore, to achieve this aim, the incidence of an exon 4 polymorphism in the PRSS1 
gene in patients with HP was analysed. A novel method was set up for this anlaysis. By 
studying this polymorphism and the distribution in the general population and in patients 
with HP with known and unknown gene mutation status, it was hoped to determine if the 
founder status of theser patients can be postulated and hence, determine the inheritance 
pattern for HP.
Secondly, the the incidence of p i6 and MGMT methylation status in the DNA from 
pancreatic juice was analysed. Again, a novel method was developed. The analysis was 
to determine if the methylation status can be used as a marker/ indication for early 
changes in the genetics of pancreatic cells and therefore, in patients with high risk of 
pancreatic cancer this would be the first step to determine that these patients are suitable 
for more intensive screening.
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Finally, the incidence of K-ras mutations from DNA from serum, pancreatic tissue and 
pancreatic juice from patients with pancreatic cancer, chronic pancreatitis and benign 
disease was studied. A novel method of detection for K-ras mutations was set up with 
adequate the sensitivity and specificity for potential future clinical used. Mutant K-ras 
sequences which were not available commercially had to be manufactured by cloning 
known mutant fragmented K-ras sequences into the pMOSBlue cloning system to 
produce sufficient amount of mutant K-ras for setting up the novel ARMS technique. 
Following successful optimization of the ARMS technique, the incidence o f K-ras 
mutations from the clinical samples were analysed to determine if there is a pattern to 
the incidence and distribution of the type of mutation occurring in the different clinical 
samples. The aim was to be able to use this technique to detect mutant K-ras in 
sufficiently small amounts to identify patients who have acquired the K-ras mutations 
prior to developing overt malignancy, again, to offer more intensive surveillance or even 
possibly preventative surgery.
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Chapter 2: Exon 4 Polymorphism PRSS1, Hereditary Pancreatitis and 
Pancreatic Cancer
Although it is clear that hereditary pancreatitis is associated with pancreatic cancer 
(Howes, Lerch et al. 2004), it is not clear whether each mutation type (R122H, N291, 
A16V or those families negative for all PRSS1 mutations) has an equivalent cancer risk. 
Furthermore, it is clear that there is considerable heterogeneity within mutation groups 
in terms of disease severity (onset of pain, incidence of exocrine and endocrine failure 
etc.) (Howes, Lerch et al. 2004). Successful screening requires targeting to the highest 
risk individuals (Vitone et al. 2005), therefore the aim of this chapter was to examine 
founder effect within the mutation groups and relate this to cancer risk. To achieve this 
aim we investigated segregation of a single nucleotide polymorphism linked to PRSS1.
Hereditary pancreatitis is a rare genetic disease, characterized by recurrent attacks of 
acute pancreatitis (usually starting from childhood), progressing to chronic pancreatitis 
in the majority of cases and a 40% increased risk of pancreatic cancer in patients aged 
between 50 and 70. This disease pattern was first described by Comfort and Steinberg in 
1952. This disease is transmitted in an autosomal dominant pattern, with incomplete 
penetrance of -80%. The clinical features of the acute pancreatitis attacks and the 
resulting chronic pancreatitis is indistinguishable from other causes of acute and chronic 
pancreatitis.
121
One of the genes responsible for hereditary pancreatitis has been mapped to the long arm 
of chromosome 7, PRSS1. One of the mutations responsible for this disease is due to a 
single point mutation, a G to A transition, in the third exon of cationic trypsionogen. 
This mutation resulted in an arganine (R) (CGC) to histidine (H) (CAC) substitution at 
the 105 amino acid trypsinogen. This mutation was numbered R122H.
The proposed mechanism of action for the R122H mutation in hereditary pancreatitis is 
as follows- R117 functions as the initial site of hydrolysis of trypsin by trypsin itself, 
followed by further degradation of the molecule (internal hydrolysis sites are exposed). 
Substitution of histidine for arginine at residue 117 eliminates this initial hydrolysis site, 
rendering trypsinogen and/or trypsin resistant to autolysis and permanent inactivation. If 
trypsinogen is activated in the pancreas in quantities that exceed the inhibitory capacity 
of the trypsiongen-pancreatic secretory trypsin inhibitor complex (only able to inhibit 
20% of potential trypsin activity), then trypsin could activate all of the other digestive 
proenzymes, initiate pancreatic autodigestion and cause pancreatitis. Thus, the cationic 
trypsinogen R122H mutation seems to cause pancreatitis by eliminating a key inhibitory 
mechanism.
A second mutation in cationic trypsinogen, involving a point mutation in exon 2, an A to 
T transversion was identified. This mutation resulted in an asparagine (N) (AAC) to 
isoleucine (I) (ATC) amino acid substitution at residue 14. This mutation was designated 
N29I. The clinical syndrome affecting patients with the R122H or N29I mutations are 
similar, although, the age of onset is slightly later and the clinical features less severe in
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patients with the N21I mutation. The R122H and N29I mutations account for about 60% 
of mutations affecting the PRSS1 gene.
Other mutations of the PRSS1 genes have been reported but these are rare in occurance- 
these include the A16V, D22G, K23R and -28delTCC. Pfutzer et al (Pfutzer et al. 2002) 
have repotted on two further novel cationic trypsinogen mutations, N29T and R122C. 
The R122C mutation eliminates the arganine autolysis site as with R122H. The N29T 
mutation may enhance intrapancreatic trypsin activity.
Another gene known to contribute to causing hereditary pancreatitis involves the 
pancreatic secretory trypsin inhibitor (PST1) gene. PST1 is a Kazal type 1 serine protease 
inhibitor (SPINK 1) which is produced as a 79 amino acid precursor protein in acinar 
cells and is processed to become a 56 amino acid mature peptide that is secreted into 
pancreatic juice. PSTI is considered to be the first-line “safeguard” system that can 
inactivate about 20% of total trypsin activation if trypsinogen is accidentally converted 
to trypsin in acinar cells. Witt and Pfutzer (Pfutzer et al. 2000; Witt et al. 2000) reported 
on an A to G substitution in exon 3 that resulted in an Asparagine (AAT) to Serine 
(AGT) transition at amino acid 34 of the PSTI protein, N34S. Another mutation 
repotted in the PSTI gene involves a C to T substitution in exon 4 that resulted in an 
Arginine (CGC) to Cysteine (TGC) transition in amino acid residue 67, R67C. A list of 
the muations involved in HP in shown in Table 2.
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Materials
New England BIOLABSinc » UK




1. AmpliTaq Gold™ (Cat. No N808-0241 )
QIAGEN, USA
1. QIAampR DNA Mini Kit (Cat. No 51304)
2. DNA Mini Kit (Cat. No 51306)
3. Q1AEX II kit (Cat. No 20021 )
SIGMA- ADRICH, UK
1. Agarose (Cat. No 13,704-9)
2. Ethidium bromide (Cat. No 56,512-1)
EQUIPMENTS
1. Polaroid camera, Kodax, UK
2. GeneAmp PCR system 9700, PE Applied Biosystems, USA
3. Centrifuge Spectrafuge 16M, National Labnet Co, USA
4. Pipette, Gilsons, USA
5. Grant hot water bath, Grant Instruments, UK
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ANALYSIS SOFTWARE
1. Statview, SAS Institute, USA




Forty nine normal population, 54 hereditary pancreatitis mutation negative and 51 
mutation positive hereditary pancreatitis DNA samples were obtained from Dr. R 
Mountford, Department of Clinical Genetics, Liverpool Women’s Hospital, Liverpool 
for this study.
Exon 4 Polymorphism Polymerase Chain Reaction
We developed the following protocol for detection of the polymorphism. AmpliTaq 
Gold™ with lOx PCR Gold Buffer and MgC^ solution was used for the PCR reaction. 
The following conditions were found to be the most suitable after optimization 
experiments. The enzyme was activated at 94°C for 12 minutes, the reaction was 
subjected to 35 cycles of 94°C denaturation for 30 seconds, followed by annealing at 
60°C for 30 seconds. This was followed by chain elongation for 1 minute.
Following amplification, 5 pi of the exon 4 PCR products was loaded on 3% agrose gel 
stained with ethidium bromide.





Desalting and Concentrating DNA from Solution
The remainder of the amplified DNA, 45 pi was purified and concentrated using the 
QIAEX II kit. The final volume of the DNA was 18 pi.
Restriction Enzyme Digestion with Fokl
The purified DNA, 18 pi, was placed in a 1.5 ml eppendorf and 2 pi of lOx NEBuffer 4 
was added. One unit of Fokl enzyme will digest 1 pg of DNA in 1 hour at 37°C in a 
total reaction of 50ul. The appropriate amount of enzyme was added to the mix and 
incubated for 1 hour at 37°C. The enzyme was then inactivated at 65°C for 20 minutes. 
The digested DNA underwent 3% agrose gel electrophoresis and the result was recorded 
using Polaroid film.
Statistics
The statistical analysis was carried out using Statview and Microsoft Excel at the 
Department o f Surgery and Oncology, University of Liverpool.
Statistical analysis o f the distribution of Exon 4 polymorphism PRSS1 in the control and 
hereditary pancreatitis family samples were calculated using the Hardy-Weinberg 
equation.
The Statview software was used to derive the cumulative survival plot for mutation 
negative HP families. Differences in cancer survival between the D32 and D32D 
mutation negative HP families were analysed using the Logrank (Mantel-Cox), Breslow- 
Geham-Wilcoxon, Tarone-Ware, Peto-Peto-Wilcoxon and Harrington-Fleming tests. A 




Forty-nine normal samples were analysed. Fifty-four mutation negative samples were 
analysed- these were derived from 38 families. Thirty-one families contributed to the 51 
HP mutation positive samples- 21 families had the R122H mutation, 9 families had the 
N29I mutation and 1 family had the A16V mutation.
Sizes of PCR Products











Heterozygote approximately 300 bp 
and an intensity 
difference between the 
145bp and 182bp bands
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Figure 14: Agarose gel stained with ethidium bromide showing PCR amplified 
products with HP4SF and HP40KUR
3% Agarose gel showing successful PCR with HP4SF (arrowed black) and HP40KUR 




D32D Ht Wt Wt Ht D32D Wt
Figure 15: Agarose gel showing PCR products digested with Fokl enzyme
3% agarose gel showing base pair sizes of PCR products after Fokl digestion- Wt Wild 
type 145bp, 295bp, 315bp; D32D 130bp, 145bp, 182bp, 295bp; Ht Heterozygote double 
band at approximately 300bp, intensity difference at 145bp and 182bp.
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Before investigating the incidence of the different alleles in HP patients, we needed to 
investigate the allele frequencies in the general population. In this study, a rapid method 
based on restriction length polymorphism was developed to identify the polymorphism. 
Wild type sequences will give a pattern of 3 bands with our amplification and 
Fokldigestion at 315, 295 and 145 bp. D32D will give 4 bands of 182, 130, 295 and 
145bp. Heterozygotes being identified by the presence of a double band at 
approximately 300 bp and an intensity difference between the 145 and 182bp bands.
Evolution is the sum total of the genetically inherited changes in the individuals who are 
the members of a population's gene pool. It is clear that the effects of evolution are felt 
by individuals, but it is the population as a whole that actually evolves. Evolution is 
simply a change in frequencies of alleles in the gene pool of a population.
In the early 20th century by Godfrey Hardy, an English mathematician, and Wilhelm 
Weinberg, a German physician developed independently the Hardy-Weinberg equation. 
Through mathematical modeling based on probability, they concluded in 1908 that gene 
pool frequencies are inherently stable but that evolution should be expected in all 
populations virtually all of the time. They resolved this apparent paradox by analyzing 
the net effects of potential evolutionary mechanisms.
Hardy, Weinberg, and the population geneticists who followed them came to understand 
that evolution will not occur in a population if seven conditions are met:
Exon 4 Polymorphism Analysis in Control Samples
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1. mutation is not occurring
2. natural selection is not occurring
3. the population is infinitely large
4. all members of the population breed
5. all mating is totally random
6. everyone produces the same number of offspring
7. there is no migration in or out of the population
These conditions are the absence of the things that can cause evolution. In other words, 
if no mechanisms of evolution are acting on a population, evolution will not occur—the 
gene pool frequencies will remain unchanged. However, since it is highly unlikely that 
any of these seven conditions, let alone all of them, will happen in the real world, 
evolution is the inevitable result.
Hardy and Weinberg went on to develop a simple equation that can be used to discover 
the probable genotype frequencies in a population and to track their changes from one 
generation to another. This has become known as the Hardy-Weinberg equilibrium 
equation. In this equation (p2 + 2pq + q2 = 1), p is defined as the frequency of the 
dominant allele and q as the frequency of the recessive allele for a trait controlled by a 
pair of alleles (A and a). In other words, p equals all of the alleles in individuals who 
are homozygous dominant (AA) and half of the alleles in people who are heterozygous 
(Aa) for this trait in a population. In mathematical terms, this is
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p = AA + '/¡Aa
Likewise, q equals all of the alleles in individuals who are homozygous recessive (aa) 
and the other half of the alleles in people who are heterozygous (Aa).
q = aa + '/¡Aa
Because there are only two alleles in this case, the frequency of one plus the frequency 
of the other must equal 100%, which is to say
p + q =  1
Since this is logically true, then the following must also be correct:
p= i -q
There were only a few short steps from this knowledge for Hardy and Weinberg to 
realize that the chances of all possible combinations of alleles occurring randomly is
(P + q)2 = 1 
or more simply 
p2 + 2pq + q2 = 1
In this equation, p2 is the predicted frequency of homozygous dominant (AA) people in a 
population, 2pq is the predicted frequency of heterozygous (Aa) people, and q2 is the 
predicted frequency of homozygous recessive (aa) ones.
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From observations of phenotypes, it is usually only possible to know the frequency of 
homozygous recessive people, or q2 in the equation, since they will not have the 
dominant trait. Those who express the trait in their phenotype could be either 
homozygous dominant (p2) or heterozygous (2pq). The Hardy-Weinberg equation 
allows us to predict which ones they are. Since p = 1 - q and q is known, it is possible to 
calculate p as well. Knowing p and q, it is a simple matter to plug these values into the 
Hardy-Weinberg equation (p2 + 2pq + q2 = 1). This then provides the predicted 
frequencies of all three genotypes for the selected trait within the population.
134
Forty nine genomic DNA samples from patients with no known pancreatic disease were 
screened in this way. O f these samples 20/ 49 were heterozygous for D32D which is 
41% Table 13.
Exon 4 Polymorphism Analysis in Control Samples










Number 20 9 20 49






















Table 14: Statistical Analysis of Distribution of Exon 4 polymorphism in Control 
Samples
Twenty nine o f the forty nine (59%) patients had the D32D polymorphism. This is 
clearly inconsistent with the Hardy-Weinberg equilibrium, the sum of p and q are greater 
than one and the heterozygotes observed (41%) is inconsistent with the predicted 
proportion given the estimated proportion of homozygous D32 or on the basis of the 
proportion of homozygous D32D. This could be explained by a selective disadvantage 
o f the heterozygote population (unlikely) or on the basis of at least two genetically 
distinct populations within our control group. The simplest explanation would be if 10 of 
the homozygous wild type controls came from a population with no D32D and the rest 
of the controls came from a population with 50% D32 and 50% D32D allele; in which 
case both populations would be in Hardy-Weinberg equilibrium assuming little or no 
contact between the populations.
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Exon 4 Polymorphism Analysis in Hereditary Pancreatitis Family Samples
Family status/ R122H N29I A16V Neg all
Exon 4 status
D32 9 (70%) 1(25) 1 (100%) 15 (80%)
D32D 4 (30%) 3 (75%) 4 (20%)
Unknown 8 5 1 19
Table 15: Distribution of Exon 4 Polymorphism in HP Families
(The percentage of unknowns is biologically irrelevant. The important proportion is 
D32:D32D.
When analysing the results for the presence of the D32D polymorphism in the hereditary 
family sample group, we have to ignore the families with unknown D32D status.
For the 18 families with mutations analysed for the D32D polymorphism, the mutation 
occurs in both allelotypes. This is true for N29I and R122H, nothing can be said about 
A16V as only one family allowed haplotyping of the mutation with the polymorphism. 
This indicates the likelihood of multiple founders for the R122H families at least one in 
a D32 allelotype and at least one in D32D. The D32 population is more common so 
either a population linked to D32 has been more successful or there have been more 
founders in this group. The opposite is true for N29I, as in the general population D32D 
is less common than D32 this is more likely to indicate a limited number o f founders -
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the most successful of which was a D32D founder. Of course a single founder is 
possible in both cases with subsequent recombination.
In the hereditary pancreatitis families (19) with no known mutations, the distribution for 
the D32 to D32D families was 15 (79%) to 4 (21%). Compared to the control 
population, the mutation negative hereditary pancreatitis families had higher incidence 
of D32. It is probable that there is no linkage of pancreatitis with PRSS1 in these 
families, but we cannot rule out the possibility of an unknown mutation lying on this 




Figure 16: Example of Exon 4 polymorphism transmission in N29I HP family
In this example, the mutation occurred on an allele with D32 homozygous wild type and 
therefore the N29I is linked to D32.
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Figure 17: Example of Exon 4 polymorphism transmission in R122H HP family
In this example, the mutation occurred on an allele with D32D homozygous wild type 
and therefore the R122H is linked to D32D.
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Number Number of Number %
Observed Cancer Censored Censored
High 49 3 46 93.878
Frequency
(D32)
Low 18 0 18 100.000
Frequency
(D32D)
Untested 215 12 203 94.419
Total 282 15 267 94.681
Table 16: R122H Exon 4 polymorphism Hereditary Pancreatitis families Cancer 
Incidence
When we analysed the number of pancreatic cancer cases occurring in the R122H 
families with either the D32 or D32D allele profile, we found that there were 3 cancers 
occurring in the D32 (high frequency) group and no cancer occurring in the D32D (low 
frequency group). However, we are unable to determine the significance o f this as the 
number analysed were too small for comment or stastistical analysis.
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17 2 15 88.235
Untested 90 4 86 95.556
Total 124 6 118 95.161
__ ____________________________________________________________
Table 17: N29I Exon 4 polymorphism Hereditary Pancreatitis families Cancer 
Incidence
In the N29I families, there were 2 cancers observed in the low frequency group but 
again, the numbers are too small for comment or stastistical analysis.
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Number Number of Number %
Observed Cancer Censored Censored
High 95 6 89 93.684
Frequency
(D32)
Low 42 2 40 95.238
Frequency
(D32D)
Untested 765 28 737 96.340
Total 902 36 866 96.009
Table 18: Mutation Negative Exon 4 Polymorphism Hereditary Pancreatitis 
families Cancer Incidence
In the mutation negative hereditary pancreatitis families, there were 6 cancers observed 
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Figure 18: Graph of Kaplan-Mier Cumulative Survival plot for Mutation Negative 
Hereditary Pancreatitis Exon 4 Polymorphism families
The Kaplan-Mier survival plot shows that there is no significant difference in the cancer 














Fleming (rho = .5)
1.140 2 0.5656
Table 19: Stastistical analysis of survival data for Mutation Negative Hereditary 
Pancreatitis Exon 4 Polymorphism families
Stastistical analysis shows no significant difference in the cancer survival between the 
the D32 and D32D mutation negative hereditary pancreatitis families.
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Discussion
The neutral polymorphism was noted on sequencing the DNA of patients with clinically 
defined hereditary pancreatitis but with no mutations in PRSS1. This polymorphism was 
the result of a single base change, cysteine to threonine, in codon 162, exon 4 of the 
PRSS1 gene not resulting in any change of the 32nd aspartate residue; we refer to this 
polymorphism as D32D. Of 49 patients examined 60% were heterozygous for the 
polymorphism. Those without the polymorphism we refer to as wild type. The 
polymorphism had previously been described (Nishimori et al. 1999) and although it 
was reported that the polymorphism appears in the general population no figures for 
frequency were presented. The high frequency we encountered with our PRSS1 wild 




Cancer is a disease in which cells suffer from multiple genetic changes resulting in the 
abberant expression of many genes which in turn from tumour specific phenotypes. The 
méthylation mediated gene silencing mechanism can contribute the tumour specific 
profile of gene expression, as a common alternative to genetic changes.
DNA méthylation is one of several post-synthetic modifications that normal DNA goes 
through after each replication- one being the Cytosine-Guanine (CG) base pair is 
méthylation. Since DNA replication is semi-conservative, one strand of the new DNA is 
already methylated and the other strand remains to be methylated by an enzyme called 
methyl transferase. Furthermore, the methyl transferases must recognize the appropriate 
base pair to be methylated as not all CG base pairs in DNA are methylated and this is to 
ensure that each piece of newly synthetized DNA is identical. In summary, the function 
of the methyl transferases are 1. the maintenance of the méthylation status of genomes 
through DNA replication and 2. for the de novo DNA méthylation in the early stages of 
development.
In humans, DNA is methylated only at cytosines located 5’ to guanosine in the CpG 
dinucleotide. This modification has important regulatory effects on gene expression, 
especially when involving CpG-rich areas known as CpG islands, concentrated within 
short pieces of DNA segments. Gardiner-Garden and Frommer defined CpG islands as 
regions of DNA greater than 200bp with a G + C content >0.5 and an observed presence 
of CpG >0.6. Over 50% of the protein coding genes have at least one CpG island within
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or near their promoters, expression of which are sensitive to the méthylation status of 
such CpG islands (Baylin et al. 2000). Almost all gene -associated islands are protected 
from méthylation on autosomal chromosomes, though extensive méthylation o f CpG 
islands has been associated with transcriptional inactivation of selected imprinted genes 
and the genes on inactivated X-chromosome of females. Abberant méthylation of 
normally unmethylated CpG islands has been associated with transcriptional inactivation 
o f a gene (Zingg et al. 1997).
P16
The p 16 gene (also known as MTS-1, INK4a, CDKN2A), located on chromosome 9p21, 
encodes for a cyclin-dependent kinase inhibitor and is a G 1-specific cell cycle regulatory 
gene. It is composed of three exons, which encode 156 amino acids. The gene is 
frequently inactivated in human cancers by 1. the genetic mechanism, that is, intragenic 
point mutations and small homozygous deletions and 2. the epigenetic mechanism, that 
is, méthylation of the position 5 of cytosine promoter region (Nobori et al. 1994; Lo et 
al. 1996). Functional inactivation of p i6 occurs when the second allele is either 
inactivated by a further inactivation event or the second allele is completely lost in a 
gene spanning deletion.
The exon 1 coding sequences of the p l6  gene resides with the 5’ CpG islands. This area 
is not methylated in most normal tissues but methylated in many human cancers.
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DNA methylation plays an important role in the development, imprinting and aging. It 
has been reported that the methylation of estrogen receptor gene CpG island links aging 
in colonic mucosa (Issa et al. 1994).
Most CpG islands associated with genes are unmethylated in the germline and are often 
located within the promoter region of genes. These promoters are of variable size 
ranging from a few hundred bases to many thousand bases, methylation of the CpG sites 
within them can effectively, and heritably, lock genes in the ‘o ff condition. As few a 
7% of methylation of CpG islands at the promoter sites can ensure gene quiescence 
(Hsieh 1997). Increased CpG island methylation is often accompanied by lowering in 
the overall level of DNA methylation and this might contribute to decreased 
chromosomal stability (Chen et al. 1998).
CpG islands can occur in the coding regions of genes and their positions relative to 
transcription sites can vary considerably- an example of a gene with an internal CpG 
island is the pi 6 gene. Methylation of a CpG island downstream of an active promoter in 
a mammalian gene does not block the formation of a transcript. CpG islands located 
downstream on transcription start sites show progressive de novo methylation changes, 
which are initiated in the aging process and reinforced during the formation of cancer.
In a study by Zhang et al. sixty paired samples of colorectal carcinoma and normal 
colonic mucosa were analysed for p i6 methylation status. Statistical significant results 
showed positive correlation between p i6 methylation and aging and no correlation
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between p i6 méthylation and the clinical pathological parameters of the colorectal 
carcinoma patients (Zhang et al. 1999).
Yu et al found in patients with hepatocellular carcinoma, hyperméthylation of the 
promoter CpG island of p i6 may occur at a very late stage within the multiple stage 
processes of hepatocellular carcinogenesis (Yu et al. 2002).
MGMT
The gene encoding the DNA repair enayme 0 6-methylguanine DNA methyltransferase 
(MGMT) has been found to be inactivated in several human cancers (Estellar et al. 
1999). Alkylation of DNA at the O6 position of guanine plays an important step in the 
formation of mutations in cancer, primarily due to the tendency of the 0 6-methylguanine 
to pair with thymine during replication, resulting in a conversion of guanine-cytosien to 
adenine-thymine pairs in DNA. The 0 6-alkylguanine-DNA adduct may cross-link with 
the opposite cytosine residues, blocking DNA replication. The MGMT protein protects 
cells from the toxicity o f alkalyting agents, which frequently target the O6 position of 
guanine. The MGMT protein rapidly reversed the formation of adducts at the O6 position 
of guanine via transfer of the alkyl adduct to an active cysteine residue within the protein 
sequence, thereby preventing the formation of lethal cross-links and other mutagenic 
effects (Ludlum 1990; Pegg et al. 1995). Hence, the ability of a cell to withstand 
mutagenic and cytotoxic damage is directly related to the number of MGMT molecules 
it contains and to the rate of de novo synthesis of MGMT.
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In human cancer, the MGMT gene is not commonly mutated, deleted or rearranged - the 
loss o f MGMT function is most frequently due to epigenetic changes, specifically 
promoter region méthylation and can play an important role in human neoplasia. Several 
studies have demonstrated hyperméthylation of the MGMT CpG island as a cause of 
MGMT transcriptional silencing in cell lines defective in O6 methylguanine repair (Qian 
et al. 1997; Watts et al. 1997; Danam et al. 1999; Estellar et al. 1999). Aberrant MGMT 
méthylation has been associated with the loss of messenger RNA (mRNA) expression, 
lack o f MGMT protein, and loss of enzymatic activity in neoplasia tissue (Estellar et al. 
1999; Herfarth et al. 1999; Estellar et al. 2000).
Therefore, because hyperméthylation of MGMT is associated with loss of mRNA 
expression and appears to be the only mechanism associated with loss o f MGMT 
activitiy, MGMT loss of function can be studied by assessing promoter 
hyperméthylation. This approach examines the epigenetic inactivation of the promoter 
itself rather than the loss of protein expression and enzyme activity.
The sequential acquisition of hyperméthylation of tumour suppressor and mismatch 
repair genes at multiple gene promoter sites may also explain tumour progression from 
in-situ to invasive. House et al studied the méthylation status of intraductal papillary 
mucinous neoplasms of the pancreas and found p i6 genes in >50 of non-invasive and 
invasive of these lesions. MGMT repair genes were found to be methylated in 45% and 
20% of invasive and non-invasive intraductal papillary mucinous neoplasms of the 
pancreas respectively. Hence, the detection of hyperméthylation at multiple gene sites
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may indicate the increased likelihood of invasive cellular behaviour and malignancy. 
This theory would be supported by our results of the méthylation status in the pancreatic 
adenocarcinoma, chronic pancreatitis and control group analysed (House et al. 2003).
Méthylation of tumour suppressor genes other than p i6 and MGMT has also been 
identified in pancreatic cancer. Jansen et al found the tumour suppressor gene TSLC1 
CpG island méthylation to be present in pancreatic cancer and high grade PanIN-3 
lesions. TSLC1 was reported to be methylated in 25/91 (27%) of pancreatic 
adenocarcinomas, 2/7 (29%) high-grade PanIN-3 lesions but not in low grade PanIN-1 




1. NuSieve® 3:1 agarose (Cat. No 50090)
FERMENTAS, USA
1. Glycogen (Cat. No R0561)
NOVAGEN, USA
1. Pellet Paint™ Co-Precipitant (Cat. No 69049-3)
ONCOR, USA
1. CpG WIZ™ Amplification Kit p i6 (Cat. No S7800) 
PERKIN ELMER, USA
1. AmpliTaq Gold™ (Perkin Elmer, (Cat.No N 808-0241) 
PROMEGA, USA
1. Wizard® DNA Clean-Up System (Cat. No A7280)
2. lOObpDNA ladder (Cat. No G2101)
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SIGMA-ALDRICH, UK
1. Agarose (Cat. No 13,704-9)
2. Ammonium acetate (Cat. No 37233-1)
3. Ethanol (Cat. No 60629-4)
4. Ethidium bromide (Cat. No 56,512-1)
5. Hydroquinone (Cat. No H 1790-2)
6. Isopropanol (Cat. No 56395-5)
7. Sodium bisulfite (Cat. No S-8890)
8. Sodium hydroxide (Cat. No 48402-4)








7. 3M Sodium bisulfite
8. 2.5mM dNTP
9. lxT A E
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EQUIPMENTS
1. Polaroid camera, Kodax, UK
2. GeneAmp PCR system 9700, PE Applied Biosystems, USA
3. Centrifuge Spectrafuge 16M, National Labnet Co, USA
4. Pipette, Gilsons, USA
5. Grant hot water bath, Grant Instruments, UK
ANALYSIS SOFTWARE
1. Statview, SAS Institute, USA
2. Microsoft Office 2003- Excel, USA
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Methods
DNA Sample Collection and Concentration
The DNA samples used for this study were obtained from the pancreatic juice collected, 
after informed consent, of patients undergoing ERCP under the EUROPAC study for 
molecular analysis. Approximately 1500pl of pancreatic juice was aspirated from the 
pancreatic duct during ERCP or at the time of transaction of the pancreas during surgery 
and transported to the laboratory on ice. The first lOOOpI was discarded from the ERCP 
samples, as this contained a high concentration of radiological contrast medium. Within 
two hours of collection the chilled pancreatic juice was transferred to sterile eppendorf 
tubes and spun at 4000g for ten minutes. The supernatant was aspirated and immediately 
stored at -80°C. The DNA had been extracted as in the QIAampRDNA Mini Kit 
protocol.
DNA Sample Extraction
The QlAampR DNA Mini Kit was used for DNA extraction from the pancreatic juice/ 
bile samples. For each DNA extraction, initially, 20 pi Q1AGEN Protease (or proteinase 
K) was pipetted into the bottom of a 1.5 ml microcentrifuge tube. Up to 200 pi of 
pancreatic juice/ bile sample was added to the microcentrifuge tube. If the sample 
volume was less than 200 pi, the appropriate volume of PBS was added.
200 pi Buffer AL was added to the sample and mixed thoroughly to yield a 
homogeneous solution by pulse-vortexing for 15 s. The mixture was incubated at 56°C 
for 10 min. The mixture was briefly centrifuged to remove drops from the inside of the
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lid. 200 pi ethanol (96-100%) was added to the sample, and mixed again by pulse- 
vortexing for 15 s. After mixing, the 1.5 ml microcentrifuge tube was briefly centrifuged 
to remove drops from the inside of the lid.
The mixture was carefully applied to the QIAamp Mini spin column (in a 2 ml collection 
tube) without wetting the rim. The cap was closed, and the spin column centrifuged at 
6000 x g (8000 rpm) for 1 min. The QIAamp Mini spin column was placed in a clean 2 
ml collection tube, and the tube containing the filtrate was discarded.
The QIAamp Mini spin column was carefully open and 500 pi Buffer AW1 was added 
without wetting the rim. The cap was closed and the spin column centrifuged at 6000 x g 
(8000 rpm) for 1 min.The QIAamp Mini spin column was placed in a clean 2 ml 
collection tube, and the collection tube containing the filtrate was discarded.
The QIAamp Mini spin column was carefully opened and 500 pi Buffer AW2 added 
without wetting the rim. The cap was closed and centrifuged at full speed (20,000 x g; 
14,000 rpm) for 3 min. The QIAamp Mini spin column was placed in a new 2 ml 
collection tube and the old collection tube with the filtrate was discarded. The spin 
column was centrifuged at full speed for 1 min.
The QIAamp Mini spin column was placed in a clean 1.5 ml microcentrifuge tube, and 
the collection tube containing the filtrate was discarded. The QIAamp Mini spin column 
was carefully opened and 200 pi Buffer AE or distilled water was added. The mixture
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was incubated at room temperature (15-25°C) for 1 min, and then centrifuged at 6000 x 
g (8000 rpm) for 1 min. A second elution step with a further 200 pi Buffer AE was 
performed to increase yields by up to 15%.
DNA Sample Concentration
The DNA in the pancreatic juice samples of patients with PDAC, chronic pancreatitis, 
and patients with biliary diseases were concentrated- 50 pi of the DNA samples were 
concentrated to a final volume of 20 pi (resuspended in PCR grade water) using Pellet 
Paint™ Co-Precipitant following the manufacturer’s protocol.
Control DNA (wild type, unmethylated and methylated) for plôand MGMT méthylation 
status was obtained from the CpG WIZ™ Amplification Kit p i6.
DNA Méthylation and Clean-Up
The patient DNA and control samples (except wild type) underwent bisulfite treatment 
following an adapted protocol from Frommer et al, as described below. Aberrant DNA 
méthylation in the CpG Island of the genes by chemical modification would result in the 
unmethylated cytosine being converted to uracil, whereas the methylated xytosine 
remains unchanged.
For each sample, 2 pi of DNA was diluted into 50 pi with distilled water in a 1.5ml 
eppendorf and 5.5 pi of 2M NaOFl added. This mixture was incubated at 37°C for 10 
minutes. Thirty pi of lOmM hydroquinone* and 520 pi of 3M sodium bisulfite* were
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The mineral oil was removed and the solution was cleaned-up using the Wizard® DNA 
Clean-Up System, following the manufacturer’s protocol using a vacuum manifold. To 
the 50 pi final solution, 5.5 pi of 3M NaOH was added and incubated at room 
temperature for 5 minutes. One pi of glycogen carrier, 33 pi of 10M Na4Ac and 270 pi 
of ethanol were added, incubated at -20°C for 30 minutes and spun in a microcentrifuge 
for 30 minutes. The supernatant was discarded; the precipitated DNA pellet washed with 
70% ethanol and resuspended in 20 pi PCR grade water.
added after the incubation period (*- these solutions must be freshly prepared). The
m ixture was thoroughly mixed, layered with mineral oil and incubated at 50°C for 20
hours.
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P16 and MGMT Méthylation Status PCR
The primer sequences used for this study are as follows:
P I6 W*  forward
5’ CAG AGG GTG GGG CGG ACC GC 3’
P16 W* reverse
5’ CGG GCC GCG GCC GTG G 3’
P I6 M* forward
5’ TTA TTA GAG GGT GGG GCG GAT CGC 3’
P I6 M* reverse
5’ GAC CCC GAA CCG CGA CCG TA A 3’
P I6 U* forward
5’ TTA TTA GAG GGT GGG GTG GAT TGT 3’
P16 U* reverse
5’ CAA CCC CAA ACC AC A ACC ATA A 3’
MGMT M* forward
5’ TTT CGA CGT TCG TAG GTT TTC GC 3’
MGMT M* reverse
5’ GCA CTC TTC CGA AAA CGA AAC G 3’
MGMT U* forward
5’ TTT GTG TTT TGA TGT TTG TAG GTT TTT GT 3’
MGMT U* reverse
5’ AAC TCC AC A CTC TTC CAA AAA AAC A 3’
* W= wild type; M= methylated; U= unmethylated status
160
The enzyme used for this PCR were AmpliTaq Gold™ with lOx PCR Gold Buffer and 
MgCb solution.
The mastermix components for each 25 pi reaction are as listed below:
lOx PCR Gold Buffer 2.5 pi
2.5 mM dNTP 2.5 pi
Primers (lpmol/pl) lp l
Taq 0.2 pi
Water 16.8 pi
Template DNA 2 pi
The enzyme is activated at 95°C for 12 minutes, and then the reaction was subjected to 
35 cycles of amplification at 94°C for 45 seconds, followed by annealing at 59.5 °C for 
45 seconds. This was followed by chain elongation at 72°C for 1 minute. The reaction 
was cooled to 4°C.
The PCR product (5 pi) was loaded onto a 5% gel (4 NuSieve®: 1 Agarose) with 
ethidium bromide (1 pi) and run in lx TAE and visualised under UV illumination.
Statistical analysis of the data was undertaken using the Statview programme and data 
was analysed using the X2 test. A p < 0.001 was considered to be o f statistical 
significance.
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The sizes (bp) of the PCR products are listed below.
Unmethylated p i6 154 bp
Methylated p i6 145 bp
Wild type p i6 142 bp
Unmethylated MGMT 93 bp
Methylated MGMT 81 bp
Statistical analysis of Méthylation status
The results from the experiments were analysed using the Statview and Microsoft Excel 
softwares at the Department of Surgery and Oncology, University of Liverpool.
Patients with a confirmed diagnosis of pancreatic ductal adenocarcinoma, chronic 
pancreatitis and benign biliary disease were taken as the reference groups. Correlation 
between p i6 and GMT méthylation and age, diagnosis and K-ras mutations categories 
were analysed using Statview Chi-square tests.
Cumulative onset of p i6 and MGMT méthylation with age and diagnosis was derived 
usong the Stativew Kaplan-Mier survival analyses. A Logrank p < 0.001 was considered 
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Figure 19: Gel picture of Methylated pl6
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Figure 20: Gel picture of Unmethylated pl6
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Figure 21: Gel picture of Unmethylated MGMT
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Figure 22: Gel picture of Methylated MGMT




The pancreatic juice DNA of 99 patients were analysed for p i6 and MGMT 
methylation. The median age for these patients was 59 years. The cut-off point for the 
young-old category was 59 years. There were 51 patients in the young category and 48 
patients in the old category. In this group, 30, 40, 25 and 4 pancreatic juice DNA 
samples were from PDAC, SpCP, Control and Cholangiocarcinoma patients 
respectively.
Correlation between p l6  and MGMT methylation and age categories
In the old category, 36/48 (75%) patients were found to have methylated p i6 compared 
to 28/51 (55%) in the young category. The expected frequency of pi 6 methylation in the 
young and old and young are 31/51 (61%) and 33/48 (69%) respectively. The number of 
patients found to have unmethylated p i6 were 12/48 (25%) versus the expected 17/48 
((35%) in the old category and 23/51 (45%) versus the expected 18/51 (35%) in the 
young category. The differences in p i6 methylation based on age category did not reach 
statistical significance. (Table 20) but we observed a trend for more methylation in older 
controls.
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Methylated old 36 31
Unmethylated old 12 17




Chi-square p-value 0.0488; Median age 59 years old; Young-Old 59 years; Young 51 
patients, Old 48 patients
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Methylated old 40 30
Un methylated old 9 19




Chi-square p-value <0.0001; median age 59 years old; Young-Old 59 years; Young 45 
patients, Old 49 patients
The analysis of MGMT méthylation based on age category showed méthylation in 40/49 
(82%) in old and 17/45 (38%) in young patients versus the expected 30/49 (61%) in old 
and 27/45 (60%) in young patients. In the analysis for unmethylated MGMT, the 
observed frequency was 9/49 (18%) in old and 28/45 (62%) in young patients compared 
to the expected frequency of 19/49 (39%) in old and 18/45 (40%) in young patients 
respectively. The méthylation status of MGMT based on the age category was statistical 
significance at a p-value <0.001 (Table 21). From the q analysis we observed more 
méthylation in older patients.
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The pancreatic juice DNA of 31 patients with PDAC were analysed for pi 6 and MGMT 
méthylation. The median age for the patients with PDAC was 60 years. The cut-off point 
for the young-old category was 60 years. There were 13 patients in the young category 
and 17 patients in the old category.






Methylated old 17 17
Unmethylated old 0 0




Table 22: Correlation between pl6 Méthylation with PDAC in Young and Old Age 
Categories
Chi-square p-value not significant; median age 60 years old; Young-Old 60 years; 
Young 13 patients, Old 17 patients
In this group of patients all patients with PDAC had p i6 méthylation (Table 22), so 






Methylated old 16 15
Unmethylated old 1 2
Methylated young 10 11
Un methylated 3 2
young
Table 23: Correlation between MGMT with PDAC in Young and Old Age 
Categories
Chi-square p-value 0.1748; median age 60 years old; Young-Old 60 years; Young 13 
patients, Old 17 patients
The analysis of MGMT methylation based on PDAC diagnosis and age category showed 
methylation in 16/17 (94%) in old and 10/13 (77%) in young patients versus the 
expected 15/17 (88%) in old and 11/13 (85%) in young patients. In the analysis for 
unmethylated MGMT, the observed frequency was 1/17 (6%) in old and 3/13 (23%) in 
young patients compared to the expected frequency of 2/17 (12%) in old and 2/13 (15%) 
in young patients. The methylation status of MGMT based on the age category did not 
reach statistical significance with a p-value 0.1748 (Table 23).
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The pancreatic juice DNA of 40 patients with SpCP were analysed for p i6 and MGMT 
méthylation. The median age for the patients with PDAC was 48 years. The cut-off point 
for the young-old category was 50 years. There were 22 patients in the young category 
and 18 patients in the old category.
Correlation between p l6  and MGMT méthylation with Chronic Pancreatitis





Methylated old 7 7
Unmethylated old 11 11




Table 24: Correlation between pl6 Méthylation with Chronic Pancreatitis in 
Young and Old Age Categories
Chi-square p-value 0.296; median age 48 years old; Young-Old 50 years; Young 22 
patients, Old 18 patients
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In the old category, 7/18 (39%) of the patients were found to have methylated pl6 
compared to 8/22 (36%) in the young patients category and the number of patients found 
to have unmethylated p i6 were 11/18 (61%) in the old category and 14/22 (64%) in the 
young category. The expected values for methylated and unmethylated p i6 in this group 
of patients are the same as the observed frequencies. The methylation status o f p i6 in 






Methylated old 1 1
Unmethylated old 15 15




Table 25: Correlation between MGMT with Chronic Pancreatitis in Young and 
Old Age Categories
Chi-square p-value 0.971; median age 48 years old; Young-Old 50 years; Young 17 
patients, Old 16 patients
The analysis of MGMT méthylation based on the chronic pancreatitis diagnosis and age 
category showed méthylation in 1/16 (6%) in old and 2/17 (12%) in young patients. In 
the analysis for unmethylated MGMT, the observed frequency was 15/16 (94%) in old 
and 15/17 (88%). The expected frequency for MGMT méthylation matched the observed 
frequency. The méthylation status of MGMT based on the chronic pancreatitis diagnosis 
and age category did not reach statistical significance with a p-value 0.971 (Table 25).
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The pancreatic juice DNA of 27 control patients were analysed for p i6 and MGMT 
méthylation. The median age for the patients with PDAC was 68 years. The cut-off point 
for the young-old category was 68 years. There were 14 patients in the young category 
and 13 patients in the old category.






Methylated old 7 8
Unmethylated old 5 4
Methylated young 9 8
Unmethylated 4 5
young
Table 26: Correlation between pl6 Methylation with Control in Young and Old 
Age Categories
Chi-square p-value not significant; median age 68 years old; Young-Old 68 years; 
Young 13 patients, Old 12 patients
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P16 méthylation results were available for 25 patients- 13 young and 12 old (young-old 
cut-off at 68 years based on median age). In the old category, 7/12 (58%) of the patients 
were found to have methylated p i6 compared to 9/13 (70%) in the young patients 
category and the number of patients found to have unmethylated p 16 were 5/12 (42%) in 
the old category and 4/13 (30%) in the young category. The expected values for 
methylated and unmethylated p i6 in the old and young patient groups are 8/12 (67%), 
4/12 (33%), 8/13 (62%) and 5/13 (38%) respectively. The méthylation status o f pi 6 in 
control patients did not reach statistical significance (Table 26). The results show a trend 






Methylated old 13 12
Unmethylated old 5 6
Methylated young 3 4
Unmethylated 4 3
young
Table 27: Correlation between pl6 Methylation with Control in Young and Old 
Age Categories
Chi-square p-value not significant; median age 68 years old; Young-Old 60 years: 
Young 7 patients, Old 18 patients
Analyses of the same data, altering the young-old cut-off to 60 years (for comparison 
with the PDAC group), p 16 methylation results were available for 7 young and 18 old 
patients. The observed frequency for p i6 methylation in the old and young patients were 







Methylated old 11 12
Unmethylated old 2 1




Table 28: Correlation between MGMT with Control in Young and Old Age 
Categories
Chi-square p-value not significant; median age 68 years old; Young-Old 68 years; 
Young 14 patients, Old 13 patients
The analysis of MGMT méthylation in young-old control patient categories showed 
méthylation in 11/13 (85%) in old and 13/14 (93%) in young patients. In the analysis for 
unmethylated MGMT, the observed frequency was 2/14 (14%) in old and 1/14 (7%). 
The expected frequencies for MGMT méthylation were 12/13 (92%) old and 12/14 
(86%) in old and young patients respectively. The méthylation status of MGMT 
analysed in control patients and age category did not reach statistical significance (Table 
28).
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The pancreatic juice DNA of 99 patients were analysed for correlation between p i6 
méthylation and K-ras mutations, age categories not taken into account. P I6 méthylation 
was found in 26/33 (79%) patients with mutant K-ras compared to 27/48 (56%) wild- 
type K-ras patients. The expected values for p i6 méthylation were 22/33 (67%) and 
31/48 (65%) in mutant and wild-type K-ras patients respectively. The correlation of pi 6 
méthylation and K-ras mutation status did not reach statistical significance (Chi- square 
p-value 0.1112) (Table 29).
Correlation between pl6 and MGMT méthylation and K-ras mutations in all
patient groups













Table 29: Correlation between pl6 Méthylation and K-ras mutations
Chi-square p-value 0.1112, total number of patients 99
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The analysis of the correlation between MGMT méthylation with K-ras mutational 
status yielded an observed frequency of MGMT méthylation in 26/33 (79%) mutant K- 
ras and 26/46 (57%) wild-type K-ras patients. The expected méthylation frequencies 
were calculated as 22/33 and 30/46 for mutant and wild-type K-ras patients respectively. 
The correlation between MGMT méthylation and K-ras mutational status did not reach 











Methylated/ K-Ras Wild 
type
26 30
Un methylated/ K-Ras 
Wild type
20 16
Table 30: Correlation between MGMT Méthylation and K-ras mutations
Chi-square p-value 0.0713, total number of patients 79
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Cumulative Onset of P16 and MGMT Méthylation with Age
The analysis of the results using Kaplan-Mier survival analyses shows a méthylation 
trend with increasing age when the patients were not divided into diagnosis subdivisions. 
This is true for p 16 and MGMT méthylation with non-significant Logrank p-values of 
0.2213 (Figure 23) and 0.0062 (Figure 24) respectively.
P16 Méthylation vs Age
15 25 35 45 55 65
Age
Figure 23: P16 Méthylation vs Age
Cumulative analysis based on disease diagnosis again yielded graphs with trends o f pi 6 
and MGMT méthylation occurring with increasing age. The general age by which p i6 
start to occurs appears to by around 30 years old in the Control, PDAC and Chronic 
Pancreatitis patients.
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MGMT Méthylation vs Age
Figure 24: MGMT Méthylation vs Age
MGMT méthylation is noted to start occurring towards the 40 years old age mark. There 














Figure 25: P16 Méthylation in PDAC Patient Group
P16 PDAC






Figure 26: P16 Méthylation in Combined General Patient Group
For the méthylation combined general analysis, méthylation status was merged into 
either none and medium and all the méthylation status for p i6 and MGMT are pooled 
together. Therefore, patients with high méthylation status would be allocated into the 
medium méthylation group. In analysing the p i6 methylated patients from this group, 




Figure 27: MGMT Méthylation in Combined General Patient Group
Cumulative Onset of P I6 and MGMT Méthylation with Age (Combined General) - 
More interestingly in the MGMT méthylation group, the analysis achieves stastistical 
significance with a Logrank p-value 0.0001
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Discussion
The risk of developing cancer, including pancreatic cancer, increases with the age of a 
general population. This risk is further exaggerated in patients with hereditary 
pancreatitis (Howes et al. 2002). It is estimate that -5-10% of cancers occur with a 
strong familial association. The association of méthylation status and sporadic/ 
hereditary cancers was looked at by Esteller et al in colon cancer. He reported that in the 
majority of cases, the p i6 and MGMT promoter region méthylation were different 
between sporadic and inherited colon cancers. He postulated that the combination of 
mismatch repair deficiency and gene silencing by promoter hyperméthylation (second 
hits) can lead to high mutational rates in colon cancer cells (Estellar et al. 2001).
In a study looking into the méthylation status of the MGMT gene, Estellar et al found no 
MGMT promoter méthylation in among all normal tissues (including brain, colonic 
mucosa, breast, pancreas, lung and peripheral blood lymphocytes) tested. Aberrant 
MGMT hyperméthylation was most frequent in primary gliomas and colorectal 
carcinomas, showing aberrant méthylation in -40%  of the cases. A second group of 
neoplasms with frequent MGMT promoter méthylation included lymphomas, non-small 
cell lung carcinomas, and head and neck carcinomas, where this alteration was found in 
-25%  of the cases. By contrast, MGMT méthylation was found in only 11% (2 of 18) 
pancreatic carcinomas (Estellar et al. 1999). The authors indicated that the tumour types 
silencing of the MGMT by aberrant promoter hyperméthylation in the study included 
those with a frequent rate of K-ras mutations (colon, lung, head and neck carcinomas) 
suggesting the role of loss of MGMT expression leading to an increased susceptibility to
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K-ras mutations. However, also found in this study, tumours with known high K-ras 
mutations (pancreatic carcinomas) were not frequent targets of MGMT promoter 
hyperméthylation, suggesting that inactivation of MGMT is not required for the 
acquisition of K-ras mutations. This conclusion is in keeping with our finding and the 
correlation of MGMT hyperméthylation with K-ras mutations in all patient groups did 
not reach stastistical significance.
A follow-up study by Estel 1er in 2000 reported that a G-A transition mutation o f the ras 
gene showed clear association with MGMT inactivation in colorectal cancer. The study 
found 71% (36/51) tumours with G-A K-ras mutation had abnormal MGMT méthylation 
compared to 32% (12/37) tumours with other K-ras mutations and 35% (55/156) 
tumours without K-ras mutations(Estellar et al. 2000). MGMT méthylation was also 
found in equal frequencies in small adenomas <lcm (9/21, 43%), large adenomas >=1 
cm (23/44, 53%) and carcinomas (71/174; 40%). This would suggest that 
hyperméthylation of MGMT occurred as an early event in colorectal tumourgenesis. The 
correlation of the MGMT méthylation status with the G-A K-ras mutation indicate that 
the epigenetic silencing of MGMT by promoter hyperméthylation may lead to a 
particular genetic change in human cancer, specifically G-A transitions in the K-ras 
oncogene.
Howes et al reported that there is a 4-fold cumulative lifetime risk o f developing 
pancreatic cancer in patients suffering with hereditary pancreatitis (Howes et al. 2002). 
In a study by House et al, it was suggested that the acquisition of hyperméthylation at
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tumour suppressor gene promoter sites may contribute to tumour formation and 
formation within the chronically inflamed gallbladder. Aberrant p i6 méthylation was 
found in 30/54 (56%), 2/18 (11%) and 0/15 (0%) gallbladder cancers, chronically
inflamed gallbladders and normal gallbladders respectively. MGMT méthylation was 
observed in 7/54 (13%), 3/18 (17%) and 0/15 (0%) gallbladder cancers, chronically 
inflamed gallbladders and normal gallbladders respectively (House et al. 2003).
We have established in the previous paragraphs that aberrant hyperméthylation of 
promoter CpG islands are an important mechanism for the inactivation o f tumour 
suppressor and repair genes and play a role in tumourgenesis. However, CpG islands are 
also aberrantly methylated as part of the aging process. Issa et al reported that age 
related méthylation seems to be gene specific, and p 16 may be one of the genes not 
affected. However, this process could be modified by tissue-specific factors (Ahuja et al. 
1998). Kang et al studied the frequency of CpG island méthylation in several genes 
including p i6 and MGMT, in non-neoplastic gastric mucosa. Two hundred and sixty 
eight non-neoplastic gastric mucosa samples were analysed and CpG island méthylation 
were found in 10% for p i6 and 10.9% for MGMT. This group found that the genes 
methylated exhibited a general progressive increase as a function of age (DAP-kinase, 
E— cadherin, p i4, THBS1, TIMP-3). Another group of gene méthylation did not follow 
the trend with age (COX-2, GSTP1, MGMT, hMLHl, p 16 and RASSF1A) (Kang et al. 
2003).
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However, there are contradictory reports of pi 6 méthylation related to aging. Waki et al 
reported the méthylation status of tissue samples obtained from autopsies and gastric 
mucosa (non-neoplastic and neoplastic) obtained from gastric cancer patients 
undergoing surgery. This group found that methylated p i6 was not detected in non- 
neoplastic cells from tissue samples from autopsies of individuals who were 22 years 
and younger but was present in 29% (4/14) of individuals who were 45 years or older. 
These finding suggest p 16 méthylation in non-neoplastic cells is age-related. PI6 
méthylation was present in 44% (41/94) o f non-neoplastic and neoplastic gastric 
mucosa from patients with gastric cancer (Waki et al. 2002). The méthylation o f pi 6 did 
not correlate with any clinicopathological characteristic.
Issa et al presented finding of two types of CpG islands méthylation in colon cancer 
from patients with ulcerative colitis. Ulcerative colitis is a disease characterized by 
chronic inflammation and a substantial risk of colon cancer. The two groups were type 
C, i.e. those that display cancer restricted méthylation and type A. i.e. those that are 
methylated initially in aging normal epithelial (Toyota et al. 1999).
Type A p i6 méthylation- Issa suggested that p i6 gene exon 1 region (known to be 
hypermethylated in ulcerative colotis patients) behaves as a type A CpG island in the 
colon, i.e. displays age-related méthylation. In his study, he found p 16 exon 1 showed 
substantial levels of méthylation in neoplastic and non-neoplastic mucosa o f ulcerative 
colitis patients with high grade dysplasia or cancer. P I6 exon 1 méthylation in this study 
averaged 2% in controls, 3 % in ulcerative colitis patients without evidence of dysplasia
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(P= 0.6 compared with control), 8% in the normal epithelium of ulcerative colitis 
patients with high grade dysplasia or cancer (P= 0.007 compared with controls), and 9% 
in dysplastic epithelium of these same patients (P= 0.03 compared with controls, P= 0.6 
compared with nondysplastic epithelium from the same patients) (Issa et al. 2001).
Type C p i6 méthylation- Issa found the p i6 upstream region (critical for transcription) 
behaves as type C, i.e. methylated in neoplasms only. His study of p 16 méthylation close 
to its transcriptional site showed a very low level of méthylation (<5%) indistinguishable 
from background was observed in all patients, with no difference between non­
ulcerative colitis controls, ulcerative colitis patients without dysplasia and ulcerative 
colitis paitents with high grade dysplasia or cancer (Issa et al. 2001).
Issa postulated that disorders characterized by increased cell turnover, such as the 
chronic inflammation of ulcerative colitis, might be accompanied by higher levels of 
age-related méthylation, that ulcerative colotis could be a disorder of premature aging in 
the colon. These findings may shed light to the increased risk of pancreatic cancer in 
patients with hereditary pancreatitis, a disease whereby the patients suffers recurrent 
attacks of acute pancreatitis resulting to chronic pancreatitis and pancreatic cancer in 
some patients.
The role of pi 6 méthylation in chronic pancreatitis patients as an indicator o f high risk 
for pancreatic cancer was investigated by Gerdes et al. The group found 10/20 (50%) of 
chronic pancreatitis specimens haboured PanfN-la lesions. In 2/10 (20%) of the PanlN-
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la lesions from these specimens, p i6 hyperméthylation was identified. Hence, p i6 
alterations, especially promoter méthylation, might indicate high-risk precursors in 
chronic pancreatitis that might progress to cancer (Gerdes et al. 2001).
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Chapter 4- Pancreatic Cancer and K-ras
As discussed in the introductory chapter, the early detection of PDAC is a crucial step in 
the potentially curative process for a patient. Unfortunately, curative treatment is not a 
frequent option for many patients inflicted by this deadly disease.
Mutations of the K-ras oncogene has been shown to be commonly occurring in PDAC, 
as discussed and referenced previously. Screenings for PDAC in high-risk populations 
have been shown to be feasible by Yan et al using 3 novel molecular screening 
techniques, one of the techniques being the main basis of this thesis. The study showed 
that the combination of the 3 novel molecular screening techniques increased the 
discrimination between patients with benign and malignant disease- allowing patients in 





1. TAE (Tris-acetate)- Concentrated stock solution 50x 242g Tris base, 57.1ml 
glacial acetic acid, 100ml 0.5M EDTA (pH 8.0)
2. Phosphate buffered solution (GibcoBRL, USA Cat No 14190-094)
3. Ethidium bromide (Sigma, UK Cat No .46047)
Enzymes:
1. AmpliTaq Gold™ (Perkin Elmer, USA Cat No. N 808-0241)
2. Bacterial Alkaline Phosphatase (Invitrogen, USA Cat No. 18011-015)
Agarose Gel:
1. Agarose (Sigma, UK Cat. No 13,704-9)
DNA Ladder:
1. lOObp DNA Ladder (Promega, USA Cat No. G2101)
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Ready Made Kits:
1. LightCycler- DNA Master SYBR Green 1 (Roche, USA Cat No. 2158817)
2. QIAEX 11 kit 09/97 (Q1AGEN, USA Cat No. 20021)
3. QIAampRDNA Mini Kit 01/99 (QIAGEN, USA Cat No. 51306)
4. QIAGEN Midi Plasmid Purification Kit (QIAGEN, USA Cat No 12143)
5. pMOSBlue blunt-ended cloning kit (Amersham, USA Cat No. RPN5110)
6. GenElute™ PCR Clean-Up Kit NA (Sigma, UK Cat No. N A 1020)
7. LightCycler- Control Kit DNA (Roche, USA Cat No. 2 158 833)
8. LightCycler- DNA Master SYBR Green 1 (Roche, USA Cat No. 2 158 817)
EQUIPMENTS
1. LightCycler, Roche Molecular Biochemicals, UK
2. Sequence detector ABI7700, P.E.Applied Biosystems
3. Polaroid camera, Kodax, UK
4. GeneAmp PCR system 9700, PE Applied Biosystems, USA
5. Centrifuge Spectrafuge 16M, National Labnet Co, USA
6. Pipette, Gilsons, USA
7. Grant hot water bath, Grant Instruments, UK
8. Sorvall Super 2 Centrifuge Sorvall, USA
9. Culton 4300 Innova Incubator Shaker, Bruswick Scientific, USA
10. Culton Incubator Haraeus, Bruswick Scientific, USA
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ANALYSIS SOFTWARE
1. Statview, SAS Institute, USA
2. Microsoft Office 2003- Excel, USA
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Methods
Recruitment of Families for EUROPAC
Families with HP based in the United Kingdom and Ireland were identified from the 
EUROPAC Registry. Following informed consent, lOmls of venous blood in EDTA was 
obtained from all family members over the age of 18 years and whole DNA extracted as 
per the protocol in the QIAampR DNA Mini Kit.
Detailed pedigrees were established in conjunction with referring clinicians and 
pancreatic and clinical genetics specialists from EUROPAC. Family members were 
questioned to determine whether they have been diagnosed with chronic pancreatitis; 
their clinical symptoms (abdominal pain, nausea, vomiting, diarrhoea and steatorrhea); 
together with the number and duration of attacks; age of onset o f symptoms and 
complications of pancreatitis. All the information obtained from the families was 
corroborated by a questionnaire, completed by the referring clinician, who provided 
supporting radiological and biochemical investigations of chronic pancreatitis.
Study protocols, questionnaires and consent forms were approved by the Local Research 
Ethical Committee.
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Extraction of DNA from Whole blood, Tissue, Pancreatic Juice and Bile
Clinical samples were collected, after informed consent, from patients undergoing 
ERCP. The juice samples were spun in a centrifuge at maximum speed room 
temperature for 15 minutes to collect cells. In samples where cell pellets were seen, 
these were washed twice with PBS before DNA extraction. In samples where pellets 
were not visible, whole juices were used for DNA extraction. Diseased tissues were 
obtained during surgical resection. These samples were initially stored in liquid nitrogen 
if DNA extraction was not carried out immediately. The DNA was extracted following 
the protocol in the QIAampR DNA Mini Kit.
The QIAampR DNA Mini Kit was used for DNA extraction from the clinical samples- 
whole blood/ pancreatic juice/ bile/ tissue. For each DNA extraction, initially, 20 pi 
QIAGEN Protease (or proteinase K) was pipetted into the bottom of a 1.5 ml 
microcentrifuge tube. Up to 200 pi of whole blood/ pancreatic juice/ bile sample was 
added to the microcentrifuge tube. If the sample volume was less than 200 pi, the 
appropriate volume of PBS was added.
200 pi Buffer AL was added to the sample and mixed thoroughly to yield a 
homogeneous solution by pulse-vortexing for 15 s. The mixture was incubated at 56°C 
for 10 min. The mixture was briefly centrifuged to remove drops from the inside of the 
lid. 200 pi ethanol (96-100%) was added to the sample, and mixed again by pulse- 
vortexing for 15 s. After mixing, the 1.5 ml microcentrifuge tube was briefly centrifuged 
to remove drops from the inside of the lid.
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The mixture was carefully applied to the QIAamp Mini spin column (in a 2 ml collection 
tube) without wetting the rim. The cap was closed, and the spin column centrifuged at 
6000 x g (8000 rpm) for 1 min. The QIAamp Mini spin column was placed in a clean 2 
ml collection tube, and the tube containing the filtrate was discarded.
The QIAamp Mini spin column was carefully open and 500 pi Buffer AW1 was added 
without wetting the rim. The cap was closed and the spin column centrifuged at 6000 x g 
(8000 rpm) for 1 min.The QIAamp Mini spin column was placed in a clean 2 ml 
collection tube, and the collection tube containing the filtrate was discarded.
The QIAamp Mini spin column was carefully opened and 500 pi Buffer AW2 added 
without wetting the rim. The cap was closed and centrifuged at full speed (20,000 x g; 
14,000 rpm) for 3 min. The QIAamp Mini spin column was placed in a new 2 ml 
collection tube and the old collection tube with the filtrate was discarded. The spin 
column was centrifuged at full speed for 1 min.
The QIAamp Mini spin column was placed in a clean 1.5 ml microcentrifuge tube, and 
the collection tube containing the filtrate was discarded. The QIAamp Mini spin column 
was carefully opened and 200 pi Buffer AE or distilled water was added. The mixture 
was incubated at room temperature (15-25°C) for 1 min, and then centrifuged at 6000 x 
g (8000 rpm) for 1 min. A second elution step with a further 200 pi Buffer AE was 
performed to increase yields by up to 15%.
198
ARMS™ Analysis
The detection of K-RAS mutation using ARMS is based on using oligonucleotide 
primers that are designed to discriminate between target sequences that differ by a single 
nucleotide. The primers are designed to differ at the 3 terminus nucleotide. This is 
important because DNA synthesis in the reaction is dependent on correct base pairing at 
the 3 end. When an ARMS primer is complementary to its target DNA sequence it is 
extended by a Taq polymerase allowing amplification to proceed thus producing an 
ARMS product. If the ARMS primer is mismatched at the 3 end, there is no 
amplification and no product.
Using fluorescently labelled molecular beacons, the ARMS generated PCR products 
were detected. The molecular beacons consisted of a loop sequence which is 
complementary to the ARMS amplicon and a stem sequence which is self 
complementary. At the start of amplification the beacon structure places a fluorophore 
and quencher molecule in close proximity to each other on the stem and the fluorophore 
is effectively quenched. As amplification proceeds, ARMS products accumulate and the 
beacon loop sequence binds to the amplicon. This results in the fluorophore being 
distanced from the quencher and fluorescence occurs. Signal is detected by the 
P.E.Applied Biosystems sequence detector (AB17700). The machine measures the 
increase in fluorescent signal over time as a function of amplification.
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Figure 28: Mutation Detection by ARMS and Molecular Beacons as used at 
AstraZeneca, Cheshire (Clayton et al. 2000) (taken without permission)
Paired tissue and pancreatic/bile juice DNA samples were analysed for K-RAS 
mutations using ARMS. DNA samples are added to 8 reactions consisting o f 7 K-ras 
mutant ARMS reactions and a control reaction. The control reaction amplifies a region
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of K-ras exon 1 around codon 12 and 13. This controls for yield and degradation by 
indicating how much K-ras exon 1 is in each sample. A negative (no DNA) control is 
included in each reaction. The enzyme used for the ARMS reaction was AmpiTaq 
Gold™ (Perkin Elmer). The beacon used was FAM with the lOx Beacons buffer. A 
ROX beacon was also used as a passive reference for comparison o f the flourescence 
from the molecular beacons. The enzyme was activated at 94°C for 20 minutes and the 
reaction was subjected to 50 cycles of 94°C denaturation for 1 minute and 60°C 
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Figure 29: Graph showing K-Ras status after ARMS analysis
PCR primers specific for individual mutations of K-Ras at codon 12 and 13 are used to 
amplify DNA extracted from pancreatic juice. The number of cycles required to produce 
detectable product is determined ©. A sequence of K-Ras not carrying the mutation is 
amplified from the same DNA and the Ct determined (ARMS Control C). The two CT 
values are plotted against each other and compared to curves produced with varying 
concentrations of pure wild type (red line) and pure mutant (blue line) K-Ras. If the test 
sample falls below the 98% confidence limit for wild type, it is classified as mutant.
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The primers used were:
Common forward
5’ GTA CTG GTG GAG TAT TTG ATA GTG TAT TAA CC 3’
Common reverse
5’ CTC ATG AAA ATG GTC AG A GAA ACC TTT ATC 3’
Control (forward)
5’ TGA CTG AAT ATA AAC TTG TGG TAG TTG GCG 3’
Cys (forward)
5’ CTG AAT ATA AAC TTG TGG TAG TTG GAG CAT 3’
Ser (forward)
5’ CTG AAT ATA AAC TTG TGG TAG TTG GAG CCA 3’
Arg (forward)
5’ CTG AAT ATA AAC TTG TGG TAG TTG GAG TTC 3’
Val (reverse)
5’ TAT CGT CAA GGC ACT CTT GCC TAC GCC TA 3’
Ala (reverse)
5’ TAT CGT CAA GGC ACT CTT GCC TAC GCC TG 3’
Asp 12 (reverse)
5’ TAT CGT CAA GGC ACT CTT GCC TAC GCC TT 3’
Asp 13 (reverse)
5’ GCT GTA TCG TCA AGG CAC TCT TGC CTA CCT 3’
The results were analysed on the ARMS analysis software (AstraZeneca Diagnostics, 
Northwich).
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Cloning of Mutant K-Ras using pMOSBlue
Prior to setting up the LightCycler™ for K-Ras analysis analysis in our clinical samples, 
we had to manufacture mutant K-Ras (for Serine, Argenine, Alanine, 13 Aspartate 
mutations) to use in the initial analysis to test the sensitivity and specificity of our 
system before proceeding to the analysis of clinical samples.
The pMOSBlue cloning kit was used. This is a blunt-ended cloning kit optimized for the 
rapid and efficient cloning of all PCR products.
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PCR reactions for DNA insert
PCR reactions were carried out using the primer sequences as listed below to produce 
DNA inserts for cloning.
K-RASFWDCOMMON
5’ GTA CTG GTG GAG TAT TTG ATA GTG TAT TAA CC 3’ 
K-RASREVCOMMON
5’CTC ATG AAA ATG GTC AGA GAA ACC TTT ATC 3’
NEW2F
5’ ATA TTA CTG GTG CAG GAC CAT TCT T 3’
NEW 1R
5’ CTC CAA CTA CCA CAA GTT TAT ATT 3’
SER-RN
5’ CAC TCG AGC CTA CGC CAC TAG CTC CAA CTA C 3’
ARG-RN
5’ CAC TCG AGC CTA CGC CAC GAG CTC CAA CTA C 3’
13D (13ASP)-FN
5’ GGC TCG AGG AGC TGG TGA CGT AGG CAA GAG T 3’
ALA-FN
5’ GGC TCG AGG AGC TGC TGG CGT AGG CAA GAG T 3’
The enzyme used for this PCR was AmpliTaq Gold™ with lOx PCR Gold Buffer and 
MgCb solution.
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Themastermix components for each 50 pi reaction are listed below:







The enzyme was activated at 94°C for 12 minutes, and then the reaction was subjected to 
35 cycles of amplification at 94°C for 30 seconds, followed by annealing at 65°C for 30 
seconds. This was followed by chain elongation at 72°C for 1 minute. The reaction was 
kept at 72°C after the 35 cycles for a further 7 minutes before being cooled to 4°C.
The PCR products (5pl) was loaded onto a 2% agarose gel stained with ethidium 
bromide (lpl) and ran in lx TAE and visualised under UV illumination.
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Figure 30: Agarose gel of PCR DNA inserts for Cloning
The gel above shows the PCR products following amplification with the named primers 
(as indicated) in preparation for cloning.
The PCR inserts were purified with the Qiaex 11 kit for optimal cloning efficiencies.
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Figure 31: Agarose gel of PCR inserts after QIAEXII purification
The agarose gel shows that the PCR products have not been lost following purification 
in preparation for cloning.
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Figure 32: Agarose gel of PCR inserts after QIAEXII purification
The agarose gel shows that the PCR products have not been lost following purification 
in preparation for cloning.
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pK Reactions
The amount of PCR inserts required for the pK reaction was calculated using the 
formula
Z x 50 x 2A = ___ng insert (where Z = size of insert in bp)
2887 1
The ratio recommended of vector: insert molar ratio by the manufacturer ranges from 
1:1 to 1:2.5.
The 10 pi pK reaction mix is set up as follows in 1.5 ml Eppendorf tubes:
Reaction mix for NEW1R, NEW2F and Control inserts:
1 Ox pK buffer lpl
lOOmM DTT 0.5pl
pK enzyme mix lpl
Insert 2pl
Water 5.5pl
(NEW1R for Colony 1 and NEW2F for Colony 2)
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Reaction mix for ALA, ARG, SER, 13ASP inserts:
1 Ox pK buffer Iftl
lOOmM DTT 0.5pl
pK. enzyme mix lpl
Insert lpl
Water 6.5pl
(ALA for Colony 3, ARG fro Colony 4, SER for Colony 5 and 13ASP for Colony 6)
The reactions were incubated at 22°C for 40 minutes and centrifuged briefly to collect 
the contents at the bottom of the tubes. To heat inactivate the kinase enzyme, the 
reactions were incubated at 75°C for 10 minutes, cooled on ice for 2 minutes (to avoid 
inactivation of the ligase in the ligation reaction) and finally, centrifuged briefly again to 
collect the condensate.
Ligation
The vectors (50 ng) were ligated with the pK reactions and the ligation reactions (12 pi) 
were prepared as follows:
pK reaction mixture lOpl
pMOSBlue vector (50ng/pl) lpl
T4 DNA ligase (4 Weiss units) lpl
The ligation mixtures were incubated at 22 °C overnight.
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Transformation
The pMOSBlue competent cells were thawed and 20pl were pipetted into the required 
number of pre-chilled microfuge tubes on ice. lpl of ligation mix was added directly to 
each microfuge tube and the tubes were left on ice for 30 minutes. The cells were then 
placed in a water bath at 42°C for exactly 40 seconds and returned to ice for a further 2 
minutes. 80pl of room temperature SOC medium was added to each tube and the tubes 
were shaken at 200-250rpm at 37 °C for 1 hour.
X-gal (35pl of 50mg/ml) and IPTG (20pl lOOmM) were spreaded on the L agar 
antibiotic plates and left to soak for 30 minutes prior to plating. 50pl of each 
transformation was spreaded on to the L agar plates (*see below). The plates were 
incubated inverted at 37 °C.
*(The L agar antibiotic plates were prepared using lOg tryptone, 5g yeast extract, lOg 
sodium chloride, 15g agar in 1 litre of solution. The solution was sterilized by 
autoclaving Ampicillin was added to a final concentration of 50pg/ml and tetracycline to 
15pg/ml. Fresh filtered sterilized stock solutions were added after the medium had 
cooled to <50 °C .)
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Figure 33: Picture of blue-white colonies from pMOSBlue cloning kit
An example of blue-white colonies following successful integration of mutant K-ras
DNA.
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Colony Harvesting and PCR Screening
The white colonies were harvested and
i) Replated or
ii) Mixed in 20pl of water, heated to 95°C for 10 minutes, spun and the 
supernatant collected ready for the PCR screen.
Colony PCR Screening
The enzyme used for this PCR was AmpliTaq Gold™ with lOx PCR Gold Buffer and 
MgCb solution.
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Themastermix components for each 30 pi reaction are listed below:





1 Ox buffer 2.5pl
Water 10.4(0.1
Enzyme 0.1 pi
PCR product 5 pi





1 Ox buffer 2.5(o.l
Water 10.4pl
Enzyme 0.1 pi
PCR product 5 pi
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The enzyme was activated at 94°C for 12 minutes, and then the reaction was subjected to 
35 cycles of amplification at 94°C for 30 seconds, followed by annealing at 55°C for 30 
seconds. This was followed by chain elongation at 72°C for 1 minute. The reaction was 
kept at 72°C after the 35 cycles for a further 7 minutes before being cooled to 4°C. The 
PCR products were loaded on an ethidium bromide stained 2% agarose gel.
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Figure 34: Agarose gel of PCR Screen for mutant Kras constructs of the correct 
orientation.
Following cloning, DNA was extracted from the colonies and screened for correct 
orientation. The agarose gel above shows (as indicated in the labelled lanes) colonies 
with the orientation for ALA, 13ASP, ARG and SER colonies.
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The colonies with the correct constructs were purified using the Qiagen Midi Plasmid 
Purification Kit following the manufacturer’s protocol. The purified products were 
loaded on an ethidium bromide stained 2% agarose gel for concentration estimation.
NEW1R NEW2F ALA ARG SER 13AS
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Figure 35: Agarose gel of PCR with mutant Kras constructs of the correct 
orientation after plasmid purification
The agarose gel shows the DNA with the correct construct orientation still present after 
purification.
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Figure 36: Agarose gel showing digestion of Consrtuct 1 (NEW1R) and 2 (NEW2F) 
with Sail and PSTI enzymes
Construct products from Colony 1 (NEW1R) and 2 (NEW2F) were double digested with 
Sail and PSTI enzymes. The digestion mixtures were incubated at 65°C for 1 hour. The 
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Figure 37: Agarose gel showing digestion of Construct 3 (ALA), 4 (ARG), 5 (SER) 
and 6 (13ASP) with Xhol and PSTI enzymes
Construct products from Colony 3 (ALA), 4 (ARG), 5 (SER) and 6 (13ASP) were 
double digested with Xhol and PSTI enzymes. The digestion mixtures were incubated at 
65°C for 1 hour. The digested products were loaded on an ethidium bromide stained 2% 
agarose gel with a 1 OObp ladder.
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Figure 38: Agarose gel showing Constructs NEW1R and NEW2F after 
dephosphorylation
Constructs from Colony 1 (NEW1R) and 2 (NEW2F) were dephosphorylated with 
bacterial alkaline phosphatase following manufacturer’s instructions at 65°c for 1 hour. 
Some of the dephosphorylated products were loaded onto a 0.8% agarose gel with a 1Kb 
ladder.
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The constructs were religated in the following combinations following the pMOSBlue 
manufacturer’s protocol as previously described.
Construct 1 (NEW1R) and Construct 3 (ALA) 
Construct 1 (NEW1R) and Construct 6 (13ASP) 
Construct 2 (NEW2F) and Construct 4 (ARG) 
Construct 2 (NEW2F) and Construct 5 (SER)
The colonies with the mutant Kras constructs were screen by PCR for the correct 
orientation. The primers used PCR mastermix and the agarose gels are shown below.
Primers used for mutant Kras screening:
5’-GTA CTG GTG GAG TAT TTG ATA GTG TAT TA A CC-3’ F Common 
5’-CTC ATG AAA ATG GTC AGA GAA ACC TTT ATC-3’ R Common 
5’ CAC TCG AGC CTA CGC CAC TAG CTC CAA CTA C 3’ SER-RN 
5’ CAC TCG AGC CTA CGC CAC GAG CTC CAA CTA C 3’ ARG-RN 
5’ GGC TCG AGG AGC TGG TGA CGT AGG CAA GAG T 3’ 13D (13ASP)-FN 
5’ GGC TCG AGG AGC TGC TGG CGT AGG CAA GAG T 3’ ALA-FN
The R (Reverse) common primer was used with FN (Forward) primers and the F 









The enzyme was activated at 94°C for 12 minutes, and then the reaction was subjected to 
35 cycles of amplification at 94°C for 30 seconds, followed by annealing at 55°C for 30 
seconds. This was followed by chain elongation at 72°C for 1 minute. The reaction was 
kept at 72°C after the 35 cycles for a further 7 minutes before being cooled to 4°C. The 
PCR products were loaded on an ethidium bromide stained 2% agarose gel.
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Figure 39: Agarose gel of Kras with mutant ALA
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Figure 40: Agarose gel of Kras with mutant 13Asp







Figure 41: Agarose gel of Kras with mutant Arg
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Figure 42: Agarose gel of Kras with mutant Ser (147bp)
The agarose gel shows successful production of DNA with mutant K-ras serine 
sequence.
The mutant Kras sequences are ready for use in the calibration and quantification 
process in setting up the LightCycler™ machine.
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Setup of LightCvcler for K-Ras Analysis and K-Ras Analysis
The LightCycler Instrument
The Lightcycler Instrument of Roche Molecular Biochemicals is a thermocycler for the 
rapid analysis of PCR applications. This innovative machine allows for carrying out and 
simultaneously evaluating PCR experiments.30 amplification steps including anaylsis of 
results can be carried out in less than 30 minutes.
Fluorimetric analysis of the PCR products formed is performed as real-time 
measurement either continuously or at a specifically defined time during each PCR 
cycle. The analysis can be monitored online by the LightCycler’s software, directly 
during the reaction.
Components of the LightCycler 
LightCycler Instrument
Sample Carousel (for 1.5mm capillary) premounted in LightCycler Instrument 
LightCycler Capillaries (96 capillaries and stoppers/box)
32 LightCycler Centrifuge Adapters in an aluminium cooling block
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Figure 43: Picture of the LightCycler from Roche Molecular Biochemicals (taken 
without permission from LightCycler Operator’s Maunal Version 3.0 May 1999)
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Figure 44: Schematic diagram of the LightCycler (taken without permission from 
LightCycler Operator’s Manual Version 3.0 May 1999)
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*The LightCycler consists of an upper unit and a lower unit. The upper unit contains the 
heating coil. The lower unit contains the thermal chamber, fluorimeter, drive units, 
electronic boards and power supply. The various elements are mounted on a 10-mm cast 
aluminium base plate. This guarantees stability, especially for the thermal chamber and 
flourimeter.
Hot or ambient temperature air, introduced into the thermal chamber, regulates the 
temperature of the sample capillaries. A heating coil heats the air, which is them fed into 
the chamber by the fan. The fan ensures efficient air circulation and temperature 
homogeneity during the heating cycle.
During the cooling cycle, the fan operates at a higher speed to ensure adequate cooling. 
During measurements, a stepper motor rotates the sample carousel to position the 
capillary tip precisely at the focal point of the fluorimeter optics. The fluorimeter itself is 
positioned radially to the maximum signal to compensate for any radial deviation of the 
capillary tip.
For online display, data are transmitted to and from the PC via a serial interface.
Temperature is controlled with hot air and air at ambient temperature. Arying the 
voltage supplied to the heating coil regulated the temperature. A sensor provides 
reference valus for control purposes.
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During the heating phase, the fan in the thermal chamber operates at low speeds to 
ensure homogenous distribution of temperature. During the cooling phase, the fan 
operates at higher speeds so that the capillaries and the heating coil can be cooled 
efficiently.
The two sensors are integrated into the LightCycler to prevent unduly high temperatures:
• Sensor I is located in the themal chamber and switches off the heat when a 
temperature of 125°C has been reached.
• Sensor II monitors the temperature on the aluminium base plate, and switches off 
the entire LightCycler to protect the electronics when the temperature exceeds 
55°C.
A three-channel fluorimeter is used for detection purposes. A blue diode (LED) with 
maximum emission of 470nm serves as the energy source for sample excitation. Screens 
are used to diffuse the light emitted by the LED to ensure uniformity. The exhaust and 
ventilation channels have been designed to prevent ambient light from entering directly 
into the thermal chamber. Flourescence is detected at 530nm, 640nm and 710nm with 
the aid of photohybrids.
233
The thermal chamber and the fluorimeter are palced optimally for sample measurement. 
Only the sample carousel, which holds the capillary, rotates during measurement of the 
various samples.*




The LightCycler was supplied with pre-installed software to allow for the analysis of 
samples. When programming a Run for an experiment, a Programming Screen appears. 
The Programming Screen allows for:
• Defining the parameters of a PCR protocol
• Starting a PCR run or
• Viewing online a PCR experiment that is currently in progress.
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Figure 45: Diagram of the Programming Screen
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An Experimental Protocol contains one or more Cycle Programs. A typical 
Experimental Protocol contains four programs:
• Program 1: Initial Denaturation
• Program 2: Amplification
• Program 3: Melt and
• Program 4: Cooling
A Program (e.g. Cycle Program) contains seceral Temperature Segments, each of which 
defines the time and parameters that will be used for denaturation, annealing, extension 
and/or melting, cooling as well as fluorescence acquisition mode used to monitor the 
amplification signal.
Data Analysis
The LightCycler Data Analysis (LCDA) sortware allows a LightCycler used to analyze 
quantification data or melting curve data acquired during a LightCycler reaction. The 
LCDA software can display and analyze in two formats:
• Quantification: Estimates the original number of target DNA copies in a sample 
by comparing it to at least two known concentration of a standard. It displays the 
amplification profile of a PCR.
• Melting Curve: Displays a fluorescence curve profile obtained during a slow 
denaturation of PCR products, and includes options for differentiationg melting 
curves to give melting peaks, integrating the area under the melting peaks, and 
defining the melting temperature of amplified products.
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Set-up for Kras Analysis
Before utilizing the LightCycler for formal analysis of patient clinical samples for the 
presence/ absence of Kras mutations, we optimized the PRC reactions for the Kras 
primers using the LightCycler. The primers used for the Kras reactions are as follows:
5’ CTG AAT ATA AAC TTG TGG TAG TTG GAG TTC 3’ F G12R
5’ CTG AAT ATA AAC TTG TGG TAG TTG GAG CCA 3’ F G12S
5’ CTG AAT ATA AAC TTG TGG TAG TTG GAG TAT 3’ F G12C
5’ TAT CGT CAA GGC ACT CTT GCC TAC GCC TAC GCC TT 3’ R G 12D 
5’ TAT CGT CAA GGC ACT CTT GCC TAC GCC TAC GCC TA 3’ R G 12V 
5’ TAT CGT CAA GGC ACT CTT GCC TAC GCC TAC GCC TG 3’ R G12A
5’ GCT GTA TCG TCA AGG CAC TCT TGC CTA CCT 3’ R 13ASP
5’ GTA CTG GTG GAG TAT TTG ATA GTG TAT TAA CC 3’ F Common
5’ CTC ATG AAA ATG GTC AGA GAA ACC TTT ATC 3’ R Common
5’ TGA GTG AAT ATA AAC TTG TGG TAG TTG GCG 3’ F Control
5 ’ CTG TAT CGT CAA GGC ACT CT 3 ’ R Control
Primers specific for each mutation were used in combination with the appropriate 
common primer. The Reverse (R) common primer was used with Forward (F) mutation 
specific primers and the F common primer was used with the R mutation specific 
primers. The control primers amplify both mutant and wild type sequences.
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The PCR reactions were set up using the LightCycler ready made kits listed previously 
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Melting curve analysis was performed from 72 to 95 °C to verify that pure PCR products 
were produced.







13 Asp ~82 °C
Control -78-82 °C
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The melting temperature of the products from the LightCycler reactions are checked to 
ensure that there is no contamination and that the correct products are being analysed.
Following optimization of the LightCycler for the primers, the PCR sensitivity for the 
detection of mutant Kras sequences was then analyzed. Mutant Kras sequences from the 
cloned Kras or from know cell lines with known Kras mutation were multiply diluted 
and analysed with the LightCycler to confirm detection sensitivity to a dilution of 1: 
10000. Again, pure PCR products were confirmed from the melting point analysis.
Samples used for analysis of mutant Kras sequences:
12Asp Panc-1 cell line
13 Asp Cloned
12Ser Cloned
12Val CFPac cell line
12Arg Cloned
12Cys MiaPACA cell line
12Ala Cloned
Statistical analyses of these dilutions were performed and graphs were produced for the 
individual Kras mutations that would enable future anaylses to be plotted on them. This 
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Figure 46: Graph to determine the Kras Valine mutation status. Markers on graph
indicate mutant Valine samples
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Figure 47: Graph to determine the Kras Alanine mutation status. Markers on
graph indicate mutant Alanine samples
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Figure 48: Graph to determine the Kras Arganine mutation status. Blue and purple 
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Figure 49: Graph to determine the Kras 12 Aspartate mutation status. Shaped 
markers on graph indicate mutant 12 Aspartate samples
243
Figure 50: Graph to determine the Kras 13 Aspartate mutation status. Shaped 
markers on graph indicate mutant 13 Aspartate samples
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Figure 51: Graph to determine the Kras Serine mutation status. Shaped markers 
on graph indicate mutant Serine samples
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Statistics for Kras Mutations Analysis
Statistical analysis was carried out using Statview and Microsoft Office Excel 2003. 
Excel worksheets, sensitivity and specificity equations were used for Kras mutational 
analysis in pancreatic juice, bile, tissue in pancreatic ductal adenocarcinoma, ampullary 
cancer, chronic pancreatitis and control patients. Also, analysed were matched tissue 
samples with pancreatic juice and bile for Kras mutations.
Excel worksheets were also used to generate the age distribution Kras mutation graphs 
in the samples in the various patient groups. Arbitary scale graphs for Kras 
concentration quantification in bile and pancreatic juice were produced using Microsoft 
Excel.
Statview was used to analyse the distribution of Kras with age using the Mann-Whitney 
U, Chi-square and Logrank tests. Kras mutation based on disease and type of mutation 
was analysed using the Logrank tests with Statview.
Results
Demographics for Kras Mutations Analysis
Overall, 276 patients with pancreatic ductal adenocarcinoma, chronic pancreatitis, 
ampullary cancer and control (benign biliary diseases) were recruited. Seventy five 
pancreatic juice, 142 bile and 59 tissue samples were analysed. The median age of 
patients for pancreatic ductal adenocarcinoma was 63 years, for chronic pancreatitis was 







PDAC 17/26 (65%) 12/28 (43%) 27/50 (54%) 20/29 (68%)
Ca. Amp 6/7 (86%) 6/9 (67%) 10/14(71%) 7/17(41%)
C. P. 10/30(33%) 4/15(27%) 12/40 (30%) 10/13 (31%)
Control 5/22 (23%) 26/90 (29%) 19/105 (28%) N/A
Sensitivity 70% 49% 58% 58%
Specificity 71% 71% 72% 69%
PDAC= pancreatic ductal adenocarcinoma, Ca. Amp= Ampullary cancer, C. P. = 
Chronic Pancreatitis.
Table 31: K-Ras Mutations Analysis
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ARMS analysis of Kras mutations in pancreatic juice of patients with PDAC, 
Ampullary Cancer, Chronic Pancreatitis and Control patients (i.e. patients with benign 
biliary diseases) showed Kras mutations to be present in 17/26 (65%) of patients with 
PDAC, 6/7 (86%) patients with ampullay cancer, 10/30 (33%) patients with chronic 
pancreatits and 5/22 (23%) control patients. These results show a positive trend that 
patients with malignancies have a higher rate of mutant Kras compared to patients with 
benign diseases (sensitivity 70%, specificity 71%).
Analysis of bile for Kras mutations show a similar trend- higher presence o f Kras 
mutations detected in patient samples with malignancy compared to non-malignant 
patient samples. The results for the bile analysis are as follows- 12/28 (43%) of patients 
with PDAC, 10/14 (67%) patients with ampullay cancer, 12/40 (30%) patients with 
chronic pancreatits and 19/105 (28%) control patients (sensitivity 58%, specificity 71%).
We also analysed tissue samples from patients and found the presence of Kras mutations 
in 20/29 (68%) of patients with PDAC, 7/17 (41%) of patients with ampullary cancer 





























Sensitivity 73% 77% 73%
Specificity 40% 60% 50%
Table 32: Matched Samples K-Ras Mutations Analysis
We next analysed matched tissue/pancreatic juice and tissue/bile samples to determine 
the correlation of tissue K-Ras status with pancreatic juice/bile K-Ras status.
In patients with PDAC, 18 patients had matched tissue/pancreatic juice samples and 10 
patients had matched tissue/bile samples. In 9 K-Ras mutant tissues, 7/9 (78%) 
pancreatic juice samples were K-Ras mutant. In 9 K-Ras wild-type tissues, 2/9 (22%) 
pancreatic juice samples were K-Ras mutant. In 8 K-Ras mutant tissues, 5/8 (63%) bile 
samples were K-Ras mutant and in 2 K-Ras wild-type tissues, 1/2 (50%) bile sample 
was K-Ras mutant.
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In the ampullary cancer group, there were 5 matched tissue/pancreatic juice samples and 
6 matched tissue/bile samples. 3 patients with K-Ras mutant tissues had corresponding 
K-Ras mutant pancreatic juice, 2 patients with K-ras wild type tissues had K-Ras wild 
type pancreatic juice. 3 patients with K-Ras mutant tissues had K-Ras mutant bile 
samples and in 3 patients with K-Ras wild type tissues, 2 (67%) had K-Ras mutant bile 
samples.
In the chronic pancreatitis patients, there were 16 matched tissue/pancreatic juice patient 
samples and 7 matched tissue/bile patient samples. For the 7 K-Ras mutant chronic 
pancreatitis tissues, 4 (57%) pancreatic juice were K-Ras mutant. For the 9 K-Ras wild 
type tissue samples, 6 (67%) were K-Ras mutant. In the matched tissue/bile group, 2 
patients with K-ras mutant tissues also had K-Ras mutant bile (100%) and of the 5 K- 




Tissue Pancreatic Juice 
and Bile
RFLP Mutant 4/4(100%) 4/4(100%)
2 PDAC, 2 Ca. 
Amp
Wild type 6/10(60%) 6/11 (55%)
3/3 PDAC, 0/2 Ca. 




Mutant 6/10(60%) 6/11 (55%)
2/2 Ca. Amp,3/4 
PDAC, 0/3 Other, 
1/1 C. P.
Wild type 2/4 (50%) 1/4(25%)
1/2 Ca. Amp, 1/2 
C. P.
RFLP= restriction fragment length PCR, LCM= Laser Capture Microscopy
Table 33: Comparison of ARMS and other techniques
The RFLP and LCM and sequencing techniques are considered the ‘Gold Standard’ for 
detecting K-Ras mutations and the Table above presents our results from analysis of 
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Figure 52: Age Distribution of K-Ras Mutation in All Samples 
Analysed
The analysis o f the presence or absence of K-Ras mutations by age across all patient 
samples (PDAC, chronic pancreatitis and control patients) revealed a trend of increasing 
presence of K-Ras mutation with increasing age. In our patients sample analysed there 
were no K-Ras mutations detected in patients less that 25 years old.
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Mutant Ras Wild type Ras Significance 
(p value)
M-WU Logrank
Total 64 (1QR: 57- 
74)
57 (IQR: 44-68) 0.003 0.046
Controls 73 (IQR: 61- 
80)
64 (IQR: 49-70) 0.056 0.027
C. P. 54 (IQR: 46- 
64)
46 (IQR: 39-55) 0.103 0.083
PDAC 63 (IQR: 59- 
73)
63 (IQR: 48-74) 0.809 0.449
Table 34: Distribution of K-Ras Mutation with Age Median Age
The table above demonstrated the median age of patient with mutant and wild type K- 
Ras in the different groups anaylsed. The median age for the Control, chronic 
pancreatitis and PDAC groups are 73 years, 54 years and 63 years respectively.
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Figure 53: Age Distribution of K-Ras Mutation in Chronic Pancreatitis Samples 
Analysed
Analysis of K-Ras mutations by age and diagnosis- in this case, patients with chronic 
pancreatitis, showed that there were no K-Ras mutations in patients under the age of 35 












Figure 54: Correlation between age and K-Ras mutation in Chronic Pancreatitis 
patients
With a slightly larger patient chronic pancreatitis group, again it is shown that K-Ras 
mutant is not present in patients under the age of 40 years and occur more frequently 
with advancing age.
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Figure 55: Age Distribution of K-Ras Mutation in Control Samples Analysed
In the Control patient group, there was a positive trend for K-Ras mutation with 
increasing age. There was no K-Ras mutation in the under 26 years old group.
256
100
< 40 40-75 >75
Age (years)
Figure 56: Correlation between age and K-Ras mutation in Control patients
The figure above demonstrated the stastistically significant positive trend for the 
presence of K-Ras mutation with increasing age in Control patients.
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Figure 57: Age Distribution of K-Ras Mutation in PDAC Samples Analysed
Lastly, in the PDAC patients, the presence of K-Ras mutation was seen mainly in the 56- 































Figure 58: Correlation between age and K-Ras mutation in PDAC patients
In the PDAC patient group, K-Ras mutation occurs in almost equal frequencies across 
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Figure 59: Analysis of K-Ras Mutations based on Disease and Number of 
Mutations
When we looked at the relationship between disease diagnosis and the number o f K-Ras 
mutations present in pancreatic juice/bile samples analysed (as shown in the figure 
above), we found that in the patient groups PDAC, Ampullary cancer and Control- there 
were one K-Ras mutation present in 60%, 80% and 79% of the samples analysed 
respectively.. In the chronic pancreatitis group, multiple K-Ras muations was detected in 
82% of the samples.
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Pancreatic Juice Bile Combination
PDAC 10/22 (45%) 8/23 (35%) 15/41 (37%)
Ca. Amp 5/6 (83%) 4/9 (45%) 8/13 (62%)
C. P. 2/27 (7%) 1/13(8%) 2/36 (5%)
Control 4/9 (44%) 10/43 (23%) 14/49 (29%)
Sensitivity 54% 37% 45%




Table 35: Distribution of Single K-Ras Mutations in Pancreatic Juice and Bile
In this table, again it show that in the diagnosis for PDAC, ampullary cancer and control 
the occurance of single K-Ras mutations occur at a frequency of 45%, 83% and 44%. 
However, when combined with the results from the K-Ras analysis of bile, this figure is 
skewed to a lower level.
In the chronic pancreatitis group, the results show consistently the high prevalence of 
multiple K-Ras mutations.
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Figure 60: Analysis of K-Ras Mutations based on Disease and Type of Mutations
In the PDAC group, there were a high proportion of K-Ras 12 Aspartate mutations, 
followed by Arganine, Valine and a small number of Cysteine and Serine mutations. In 
the Ampullary cancer group, the most prevalent K-Ras mutation was the Valine 
mutation followed by the 12 Aspartate, Arganine and Cysteine mutations. In both the 
PDAC and Ampullary cancer groups analysed, the Alanine K-Ras mutation is not 
present.
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In the chronic pancreatitis group, there are high levels of the Arganine and 12 Aspartate 
K-Ras mutations followed by lower levels of Valine, Alanine and Cysteine mutations. 
The 12 Aspartate is again the most prevalent mutation in the Control group.
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Figure 61: Quantification: Concentration of K-Ras in Pancreatic Juice
Arbitary quantification of K-Ras concentration in pancreatic juice in the different patient 
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Figure 62: Quantification: Concentration of K-Ras in Bile
The K-Ras mutations concentration bile are roughly equivalent to that in pancreatic 




Premalignant molecular changes can be detected in the pancreatic juice o f patients. Thus 
the application of molecular screening in patients with HP is potentially the most 
powerful method of pancreatic early cancer detection. Although mutant K-ras can be 
detected in the pancreatic juice of most patients with pancreatic cancer, it is also present 
in patients with non-inherited chronic pancreatitis who do not progress to pancreatic 
cancer (at least in the short- to medium-term) as well as increasingly in the older 
population without pancreatic disease as described in this thesis. Nevertheless the 
presence of mutant K-ras may identify a genuinely higher risk group enabling additional 
diagnostic imaging and molecular resources to be focussed onto such a group.
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Chapter 5- Conclusion
Exon 4 Polymorphism PRSS1
For both R122H and N29I there is no strong evidence for a single recent founder. For 
patients with no PRSS1 mutation there is no evidence for a link to PRSS1.
There no evidence that the R122H and N291 hereditary pancreatitis families come from 
a single population (defined by PRSS1). The proportion of the mutation linked to the 
low frequency allele was 30% and 75%. The expected frequency from the control 
population would be between 36 and 46%. So the number of families with mutations 
linked to the low frequency allele is somewhat higher than expected for N291 and 
somewhat lower for R122H, but there are clearly 2 founder populations for each 
mutation type.
If an as yet unidentified mutation in PRSS1 is responsible for the disease in HP patients 
with none of the established mutations then we would again expect a disproportionate 
number of families with either the low frequency or the high frequency allele linked to 
the disease. In fact 21% of families had association with the low frequency allele, 
slightly lower than expected (36 to 46%) but certainly not consistent with a single 
common founder having a mutation on PRSS1.
As mentioned previously, the D32D polymorphism had been observed by Nishimori et 
al when analysing the cationic trypsinogen gene in Japanese families with HP
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(Nishimori et al. 1999). This group also reported a polymorphism (a single C to T 
transition without amino acid substitution) in exon 5 in some patients with HP, sporadic 
pancreatitis and in normal subjects. Gorry et al also reported a normal polymorphism in 
exon 4 of the PRSSI gene (Gorry et al. 1997).
Future work
During the time of the study, the available samples limited the power and analysis of the 
study. The incidence of this polymorphism is worth further investigation in order to 
establish any possible founder effect. This is important because cancer risk is almost 
certainly influenced by the broader genetic background. Thus it is likely that some 
families have more risk of cancer than others and so different founder populations 
should be screened differently.
Conceptually the simplest way to investigate a founder effect is to simply increase 
numbers and with the current much larger database of patients available this seems a 
very attractive approach. However, power calculations put this study in perspective. If 
we assume a null hypothesis that our incidence of low and high frequency alleles in 
R122H and N291 are equivalent to controls (36-46%) and the hypothesis that the 
percentages seen in this preliminary study are as defined then how many controls and 
families would need to be tested? Let us assume we could test 500 controls this would 
mean that to show that R122H has significantly less low frequency allele carriers we 
would need to test 470 families (this is still beyond the scope of the EUROPAC registry.
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It is perhaps of more academic interest to determine if there is any founder effect in 
those families with no PRSS1 mutation. Given the same assumptions as above we could 
prove a founder effect with just 50 negative for all families. This would mean that 
further work could be focused on finding the elusive additional PRSS1 mutation, 
focussing on the families with the high frequency allele.
An alternative approach to studying founders in all HP families would be the use of SNP 
array analysis, this could be used in an association study to identify other loci that cause 
or influence outcome in HP. Again the biggest problem would be power. This is more 
difficult to calculate given that we know little about relative allele frequencies in the 
different populations, but it is unlikely to require fewer families than with the more 
specific analysis of the PRSS1 locus.
In all the analyses above a correlation between the polymorphisms and cancer risk 
would have to be established, this will require survival analysis in the different groups.
In contrast only 20 N29I families would be needed, this is feasible and should be
attempted.
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P16 and MGMT méthylation
In this study, we looked at the méthylation status of DNA found in pancreatic juice as 
indication about the diagnosis status and age of the patient. Free DNA can be detected in 
different body fluids- urine, synovial fluid, pancreatic duct secretions, sputum and 
serum/plasma. This circulating DNA in serum/plasma is found in small amounts in 
healthy individuals, but in cancer patients, higher concentrations of DNA are present. 
The serum of cancer patients is enriched in DNA, containing on average ~4 times the 
amount o f free DNA, compared to normal controls (Shapiro et al. 1983; Wong et al. 
2000). p53 and ras gene mutations are detected in plasma and serum of pancreatic and 
colorectal carcinomas (Sorenson et al. 1994; Mulcahy et al. 1998). However, in previous 
work in our laboratory no mutations could be detected in the plasma or serum of patients 
with respectable pancreatic cancer (Howes 2003).
Similarly, aberrant promoter méthylation has been detected in serum of patients with 
malignancies. Estellar et al found correlation of DNA méthylation status in serum and 
tissue samples in non-small cell lung carcinoma primary tumours. Promoter 
hyperméthylation in serum DNA was 33% (3 of 9 cases) for p 16 and 66% (4 o f 6 cases) 
for MGMT. Two important points to note in this study are 1. The patients who have 
abnormal promoter hyperméthylation in the serum DNA demonstrated identical 
alterations in the primary tumour DNA (this is not within the scope of this study) and 2. 
Only patients whose tumours harboured a hypermethylated marker showed aberrant 
méthylation of the same genes in serum. In essence, this study showed, for the first time, 
that it was possible to detect promoter hyperméthylation in serum DNA from cancer
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patients. Ramirez et al found found good correlation between tissue and serum MGMT 
and p l6  methylation in patients with glioblastoma (MGMT tissue 38.1%, MGMT serum 
39.3%, p l6  tissue 66.7%, and p 16 serum 53.6%) (Ramirez et al. 2003). In light of our 
previous work where tumour DNA could not be detected in the plasma or serum of 
patients with resectable tumours we decided to concentrate our efforts at methylation 
analysis on pancreatic juice samples, which have a far more intimate contact with 
tumour tissue (Howes 2003).
The results for methylation in serum are supported by my study in as much as 
hypermethylation of pi 6 and MGMT were detectable in the pancreatic juice samples for 
methylation status analysis from our cohort of patients and can be reliably used as a 
technique for the molecular diagnosis of pancreatic cancer.
Recently, Fukushima et al reported his findings of methylated p i6 DNA in pancreatic 
juice (Fukushima et al. 2003). Using methylation specific PCR, methylated p i6 were 
detected in 11.1% (5/45) of pancreatic juice and in 18.2% (6 of 33) of tissue samples 
analysed in patients with primary pancreatic adenocarcinoma. In contrast, no methylated 
p i6 DNA was detected in the pancreatic juice samples of the benign patient group (20 
patients, including 12 chronic pancreatitis patients). Interestingly, pancreatic juice 
samples obtained from the duodenum of patients without pancreatic cancer were positive 
for methylated p 16 in 11.1%.
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From our analysis of pancreatic juice, we found 100% (30/30) p i6 and 87% (26/30) 
MGMT methylation in patients diagnosed with pancreatric ductal adenocarcinoma 
(compared to 18.2% p 16 methylation by Fukushima et al). In our benign disease group 
(combining the control and chronic pancreatitis patients), 48% (31/65) and 45% (27/60) 
patients had p i6 and MGMT methylation respectively. The only variable not taken into 
account in our study is whether the pancreatic juice were obtained from the pancreatic 
duct or the ampulla of Vater, as it has been shown by Fukushima et al, that the site of 
pancreatic juice sample collection could influence the methylation status o f samples. If 
the findings can be reproducible, that is, pancreatic juice from patients with benign 
diseases does not contain methylated p 16 or MGTM, then it may be possible to detect 
early PDAC from the methylation status of p i6 and MGMT from pancreatic juice 
obtained from the pancreatic duct.
Future work
In subsequent work by my colleague Dr Li Yan methylation in control samples was 
reported, but the level was much lower than in the pancreatic juice from cancer patient 
(Yan et al. 2005).
Current work is being undertaken to determine whether DNA methylation from 
pancreatic juice can be validated and used as an effective biomarker for the detection for 
pancreatic cancer.
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According to previous results, using quantitative pl6 promoter methylation together 
with p53 and K-ras mutation in DNA from pancreatic juice could distinguish the control 
individuals from those suffering from chronic pancreatitis or cancer. This combination 
seems to be useful to assess cancer risk in high risk individuals.
In the current study ten tumor-suppressor, growth regulatory or mismatch repair-related 
genes were screened for aberrant methylation in pancreatic cancer, including pl6 
(tumor-suppressor gene), hMLHl (Mut-L homologue 1, involved in mismatch repair and 
associated with Hereditary Non-Polyposis Colorectal Cancer), MGMT (0-6- 
methylguanine-DNA methyltransferase, removes adducts from the 0 6  position of 
guanine), MINT2, MINT31, MINT32, ppENK (preproenkephalin, encoding for a native 
opioid peptide with growth-suppressor properties), FOXE1, TFPI2, NPTX2. Quantitative 
methylation analyses are being performed on pancreatic juice DNA.
Pancreatic Cancer and K-Ras
It is essential that the test used to identify mt-K-ras is highly sensitive and specific. We 
have developed the application of ARMS™ technology, which is sensitive enough to 
detect one mutant copy of DNA in 5000 copies of wild type and has the additional 
advantage of being quantitative for mutant DNA in the sample, without reducing the 
overall sensitivity of the technique (Wong et al. 2000). We are unaware o f better 
technology in place and being used in a clinical setting (Howes et al. 2000).
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What is clear is that prospective multi-centre studies, such as that being pursued by 
EUROPAC, is essential for the development of an effective secondary screening 
programme for these patients. Very early cancers (<lcm in diameter and no lymph node 
métastasés) may result in five-year survival rates of ~50% and the prospect o f genuine 
cure -  unfortunately such tumours are rarely found in routine clinical practice except by 
serendipity (Tsuchiya et al. 1986). Nevertheless this observation shows that a 
meaningful proportion of patients might be cured if the tumours could be detected early 
enough. Thus the question arises as to the possibility of primary screening of the healthy 
population.
Future work
Unfortunately, K-ras mutations are not specific for invasive pancreatic cancer. Previous 
investigations on K-ras mutations in pancreatic tissue, pancreatic juice and stool 
revealed its occurrence in patients with chronic pancreatitis, in individuals who smoke, 
and in PanlNs from patients without pancreatic cancer. To increase the power, 
sensitivity and specificity of the studies, large numbers of patient samples needs to be 
analysed especially with regards to paired samples for correlation between Kras 
mutations found in blood/ pancreatic juice/ bile and diseased tissue samples.
During the interim of this thesis being prepared and submitted, the technique developed 
has been used in research studies at the Department of Surgery and Oncology, 
University of Liverpool, for the analysis of K-ras mutations in patients identified as
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